Conjugate of urea derivative compound having neosubstrate-degrading activity and therapeutic pharmaceutical composition comprising same
The urea derivative compounds address the challenge of targeting difficult-to-drug proteins by promoting targeted protein degradation, providing a less toxic cancer treatment option through the ubiquitin-proteasome system.
Patent Information
- Application Number
- PCT/KR2026/005687
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-12-12
- Filing Date
- 2026-04-29
- Publication Date
- 2026-11-19
AI Technical Summary
Conventional drug discovery methods struggle to effectively target nuclear transcription factors and scaffold proteins due to the lack of docking pocket structures, limiting the development of drugs for about 85% of known disease-related proteins, and existing FDA-approved compounds for cancer treatment, such as IMIDs, have high toxicity.
A conjugate of a urea derivative compound with neosubstrate degradation activity, represented by specific chemical formulas, is developed to target and degrade disease-related proteins using the ubiquitin-proteasome system, potentially treating cancer.
The urea derivative compounds effectively promote the targeted degradation of pathogenic proteins, offering a less toxic alternative for cancer treatment by leveraging the body's existing protein degradation systems.
Smart Images

Figure KR2026005687_19112026_PF_FP_ABST
Abstract
Description
Conjugate of a urea derivative compound having neo-substrate degradation activity and a therapeutic pharmaceutical composition comprising the same
[0001] The present invention relates to a conjugate of a urea derivative compound having neosubstrate degradation activity and a therapeutic pharmaceutical composition containing the same. More specifically, the invention relates to a conjugate of a urea derivative compound having neosubstrate degradation activity that can be usefully employed for the prevention or treatment of cancer by degrading neosubstrates, and a therapeutic pharmaceutical composition containing the same.
[0002] Most existing drug discovery involves directly regulating protein activity by binding drugs to specific active sites of disease-related proteins, such as enzymes and receptor proteins. Consequently, nuclear transcription factors, scaffold proteins, and aggregates remain impregnable targets in drug development because they lack docking pocket structures. According to the Human Protein Atlas, there are FDA-approved drugs for only about 15% of the approximately 4,500 known disease-related proteins.
[0003] To overcome the limitations of conventional drug discovery, research on targeted protein degradation technology targeting difficult-to-identify targets has recently been actively underway.
[0004] Targeted protein degradation techniques aim to treat diseases by utilizing the body's existing protein degradation systems to remove disease-related proteins. Intracellular protein degradation is carried out by lysosomes and proteasomes, and about 80% of cellular proteins are labeled with ubiquitin by the ubiquitin-proteasome system (UPS) and then degraded by proteasomes.
[0005] Ubiquitin is a protein composed of 76 amino acids. E1, E2, and E3 ubiquitin ligases are involved in the process of ubiquitination, in which proteins are labeled with ubiquitin for degradation by UPS. The labeled proteins are then degraded by the 26S proteasome, an ATP-dependent protease complex. E3 ubiquitin ligase binds to both E2 ligase and the substrate protein and plays a role in recognizing the substrate protein to be labeled with ubiquitin.
[0006] Some small molecules can manipulate the ubiquitin proteasome system to induce the degradation of targeted proteins. Promoting the targeted degradation of pathogenic proteins using small molecule degraders is emerging as a new modality in disease treatment. One such modality involves small molecular weight compounds called molecular adhesives, which promote polyubiquitination and ultimately proteasome degradation by binding E3 ligases, such as cereblon, to protein substrates associated with disease development.
[0007] Molecular adhesives of the IMID (immunomodulatory imide drug) class, including thalidomide, lenalidomide, and pomalidomide, bind to both E3 ligase and target proteins and degrade the neosubstrate.
[0008] While these IMIDs have been approved by the FDA for use in blood cancers, they have a high potential for toxicity, and efficient compounds targeting other diseases, particularly other types of cancer, are still needed.
[0009] To solve the aforementioned problem, the present invention aims to provide a conjugate of a urea derivative compound having neosubstrate degradation activity that can be usefully used for the prevention or treatment of cancer by degrading neosubstrates, and a therapeutic pharmaceutical composition containing the same.
[0010] To solve the above-mentioned problem, the present invention provides a compound selected from a urea derivative compound represented by the following chemical formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a stereoisomer thereof.
[0011] [Chemical Formula 1]
[0012]
[0013] (In the above chemical formula 1, the above A 1 is R 7 -(R 8 )NO-, R 9 -O-(R 10 )N-, R 11 -(R 12 )N-(R 13 )N- and; above R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 Each is independently hydrogen, an alkyl group, an aminoalkyl carbonyl group, an alkylaminoalkyl carbonyl group, a heterocycloalkyl carbonyl group, an aminoalkyl group, an alkylaminoalkyl group, a hydroxyalkyl carbonyl group, a cycloalkyl group, a halocycloalkyl group, a heterocycloalkyl group, a heterobicycloalkyl group, a cycloalkyl-alkyl group, a heterocycloalkyl-alkyl group, a hydroxycarbonylalkyl group, an alkylhydroxycarbonylalkyl group, an aminecarbonylalkyl group, or an alkylaminecarbonylalkyl group; and R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 The above alkyl group, cycloalkyl group, and heterocycloalkyl group of are substituted or unsubstituted with one or more selected from the group of halogens and alkyls; and the above A 2is an alkyl group, an alkoxyalkyl group, an alkylaminocarbonylalkyl group, an alkylcarbonylaminoalkyl group, a carbonylalkyl group, an alkylaminoalkyl-alkyl group, an alcoholcy-alkoxyalkyl group, an alkylalkoxy-alkoxy group, or an alkylaminoalkyloxyalkyl group; and the above A 2 The above alkyl group and alkoxy group are substituted or unsubstituted with one or more selected from the group of halogens and alkyls; and the above R 1 , R 2 , R 4 and R 5 Each is independently hydrogen, a halogen group, an alkyl group, a hydroxyl group, an alkoxy group, an amine group, an alkylamine group, a nitrile group, a difluoromethyl group, or a trifluoromethyl group; and R 3 is hydrogen or an alkyl group; and R 6 is hydrogen, deuterium, or an alkyl group; and the X 1 is NH, C(=O), O, or CF2; and the above X 2 is O, S, and NH; and the above Y is CH2 or C(=O))
[0014] In one embodiment, the A 1 is R 7 -(R 8 )NO-, R 9 -O-(R 10 )N-, R 11 -(R 12 )N-(R 13 )N- and; above R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13are each independently hydrogen, (C1-C5 alkyl) group, H2N-(C1-C5 alkyl)-C(=O)-, (C1-C5 alkyl)HN-(C1-C5 alkyl)-C(=O)-, (C3-C8 heterocycloalkyl)-C(=O)-, H2N-(C1-C5 alkyl)-, (C1-C5 alkyl)HN-(C1-C5 alkyl)-, HO-(C1-C5 alkyl)-C(=O)-, (C3-C8 cycloalkyl) group, (C3-C8 heterocycloalkyl) group, (C7-C 11 Heterobicycloalkyl) group, (C3-C8 cycloalkyl)-(C1-C5 alkyl)-, (C3-C8 heterocycloalkyl)-(C1-C5 alkyl)-, HO-C(=O)-(C1-C5 alkyl)-, (C1-C5 alkyl)-OC(=O)-(C1-C5 alkyl)-, H2N-C(=O)-(C1-C5 alkyl)- or (C1-C5 alkyl)HN-C(=O)-(C1-C5 alkyl)-; and R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 The above (C1-C5 alkyl) group, (C3-C8 cycloalkyl) group and (C3-C8 heterocycloalkyl) group are substituted or unsubstituted with one or more selected from the group consisting of halogens and C1-C5 alkyls; and the above A 2 is -(C1-C5alkyl)-, -(C1-C5alkyl)-O-(C1-C5alkyl)-, -(C1-C5alkyl)HN-C(=O)-(C1-C5alkyl)-, -(C1-C5alkyl)-C(=O)-NH(C1-C5alkyl)-, -C(=O)-(C1-C5alkyl)-, -(C1-C5alkyl)-N(C1-C5alkyl)-(C1-C5alkyl)-, -(C1-C5alkyl)-O-(C1-C5alkyl)-O-(C1-C5alkyl)-, -(C1-C5alkyl)-O-(C1-C5alkyl)-O- or -(C1-C5alkyl)HN-(C1-C5alkyl)-O-(C1-C5alkyl)-; and above A 2 The above (C1-C5 alkyl) and (C1-C5 alkyl)-O are each independently substituted or unsubstituted with one or more selected from the group consisting of halogens and (C1-C5 alkyl); and the above R1 , R 2 , R 4 and R 5 Each is independently hydrogen, a halogen group, a (C1-C5 alkyl) group, a hydroxyl group, an alkoxy group, an amine group, a (C1-C5 alkyl)amine group, a nitrile group, a difluoromethyl group, or a trifluoromethyl group; and R 3 is hydrogen or a (C1-C5 alkyl) group; and R 6 is hydrogen, deuterium, or a (C1-C5 alkyl) group; and the X 1 is NH, C(=O), O, or CF2; and the above X 2 is O, S, or NH; and the above Y can be CH2 or C(=O).
[0015] In one embodiment, the formula 1 is the following formula 1a, 1b, or 1c;
[0016] [Chemical Formula 1a]
[0017]
[0018] [Chemical Formula 1b]
[0019]
[0020] [Chemical Formula 1c]
[0021]
[0022] In the above chemical formulas 1a, 1b, and 1c, R 7 , R 8 , R 9 ,R 10 , R 11 , R 12 and R 13Each is independently hydrogen, (C1-C3 alkyl) group, H2N-(C1-C3 alkyl)-C(=O)-, (C1-C3 alkyl)HN-(C1-C3 alkyl)-C(=O)-, (C3-C6 heterocycloalkyl)-C(=O)-, H2N-(C1-C3 alkyl)-, (C1-C3 alkyl)HN-(C1-C3 alkyl)-, HO-(C1-C3 alkyl)-C(=O)-, (C3-C6 cycloalkyl) group, (C3-C6 heterocycloalkyl) group, (C7-C9 heterobicycloalkyl) group, (C3-C6 cycloalkyl)-(C1-C3 alkyl)-, (C3-C6 heterocycloalkyl)-(C1-C3 alkyl)-, HO-C(=O)-(C1-C5 alkyl)-, (C1-C5 alkyl)-OC(=O)-(C1-C5 alkyl)-, H2N-C(=O)-(C1-C5 alkyl)- or (C1-C5 alkyl)HN-C(=O)-(C1-C5 alkyl)- and R 12 and R 13 It may be connected and formed into a loop.
[0023] In one embodiment, the (C1-C3 alkyl) group, the (C3-C6 cycloalkyl) group, or the (C3-C6 heterocycloalkyl) group may be substituted or unsubstituted with one or more selected from the group consisting of F, Cl, and (C1-C3 alkyl).
[0024] In one embodiment, the A 2 It may be -(C1-C3alkyl)-, -(C1-C3alkyl)-O-(C1-C3alkyl)-, -(C1-C3alkyl)HN-C(=O)-(C1-C3alkyl)-, -(C1-C3alkyl)-C(=O)-NH(C1-C3alkyl)-, -C(=O)-(C1-C3alkyl)-, -(C1-C3alkyl)-N(C1-C3alkyl)-(C1-C3alkyl)-, -(C1-C3alkyl)-O-(C1-C3alkyl)-O-(C1-C3alkyl)-, -(C1-C3alkyl)-O-(C1-C3alkyl)-O- or -(C1-C3alkyl)HN-(C1-C3alkyl)-O-(C1-C3alkyl)-.
[0025] In one embodiment, the (C1-C3alkyl) and (C1-C3alkyl)-O may each be independently substituted or unsubstituted with one or more types selected from the group consisting of F, Cl, and (C1-C3alkyl).
[0026] In one embodiment, the R 1 , R 2 , R 4 and R 5 Each can independently be hydrogen, F, Cl, Br, (C1-C5 alkyl) group, hydroxyl group, alkoxy group, or trifluoromethyl group.
[0027] In one embodiment, the R 3 It can be hydrogen, methyl group, ethyl group, propyl group, or iso-propyl group.
[0028] In one embodiment, the R 6 It can be hydrogen, deuterium, or a methyl group.
[0029] In one embodiment, the X 1 It can be NH, C(=O), or CF2.
[0030] In one embodiment, the X 2 can be O or S.
[0031] In one embodiment, Y may be CH2 or C(=O).
[0032] In one embodiment, the compound of Formula 1 may be any one selected from the group consisting of the following compound numbers 1 to 81.
[0033] Compound No. 1: 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0034] Compound No. 2: 1-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-(4-(((methylamino)oxy)methyl)phenyl)urea;
[0035] Compound No. 3: 1-(4-(2-(2-(aminooxy)ethoxy)ethyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride;
[0036] Compound No. 4: 1-(3-chloro-4-(((methylamino)oxy)methyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0037] Compound No. 5: 1-(4-((aminooxy)methyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride;
[0038] Compound No. 6: 2-amino-N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)acetamide;
[0039] Compound No. 7: N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-2-(methylamino)acetamide;
[0040] Compound No. 8: N-((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)azetidine-3-carboxamide;
[0041] Compound No. 9: 3-amino-N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)propanamide hydrochloride;
[0042] Compound No. 10: N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-3-(methylamino)propanamide hydrochloride;
[0043] Compound No. 1: 4-amino-N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)butanamide hydrochloride;
[0044] Compound No. 12: N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-4-(methylamino)butanamide hydrochloride;
[0045] Compound No. 13: 2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-N-(2-((methylamino)oxy)ethyl)acetamide;
[0046] Compound No. 14: 2-(aminooxy)-N-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethyl)acetamide;
[0047] Compound No. 15: N-(2-aminoethoxy)-2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)acetamide hydrochloride;
[0048] Compound No. 16: 2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-N-(2-(methylamino)ethoxy)acetamide;
[0049] Compound No. 17: N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-2-hydroxyacetamide;
[0050] Compound No. 18: N-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)2-hydroxy-N-methylacetamide;
[0051] Compound No. 19: (2R)-N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-2-hydroxypropanamide;
[0052] Compound No. 20: (2R)-N-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)2-hydroxy-N-methylpropanamide;
[0053] Compound No. 21: 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)urea;
[0054] Compound No. 22: 1-(3-chloro-4-(2-(2-((ethylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride;
[0055] Compound No. 23: 1-(3-chloro-4-(2-(2-((isopropylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride;
[0056] Compound No. 24: 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)thiourea hydrochloride;
[0057] Compound No. 25: 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea hydrochloride;
[0058] Compound No. 26: 1-(3-chloro-4-(1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride;
[0059] Compound No. 27: 1-(3-chloro-4-(1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea hydrochloride;
[0060] Compound No. 28: 1-(3-chloro-4-(1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)methyl)thiourea hydrochloride;
[0061] Compound No. 29: 1-(3-chloro-4-(1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)thiourea hydrochloride;
[0062] Compound No. 30: 1-(4-(2-(2-(aminooxy)ethoxy)ethyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)methyl)thiourea hydrochloride;
[0063] Compound No. 31: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0064] Compound No. 32: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0065] Compound No. 33: 1-(3-chloro-4-(2-(methyl(2-((methylamino)oxy)ethyl)amino)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride;
[0066] Compound No. 34: 1-(4-((aminooxy)methyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)thiourea hydrochloride;
[0067] Compound No. 35: 1-(3-chloro-4-(2-(2-((dimethylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0068] Compound No. 36: 1-(3-chloro-4-(2-(2-((cyclopentylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0069] Compound No. 37: 1-(3-chloro-4-(2-(2-((cyclobutylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0070] Compound No. 38: 1-(3-chloro-4-((4-(((methylamino)oxy)methyl)piperidine-1-yl)methyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea 2,2,2-trifluoroacetate;
[0071] Compound No. 39: 1-(3-chloro-4-(3,6,9-trioxa-2-azaudecane-11-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)methyl)urea hydrochloride;
[0072] Compound No. 40: 1-(3-chloro-4-(6-methyl-3,7-dioxa-2,6-diazanonnan-9-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0073] Compound No. 41: 1-(3-chloro-4-(1-(2-((cyclobutylamino)oxy)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0074] Compound No. 42: 1-(3-chloro-4-(1-(2-((cyclobutylamino)oxy)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea;
[0075] Compound No. 43: N-(2-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenyl)-2-methylpropoxy)ethoxy)-2-hydroxy-N-methylacetamide;
[0076] Compound No. 44: (2R)-N-(2-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenyl)-2-methylpropoxy)ethoxy)-2-hydroxy-N-methylpropanamide;
[0077] Compound No. 45: 1-(3-chloro-4-(1-(2-(((3,3-difluorocyclobutyl)amino)oxy)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0078] Compound No. 46: 2-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-N-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-oxoacetamide;
[0079] Compound No. 47: N-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-2-oxoacetamide;
[0080] Compound No. 48: 2-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-N-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-oxoacetamide;
[0081] Compound No. 49: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)thiourea;
[0082] Compound No. 50: 1-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-(3-methyl-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)urea;
[0083] Compound No. 51: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1R)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea;
[0084] Compound No. 52: 1-(3-chloro-4-(2-methyl-1-(2-((oxetane-3-ylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea;
[0085] Compound No. 53: 1-(4-(1-(2-(aminooxy)ethoxy)-2-methylpropane-2-yl)-3-chlorophenyl)-3-((1R)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea;
[0086] Compound No. 54: 1-(4-(1-(2-(aminooxy)ethoxy)-2-methylpropane-2-yl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea;
[0087] Compound No. 55: 1-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)-3-(3-methyl-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)urea 2,2,2-trifluoroacetate;
[0088] Compound No. 56: 1-(3-chloro-4-(2-((methylamino)oxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0089] Compound No. 57: 1-(3-chloro-4-(2-(2-((isopropylamino)oxy)ethoxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0090] Compound No. 58: 1-(3-chloro-4-(2-(2-(methoxyamino)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0091] Compound No. 59: 1-(3-chloro-4-(2-(2-(methoxyamino)ethoxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0092] Compound No. 60: 1-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-(4-(2-(2-((methylamino)oxy)ethoxy)ethyl)-3-(trifluoromethyl)phenyl)urea;
[0093] Compound No. 61: 1-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)-3-(4-(2-(2-((methylamino)oxy)ethoxy)ethyl)-3-(trifluoromethyl)phenyl)urea;
[0094] Compound No. 62: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)methyl)urea;
[0095] Compound No. 63: 1-(4-(1-(2-(((2-azaspiro[3,3]heptane-6-yl)amino)oxy)ethoxy)-2-methylpropane-2-yl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea;
[0096] Compound No. 64: 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((1R)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0097] Compound No. 65: 1-(3-chloro-4-(2-(2-((cyclobutylamino)oxy)ethoxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0098] Compound No. 66: 1-(3-chloro-4-(2-methyl-1-(2-(((1-methylazetidin-3-yl)amino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0099] Compound No. 67: 1-(3-chloro-4-(1-(2-(((1,1-dioxydothiethane-3-yl)amino)oxy)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)methyl)urea;
[0100] Compound No. 68: 1-(3-chloro-4-(2-((((cyclopropylmethyl)amino)oxy)ethoxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0101] Compound No. 69: 1-(3-chloro-4-(2-((((cyclopropylmethyl)amino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0102] Compound No. 70: 1-(4-(1-(2-(((2-oxaspyro[3,3]heptane-6-yl)amino)oxy)ethoxy)-2-methylpropane-2-yl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea;
[0103] Compound No. 71: 1-(4-(2-(4-aminopiperazine-1-yl)ethyl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea 2,2,2-trifluoroacetate;
[0104] Compound No. 72: 1-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)-3-(4-(1-(2-((methylamino)oxy)ethoxy)propane-2-yl)-3-(trifluoromethyl)phenyl)urea;
[0105] Compound No. 73: 1-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)-3-(4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)-3-(trifluoromethyl)phenyl)urea;
[0106] Compound No. 74: 1-(3-chloro-4-(1-(2-(((cyclopropylmethyl)amino)oxy)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0107] Compound No. 75: 1-(3-chloro-4-(1-(2-(methoxyamino)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea;
[0108] Compound No. 76: 1-(3-chloro-4-(1-(2-(isopropoxyamino)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea;
[0109] Compound No. 77: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)propyl)urea;
[0110] Compound No. 78: 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethoxy)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0111] Compound No. 79: 1-(3-chloro-4-((2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)oxy)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0112] Compound No. 80: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-4-methoxy-1-oxoisoindolin-5-yl)methyl)urea;
[0113] Compound No. 81: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-4-hydroxy-1-oxoisoindolin-5-yl)methyl)urea.
[0114] In one embodiment, the pharmaceutically acceptable salt may be a salt of an inorganic or organic acid selected from the group consisting of hydrochloric acid, hydrobromide, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvate, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid, and toluenesulfonic acid.
[0115] The present invention also provides a pharmaceutical composition for the prevention, alleviation, or treatment of cancer comprising the above compound as an active ingredient.
[0116] In one embodiment, the pharmaceutical composition may have neo-substrate decomposition activity.
[0117] The urea derivative compound according to the present invention can be usefully used for the prevention, alleviation, or treatment of cancer by decomposing the neosubstrate.
[0118] The urea derivative compound according to the present invention can improve the neosubstrate degradation rate and maximum degradation capacity by specifically introducing -NO-, -ON-, or -NN- type functional groups at the structural ends, thereby influencing the binding affinity between cereblon and the target protein, and consequently, the cancer cell killing effect can also be enhanced. Furthermore, due to its structural characteristics, it can be used as an antibody conjugate drug.
[0119] Preferred embodiments of the present invention are described in detail below. In describing the present invention, detailed descriptions of related prior art are omitted if it is determined that such detailed descriptions may obscure the essence of the invention. Throughout the specification, singular expressions should be understood to include plural expressions unless the context clearly indicates otherwise, and terms such as “comprising” or “having” are intended to specify the existence of the described features, numbers, steps, actions, components, parts, or combinations thereof, and should not be understood as precluding the existence or addition of one or more other features, numbers, steps, actions, components, parts, or combinations thereof. Furthermore, in carrying out the method or manufacturing method, each process constituting the method may occur in a different order than specified unless the context clearly indicates a specific order. That is, each process may occur in the same order as specified, may be performed substantially simultaneously, or may be performed in the reverse order.
[0120] The technology disclosed in this specification is not limited to the embodiments described herein and may be embodied in other forms. The embodiments introduced herein are provided merely to ensure that the disclosed content is thorough and complete, and to ensure that the technical concept of the technology is sufficiently conveyed to those skilled in the art. In the drawings, the dimensions, such as the width or thickness of each component, have been slightly enlarged to clearly represent the components of each device. The drawings are described from the perspective of an observer, and where one element is mentioned as being positioned above another element, this implies both that the element is positioned directly above the other element and that an additional element may be interposed between them. Furthermore, those skilled in the art may embody the concept of the invention in various other forms without departing from the technical concept of the invention. Also, in multiple drawings, the same reference numerals refer to substantially identical elements.
[0121] In this specification, the term "and / or" includes a combination of the plurality of described items or any one of the plurality of described items. In this specification, "A or B" may include "A," "B," or "both A and B."
[0122] In the present invention, the terms “individual(s),” “object(s),” and “patient(s)” refer to any mammal. In some embodiments, the mammal may be a human. In some embodiments, the mammal may not be a human. No term requires, or is not limited to, a situation characterized (e.g., constant or intermittent) by a healthcare worker (e.g., physician, licensed nurse, apprentice nurse, physician assistant, janitor, or hospice worker).
[0123] In the present invention, the term "treatment" refers to an attempt made with the intention of preventing the development or alteration of a lesion of a disease. Thus, "treatment" refers to both therapeutic and preventive aspects. Things requiring treatment include not only conditions where the disease is already present, but also conditions where the disease must be prevented. In the treatment of tumors, a therapeutic agent may mean directly reducing the pathology of tumor cells or making tumor cells more sensitive to treatment by other therapeutic agents, e.g., radiation and / or chemotherapy and / or immunotherapy. The terms "reduction" or "treated" as used herein mean an indication of approaching a normalized value measured by conventional statistical tests. An indication of approaching a normalized value may be, for example, a value that differs by less than 50% from a value obtained from a healthy patient or individual, preferably by less than 25%, more preferably by less than 10%, and even more preferably by no significant difference from the normalized value.
[0124] In the present invention, “treatment of cancer” means one or more of the following effects: 1) inhibition of tumor growth, including i) slowing or ii) complete cessation of growth; 2) reduction in the number of tumor cells; 3) maintenance of tumor size; 4) reduction in tumor size; 5) inhibition of tumor cell invasion into peripheral organs, including i) reduction or ii) slowing or iii) complete prevention; 6) inhibition of metastasis, including i) reduction or ii) slowing or iii) complete prevention; 7) enhancement of an anti-tumor immune response, which may cause i) maintenance of tumor size or ii) reduction in tumor size or iii) slowing of tumor growth or iv) reduction, slowing or prevention of invasion.
[0125] Pharmaceutically acceptable excipients, such as vehicles, adjuvants, carriers, or diluents, are readily available to a person skilled in the art when preparing the pharmaceutical composition of the present invention. Pharmaceutically acceptable auxiliary substances, such as pH adjusters and buffers, isotonic adjusters, stabilizers, and wetting agents, are readily available to a person skilled in the art.
[0126] In some embodiments, the compounds of the present invention may be formulated as aqueous buffers. Suitable aqueous buffers include, but are not limited to, acetate, succinate, citrate, and phosphate buffers with varying strengths from 5 mM to 1000 mM. In some embodiments, the aqueous buffer comprises a reagent that provides an isotonic solution. Such reagents include, but are not limited to, sodium chloride, sugars, e.g., mannitol, dextrose, sucrose, etc. In some embodiments, the aqueous buffer may further comprise a nonionic surfactant such as polysorbate 20 or 80. Optionally, the formulation may further comprise a preservative. Suitable preservatives include, but are not limited to, benzyl alcohol, phenol, chlorobutanol, benzalkonium chloride, etc. In other embodiments, the formulation may be stored at about 4 °C. The formulations can also be freeze-dried, and they may generally contain antifreeze agents such as sucrose, trehalose, lactose, maltose, mannitol, etc. Freeze-dried formulations can be stored for a long period of time even at room temperature.
[0127] The pharmaceutical composition of the present invention may comprise or essentially consist of the compound disclosed in the present invention, or its pharmaceutically acceptable salt, isomer, or tautomeric isomer, and additionally, the pharmaceutical composition may comprise or essentially consist of one or more additional active agents of interest. Any active agent may be used in the method together with the compound of the present invention. In one embodiment, the compound of the present invention and the immune checkpoint inhibitor, as well as additional therapeutic agents as described in the present invention for combination therapy, may be administered orally, subcutaneously, intramuscularly, intranasally, parenterally, or by other routes. In another embodiment, the compound of the present invention and the chemotherapy agent and additional therapeutic agents described in the present invention for combination therapy may be administered orally, subcutaneously, intramuscularly, intranasally, parenterally, or by other routes. The compound of the present invention and the second active agent (if present) may be administered by the same route of administration or by different routes of administration. The above therapeutic agent may be administered to the affected organ by any suitable means including, but not limited to, oral, rectal, nasal, topical, vaginal, parenteral, intravenous, intranasal, and intratumoral injections.
[0128] The compound of the present invention may be administered in a unit dosage form and may be prepared by any method well known in the art. Such methods may include the step of combining the compound of the present invention with a pharmaceutically acceptable carrier or diluent constituting one or more auxiliary components. The pharmaceutically acceptable carrier may be selected based on the selected route of administration and standard pharmaceutical practice. Each carrier must be "pharmaceutically acceptable" in that it is compatible with other components of the formulation and does not cause harm to the object or patient. The carrier may be solid or liquid, and the type may be selected according to the type of administration commonly used.
[0129] Examples of suitable solid carriers may include lactose, sucrose, gelatin, agar, and bulk powder. Examples of suitable liquid carriers may include water, pharmaceutically acceptable fats and oils, alcohols or other organic solvents, for example, esters, emulsions, syrups or elixirs, suspensions, and solutions and / or suspensions reconstituted from non-foaming granules. These liquid carriers may contain, for example, suitable solvents, preservatives, emulsifiers, suspending agents, diluents, sweeteners, thickeners, and fluxes.
[0130] In this specification, when described as “C1-C5 alkyl,” it means that the number of carbon atoms is 1 to 5. For example, C1-C3 alkyl means an alkyl having 1 to 3 carbon atoms, and C1-C5 alkyl means an alkyl having 1 to 5 carbon atoms.
[0131] In this specification, when described as “3 to 8 atoms of heterocycloalkyl,” it means a heterocycloalkyl having 3 to 8 atoms having at least one heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur.
[0132] As used herein, the term "alkyl" refers to an aliphatic hydrocarbon radical. An alkyl may be a "saturated alkyl" that does not contain an alkenyl or alkynyl group, or an "unsaturated alkyl" that contains at least one alkenyl or alkynyl group. "Alkenyl" refers to a group containing at least one carbon-carbon double bond, and "alkynyl" refers to a group containing at least one carbon-carbon triple bond. When used alone or in combination, an alkyl may be cyclic, branched, or straight-chain, respectively. Representative saturated straight-chain alkyls include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, and n-decyl. The alkyl group may be optionally substituted.
[0133] The terms “halogen” and “halo” as used in this specification mean fluorine, chlorine, bromine, or iodine.
[0134] As used herein, the term “aryl” means a carbocyclic aromatic monocyclic group comprising six carbon atoms or a polycyclic group in which at least one ring is aromatic, which may be further fused to a second pentagonal or hexagonal carbocyclic group that may be aromatic, saturated, or unsaturated, either alone or in combination with other radicals. Representative examples of aryls include, but are not limited to, phenyl, tolyl, xylyl, naphthyl, tetrahydronaphthyl, anthracenyl, fluorenyl, indenyl, azulenyl, etc. The aryl group may be optionally substituted and may be connected to another group at an appropriate position on the aromatic ring.
[0135] As used herein, "heteroaryl" is an aromatic heterocycle ring comprising at least one carbon atom having at least one heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur, and comprising monocyclic and bicyclic ring systems. Preferably, the heteroaryl group may include, but is not limited to, a furyl group, a thienyl group, a pyrrolyl group, an imidazolyl group, a pyrazolyl group, a triazolyl group, a tetrazolyl group, a thiazolyl group, an oxazolyl group, an oxadiazolyl group, an oxadiazolyl group, a thiazolyl group, a thiazolyl group, an isothiazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a benzofuryl group, a benzothienyl group, an indolyl group, an indazolyl group, a quinoxalinyl group, a quinazolinyl group, a pyridopyrazinyl group, a benzoxadiazolyl group, a benzthiazolyl group, a benztriazolyl group, or a naphthiridinyl group. The heteroaryl group may be optionally substituted.
[0136] In the present invention, the term 'spiro compound' refers, unless otherwise noted, to a compound in which two rings among a cycloalkyl group and a heterocyclyl group are joined by sharing one atom. Preferably, the spiro compound may include a diazaspiro[5,5]undecane group and a diazaspiro[3,5]nonane group, but is not limited thereto.
[0137] As used herein, the term "cycloalkyl" means a monocyclic, spirocyclic, or polycyclic ring having carbon and hydrogen atoms, excluding aromatics. Examples of C3-C8 cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. Cycloalkyl groups may be optionally substituted.
[0138] As used herein, the term "heterocycloalkyl" means a monocyclic, spirocyclic, or polycyclic ring excluding aromatics having at least one heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur. Preferably, the heterocyclyl group may include a dioxalanyl group, a pyrrolyl group, an oxazolyl group, a thiazolyl group, an imidazolyl group, an oxadiazolyl group, a thiadiazolyl group, a triazolyl group, a triazinyl group, an isothiazolyl group, an isooxazolyl group, a thiophenyl group, a pyrazolyl group, a tetrazolyl group, a pyridyl group, a pyridazinyl group, a pyrimidinyl group, a pyrazinyl group, a triazinyl group, or a tetrazinyl group, a pyrrolidinyl group, a furyl group, a morpholine group, a piperazinyl group, or a piperidinyl group, and more preferably may include a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, or a morpholine group, but is not limited thereto. The heterocycloalkyl group may be optionally substituted.
[0139] In this name, the term 'alkoxy' means an alkyl group (i.e., -O-alkyl) connected to another group through an oxygen atom. The alkoxy group may be unsubstituted or substituted with one or more suitable substituents. Examples of alkoxy groups include (C1-C6)alkoxy groups, e.g., -O-methyl, -O-ethyl, -O-propyl, -O-isopropyl, -O-2-methyl-1-propyl, -O-2-methyl-2-propyl, -O-2-methyl-1-butyl, -O-3-methyl-1-butyl, -O-2-methyl-3-butyl, -O-2,2-dimethyl-1-propyl, -O-2-methyl-1-pentyl, 3-O-methyl-1-pentyl, -O-4-methyl-1-pentyl, -O-2-methyl-2-pentyl, -O-3-methyl-2-pentyl, -O-4-methyl-2-pentyl, -O-2,2-dimethyl-1-butyl, -O-3,3-dimethyl-butyl, -O-2-ethyl-1-butyl, -O-butyl, -O-isobutyl, -Ot-butyl, -O-pentyl, -O-isopentyl, -O-neopentyl, and -O-hexyl are included, but not limited to, -O-pentyl, -O-neopentyl, and -O-hexyl.
[0140] In the present invention, the term 'phenoxy' means a phenyl group (i.e., -O-aryl) connected to another group through an oxygen atom. The phenoxy group may be unsubstituted or substituted with one or more halogens; alkyl groups; aryl groups and heteroaryl groups, but is not limited thereto.
[0141] In the present invention, the term 'amino group' means an alkyl group (i.e., -NH- or -N-alkyl) connected to another group through a nitrogen atom. The amino group may be unsubstituted or substituted with one or more suitable substituents. Examples of amino groups include (C1-C6)amino groups, e.g., -NH-methyl, -NH-ethyl, -NH-propyl, -NH-isopropyl, -NH-2-methyl-1-propyl, -NH-2-methyl-2-propyl, -NH-2-methyl-1-butyl, -NH-3-methyl-1-butyl, -NH-2-methyl-3-butyl, -NH-2,2-dimethyl-1-propyl, -NH-2-methyl-1-pentyl, 3-NH-methyl-1-pentyl, -NH-4-methyl-1-pentyl, -NH-2-methyl-2-pentyl, -NH-3-methyl-2-pentyl, -NH-4-methyl-2-pentyl, -NH-2,2-dimethyl-1-butyl, -NH-3,3-dimethyl-butyl, -NH-2-ethyl-1-butyl, -NH-butyl, -NH-isobutyl, -NH-t-butyl, -NH-pentyl, -NH-isopentyl, -NH-neopentyl, -NH-hexyl, -N,N-dimethyl, -N-methyl-N-ethyl, -N-methyl-N-propyl, -N-methyl-isopropyl, -N-methyl-N-butyl, -N-methyl-N-isobutyl, -N-methyl-N-pentyl, -N-methyl-N-isopentyl, N-methyl-N-hexyl, N-methyl-N-isohexyl, -N,N-diethyl, -N-ethyl-N-propyl, -N-ethyl-N-isopropyl, -N-ethyl-N-butyl, -N-ethyl-N-isobutyl, -N-ethyl-N-pentyl, -N-ethyl-N-isopentyl, -N-ethyl-N-hexyl, , Includes, but is not limited to, -N-ethyl-N-isohexyl, -N,N-dipropyl, -N-propyl-N-isopropyl, -N-propyl-N-butyl, -N-propyl-N-isobutyl, -N-propyl-N-pentyl, -N-propyl-N-isopentyl, -N-propyl-N-hexyl, -N-propyl-N-isohexyl, -N,N-dibutyl, -N-butyl-N-isobutyl, -N-butyl-N-pentyl, -N-butyl-N-isopentyl, -N-butyl-N-hexyl, -N-butyl-N-isohexyl, -N,N-dipentyl, -N-pentyl-N-hexyl, -N-pentyl-N-isohexyl, -N,N-dihexyl
[0142] In the present invention, “-” expressed before or after a substituent signifies a “group.” For example, H2N-(C1-C3alkyl)- signifies an H2N-(C1-C3alkyl) group. Additionally, the “-” may signify a portion of the substituent that is bonded to another molecule.
[0143] In the present invention, the isomer refers to all of the structural isomer, cis-trans isomer, diastereomer, and optical isomer.
[0144] The present invention will be described in detail below.
[0145] The present invention relates to a compound selected from urea derivative compounds represented by the following chemical formula 1, pharmaceutically acceptable salts thereof, hydrates thereof, and stereoisomers thereof (hereinafter "urea derivative compounds").
[0146] [Chemical Formula 1]
[0147]
[0148] (In the above chemical formula 1, the above A 1 is R 7 -(R 8 )NO-, R 9 -O-(R 10 )N-, R 11 -(R 12 )N-(R 13 )N- and; above R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13Each is independently hydrogen, an alkyl group, an aminoalkyl carbonyl group, an alkylaminoalkyl carbonyl group, a heterocycloalkyl carbonyl group, an aminoalkyl group, an alkylaminoalkyl group, a hydroxyalkyl carbonyl group, a cycloalkyl group, a halocycloalkyl group, a heterocycloalkyl group, a heterobicycloalkyl group, a cycloalkyl-alkyl group, a heterocycloalkyl-alkyl group, a hydroxycarbonylalkyl group, an alkylhydroxycarbonylalkyl group, an aminecarbonylalkyl group, or an alkylaminecarbonylalkyl group; and R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 The above alkyl group, cycloalkyl group, and heterocycloalkyl group are each independently substituted or unsubstituted with one or more types selected from the group of halogens and alkyls; and the above A 2 is an alkyl group, an alkoxyalkyl group, an alkylaminocarbonylalkyl group, an alkylcarbonylaminoalkyl group, a carbonylalkyl group, an alkylaminoalkyl-alkyl group, an alcoholcy-alkoxyalkyl group, an alkylalkoxy-alkoxy group, or an alkylaminoalkyloxyalkyl group; and the above A 2 The above alkyl group and alkoxy group are substituted or unsubstituted with one or more selected from the group of halogens and alkyls; and the above R 1 , R 2 , R 4 and R 5 Each is independently hydrogen, a halogen group, an alkyl group, a hydroxyl group, an alkoxy group, an amine group, an alkylamine group, a nitrile group, a difluoromethyl group, or a trifluoromethyl group; and R 3 is hydrogen or an alkyl group; and R 6 is hydrogen, deuterium, or an alkyl group; and the X 1 is NH, C(=O), O, or CF2; and the above X 2 is O, S, and NH; and the above Y is CH2 or C(=O))
[0149] The urea derivative compound represented by Formula 1 according to the present invention can be prepared by methods conventional in the art. Pharmaceutically acceptable salts should have low toxicity to the human body and should not adversely affect the biological activity and physicochemical properties of the parent compound. Free acids that can be used to prepare pharmaceutically acceptable salts can be divided into inorganic acids and organic acids. Inorganic acids may include hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, bromic acid, etc. Organic acids may include acetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, fumaric acid, maleic acid, malonic acid, phthalic acid, succinic acid, lactic acid, citric acid, gluconic acid, tartaric acid, salicylic acid, malic acid, oxalic acid, benzoic acid, emvonic acid, aspartic acid, glutamic acid, etc. Organic bases that can be used for the preparation of organic base addition salts include tris(hydroxymethyl)methylamine and dicyclohexylamine. Amino acids that can be used for the preparation of amino acid addition bases are natural amino acids such as alanine and glycine.
[0150] The urea derivative compound represented by Formula 1 according to the present invention may include all hydrates and solvates in addition to the pharmaceutically acceptable salt mentioned above. Hydrates and solvates may be crystallized or recrystallized after dissolving the compound represented by Formula 1 in a water-miscible solvent such as methanol, ethanol, acetone, or 1,4-dioxane, and then adding a free acid or free base. In such cases, solvates (particularly hydrates) may be formed. Thus, in addition to compounds containing various amounts of water that can be prepared by methods such as freeze-drying, the compounds of the present invention may include stoichiometric solvates, including hydrates.
[0151] In one aspect of the present invention,
[0152] Above A 1 is R 7 -(R 8 )NO-, R 9 -O-(R 10 )N-, R 11-(R 12 )N-(R 13 )N- and; above R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 are each independently hydrogen, (C1-C5 alkyl) group, H2N-(C1-C5 alkyl)-C(=O)-, (C1-C5 alkyl)HN-(C1-C5 alkyl)-C(=O)-, (C3-C8 heterocycloalkyl)-C(=O)-, H2N-(C1-C5 alkyl)-, (C1-C5 alkyl)HN-(C1-C5 alkyl)-, HO-(C1-C5 alkyl)-C(=O)-, (C3-C8 cycloalkyl) group, (C3-C8 heterocycloalkyl) group, (C7-C 11 Heterobicycloalkyl) group, (C3-C8 cycloalkyl)-(C1-C5 alkyl)-, (C3-C8 heterocycloalkyl)-(C1-C5 alkyl)-, HO-C(=O)-(C1-C5 alkyl)-, (C1-C5 alkyl)-OC(=O)-(C1-C5 alkyl)-, H2N-C(=O)-(C1-C5 alkyl)- or (C1-C5 alkyl)HN-C(=O)-(C1-C5 alkyl)-; and R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 The above (C1-C5 alkyl) group, (C3-C8 cycloalkyl) group and (C3-C8 heterocycloalkyl) group are substituted or unsubstituted with one or more selected from the group consisting of halogens and C1-C5 alkyls; and the above A 2is -(C1-C5alkyl)-, -(C1-C5alkyl)-O-(C1-C5alkyl)-, -(C1-C5alkyl)HN-C(=O)-(C1-C5alkyl)-, -(C1-C5alkyl)-C(=O)-NH(C1-C5alkyl)-, -C(=O)-(C1-C5alkyl)-, -(C1-C5alkyl)-N(C1-C5alkyl)-(C1-C5alkyl)-, -(C1-C5alkyl)-O-(C1-C5alkyl)-O-(C1-C5alkyl)-, -(C1-C5alkyl)-O-(C1-C5alkyl)-O- or -(C1-C5alkyl)HN-(C1-C5alkyl)-O-(C1-C5alkyl)-; and above A 2 The above (C1-C5 alkyl) and (C1-C5 alkyl)-O are each independently substituted or unsubstituted with one or more selected from the group consisting of halogens and (C1-C5 alkyl); and the above R 1 , R 2 , R 4 and R 5 Each is independently hydrogen, a halogen group, a (C1-C5 alkyl) group, a hydroxyl group, an alkoxy group, an amine group, a (C1-C5 alkyl)amine group, a nitrile group, a difluoromethyl group, or a trifluoromethyl group; and R 3 is hydrogen or a (C1-C5 alkyl) group; and R 6 is hydrogen, deuterium, or a (C1-C5 alkyl) group; and the X 1 is NH, C(=O), O, or CF2; and the above X 2 is O, S, or NH; and the above Y can be CH2 or C(=O).
[0153] In one aspect of the present invention,
[0154] The above chemical formula 1 is the following chemical formula 1a, 1b, or 1c;
[0155] [Chemical Formula 1a]
[0156]
[0157] [Chemical Formula 1b]
[0158]
[0159] [Chemical Formula 1c]
[0160]
[0161] In the above chemical formulas 1a, 1b, and 1c, R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 Each is independently hydrogen, (C1-C3 alkyl) group, H2N-(C1-C3 alkyl)-C(=O)-, (C1-C3 alkyl)HN-(C1-C3 alkyl)-C(=O)-, (C3-C6 heterocycloalkyl)-C(=O)-, H2N-(C1-C3 alkyl)-, (C1-C3 alkyl)HN-(C1-C3 alkyl)-, HO-(C1-C3 alkyl)-C(=O)-, (C3-C6 cycloalkyl) group, (C3-C6 heterocycloalkyl) group, (C7-C9 heterobicycloalkyl) group, (C3-C6 cycloalkyl)-(C1-C3 alkyl)-, (C3-C6 heterocycloalkyl)-(C1-C3 alkyl)-, HO-C(=O)-(C1-C5 alkyl)-, (C1-C5 alkyl)-OC(=O)-(C1-C5 alkyl)-, H2N-C(=O)-(C1-C5 alkyl)- or (C1-C5 alkyl)HN-C(=O)-(C1-C5 alkyl)- and R 12 and R 13 It may be cyclic.
[0162] In one aspect of the present invention,
[0163] The above (C1-C3 alkyl) group, the above (C3-C6 cycloalkyl) group, or the above (C3-C6 heterocycloalkyl) group may be substituted or unsubstituted with one or more types selected from the group consisting of F, Cl, and (C1-C3 alkyl).
[0164] In one aspect of the present invention,
[0165] Above A 2It may be -(C1-C3alkyl)-, -(C1-C3alkyl)-O-(C1-C3alkyl)-, -(C1-C3alkyl)HN-C(=O)-(C1-C3alkyl)-, -(C1-C3alkyl)-C(=O)-NH(C1-C3alkyl)-, -C(=O)-(C1-C3alkyl)-, -(C1-C3alkyl)-N(C1-C3alkyl)-(C1-C3alkyl)-, -(C1-C3alkyl)-O-(C1-C3alkyl)-O-(C1-C3alkyl)-, -(C1-C3alkyl)-O-(C1-C3alkyl)-O- or -(C1-C3alkyl)HN-(C1-C3alkyl)-O-(C1-C3alkyl)-.
[0166] In one aspect of the present invention,
[0167] The above (C1-C3alkyl) and (C1-C3alkyl)-O may be substituted or unsubstituted with one or more types selected from the group consisting of F, Cl and (C1-C3alkyl).
[0168] In one aspect of the present invention,
[0169] The above R 1 , R 2 , R 4 and R 5 Each can independently be hydrogen, F, Cl, Br, (C1-C5 alkyl) group, hydroxyl group, alkoxy group, or trifluoromethyl group.
[0170] In one aspect of the present invention,
[0171] The above R 3 It can be hydrogen, methyl group, ethyl group, propyl group, or iso-propyl group.
[0172] In one aspect of the present invention,
[0173] The above R 6 It can be hydrogen, deuterium, or a methyl group.
[0174] In one aspect of the present invention,
[0175] The above X 1 It can be NH, C(=O), or CF2.
[0176] In one aspect of the present invention,
[0177] The above X 2 can be O or S.
[0178] In one aspect of the present invention,
[0179] The above Y can be CH2 or C(=O).
[0180] In one aspect of the present invention,
[0181] The compound of Chemical Formula 1 above may be any one selected from the group consisting of the following compound numbers 1 to 81.
[0182] Compound No. 1: 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0183] Compound No. 2: 1-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-(4-(((methylamino)oxy)methyl)phenyl)urea;
[0184] Compound No. 3: 1-(4-(2-(2-(aminooxy)ethoxy)ethyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride;
[0185] Compound No. 4: 1-(3-chloro-4-(((methylamino)oxy)methyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0186] Compound No. 5: 1-(4-((aminooxy)methyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride;
[0187] Compound No. 6: 2-amino-N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)acetamide;
[0188] Compound No. 7: N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-2-(methylamino)acetamide;
[0189] Compound No. 8: N-((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)azetidine-3-carboxamide;
[0190] Compound No. 9: 3-amino-N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)propanamide hydrochloride;
[0191] Compound No. 10: N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-3-(methylamino)propanamide hydrochloride;
[0192] Compound No. 1: 4-amino-N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)butanamide hydrochloride;
[0193] Compound No. 12: N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-4-(methylamino)butanamide hydrochloride;
[0194] Compound No. 13: 2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-N-(2-((methylamino)oxy)ethyl)acetamide;
[0195] Compound No. 14: 2-(aminooxy)-N-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethyl)acetamide;
[0196] Compound No. 15: N-(2-aminoethoxy)-2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)acetamide hydrochloride;
[0197] Compound No. 16: 2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-N-(2-(methylamino)ethoxy)acetamide;
[0198] Compound No. 17: N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-2-hydroxyacetamide;
[0199] Compound No. 18: N-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)2-hydroxy-N-methylacetamide;
[0200] Compound No. 19: (2R)-N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-2-hydroxypropanamide;
[0201] Compound No. 20: (2R)-N-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)2-hydroxy-N-methylpropanamide;
[0202] Compound No. 21: 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)urea;
[0203] Compound No. 22: 1-(3-chloro-4-(2-(2-((ethylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride;
[0204] Compound No. 23: 1-(3-chloro-4-(2-(2-((isopropylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride;
[0205] Compound No. 24: 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)thiourea hydrochloride;
[0206] Compound No. 25: 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea hydrochloride;
[0207] Compound No. 26: 1-(3-chloro-4-(1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride;
[0208] Compound No. 27: 1-(3-chloro-4-(1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea hydrochloride;
[0209] Compound No. 28: 1-(3-chloro-4-(1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)methyl)thiourea hydrochloride;
[0210] Compound No. 29: 1-(3-chloro-4-(1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)thiourea hydrochloride;
[0211] Compound No. 30: 1-(4-(2-(2-(aminooxy)ethoxy)ethyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)methyl)thiourea hydrochloride;
[0212] Compound No. 31: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0213] Compound No. 32: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0214] Compound No. 33: 1-(3-chloro-4-(2-(methyl(2-((methylamino)oxy)ethyl)amino)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride;
[0215] Compound No. 34: 1-(4-((aminooxy)methyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)thiourea hydrochloride;
[0216] Compound No. 35: 1-(3-chloro-4-(2-(2-((dimethylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0217] Compound No. 36: 1-(3-chloro-4-(2-(2-((cyclopentylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0218] Compound No. 37: 1-(3-chloro-4-(2-(2-((cyclobutylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0219] Compound No. 38: 1-(3-chloro-4-((4-(((methylamino)oxy)methyl)piperidine-1-yl)methyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea 2,2,2-trifluoroacetate;
[0220] Compound No. 39: 1-(3-chloro-4-(3,6,9-trioxa-2-azaudecane-11-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)methyl)urea hydrochloride;
[0221] Compound No. 40: 1-(3-chloro-4-(6-methyl-3,7-dioxa-2,6-diazanonnan-9-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0222] Compound No. 41: 1-(3-chloro-4-(1-(2-((cyclobutylamino)oxy)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0223] Compound No. 42: 1-(3-chloro-4-(1-(2-((cyclobutylamino)oxy)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea;
[0224] Compound No. 43: N-(2-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenyl)-2-methylpropoxy)ethoxy)-2-hydroxy-N-methylacetamide;
[0225] Compound No. 44: (2R)-N-(2-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenyl)-2-methylpropoxy)ethoxy)-2-hydroxy-N-methylpropanamide;
[0226] Compound No. 45: 1-(3-chloro-4-(1-(2-(((3,3-difluorocyclobutyl)amino)oxy)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0227] Compound No. 46: 2-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-N-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-oxoacetamide;
[0228] Compound No. 47: N-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-2-oxoacetamide;
[0229] Compound No. 48: 2-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-N-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-oxoacetamide;
[0230] Compound No. 49: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)thiourea;
[0231] Compound No. 50: 1-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-(3-methyl-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)urea;
[0232] Compound No. 51: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1R)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea;
[0233] Compound No. 52: 1-(3-chloro-4-(2-methyl-1-(2-((oxetane-3-ylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea;
[0234] Compound No. 53: 1-(4-(1-(2-(aminooxy)ethoxy)-2-methylpropane-2-yl)-3-chlorophenyl)-3-((1R)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea;
[0235] Compound No. 54: 1-(4-(1-(2-(aminooxy)ethoxy)-2-methylpropane-2-yl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea;
[0236] Compound No. 55: 1-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)-3-(3-methyl-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)urea 2,2,2-trifluoroacetate;
[0237] Compound No. 56: 1-(3-chloro-4-(2-((methylamino)oxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0238] Compound No. 57: 1-(3-chloro-4-(2-(2-((isopropylamino)oxy)ethoxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0239] Compound No. 58: 1-(3-chloro-4-(2-(2-(methoxyamino)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0240] Compound No. 59: 1-(3-chloro-4-(2-(2-(methoxyamino)ethoxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0241] Compound No. 60: 1-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-(4-(2-(2-((methylamino)oxy)ethoxy)ethyl)-3-(trifluoromethyl)phenyl)urea;
[0242] Compound No. 61: 1-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)-3-(4-(2-(2-((methylamino)oxy)ethoxy)ethyl)-3-(trifluoromethyl)phenyl)urea;
[0243] Compound No. 62: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)methyl)urea;
[0244] Compound No. 63: 1-(4-(1-(2-(((2-azaspiro[3,3]heptane-6-yl)amino)oxy)ethoxy)-2-methylpropane-2-yl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea;
[0245] Compound No. 64: 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((1R)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0246] Compound No. 65: 1-(3-chloro-4-(2-(2-((cyclobutylamino)oxy)ethoxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0247] Compound No. 66: 1-(3-chloro-4-(2-methyl-1-(2-(((1-methylazetidin-3-yl)amino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0248] Compound No. 67: 1-(3-chloro-4-(1-(2-(((1,1-dioxydothiethane-3-yl)amino)oxy)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)methyl)urea;
[0249] Compound No. 68: 1-(3-chloro-4-(2-((((cyclopropylmethyl)amino)oxy)ethoxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0250] Compound No. 69: 1-(3-chloro-4-(2-((((cyclopropylmethyl)amino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0251] Compound No. 70: 1-(4-(1-(2-(((2-oxaspyro[3,3]heptane-6-yl)amino)oxy)ethoxy)-2-methylpropane-2-yl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea;
[0252] Compound No. 71: 1-(4-(2-(4-aminopiperazine-1-yl)ethyl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea 2,2,2-trifluoroacetate;
[0253] Compound No. 72: 1-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)-3-(4-(1-(2-((methylamino)oxy)ethoxy)propane-2-yl)-3-(trifluoromethyl)phenyl)urea;
[0254] Compound No. 73: 1-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)-3-(4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)-3-(trifluoromethyl)phenyl)urea;
[0255] Compound No. 74: 1-(3-chloro-4-(1-(2-(((cyclopropylmethyl)amino)oxy)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0256] Compound No. 75: 1-(3-chloro-4-(1-(2-(methoxyamino)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea;
[0257] Compound No. 76: 1-(3-chloro-4-(1-(2-(isopropoxyamino)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea;
[0258] Compound No. 77: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)propyl)urea;
[0259] Compound No. 78: 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethoxy)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0260] Compound No. 79: 1-(3-chloro-4-((2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)oxy)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0261] Compound No. 80: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-4-methoxy-1-oxoisoindolin-5-yl)methyl)urea;
[0262] Compound No. 81: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-4-hydroxy-1-oxoisoindolin-5-yl)methyl)urea.
[0263] The urea derivative compound according to the present invention can improve the neosubstrate degradation rate and maximum degradation capacity by specifically introducing -NO-, -ON-, or -NN- type functional groups at the structural ends, thereby influencing the binding affinity between cereblon and the target protein, and consequently, the cancer cell killing effect can also be enhanced. Furthermore, due to its structural characteristics, it can be used as an antibody conjugate drug.
[0264] In the case of conventionally used compounds, the functional group at the structural end is an alkyl group or has oxygen or nitrogen independently in the alkyl group, but in the case of the present invention, as described above, it has a specific functional group containing nitrogen and oxygen consecutively at the structural end, so it can have higher activity compared to conventionally used compounds.
[0265] Generally, a neosubstrate refers to a protein that was not originally a substrate of E3 ubiquitin ligase, but becomes a new substrate of E3 ligase through specific technology (PROTAC, molecular glue, etc.) and is subsequently ubiquitinated and degraded.
[0266] Among various neosubstrates, for example, GSPT1 (G1 to S phase transition protein 1) has been identified as an oncogenic driver involved in various cellular processes such as cell cycle progression, cytoskeletal formation, and apoptosis. It is overexpressed in various types of cancer, including acute myeloid leukemia, gastric cancer, breast cancer, and liver cancer. Since reduced function and decreased expression of GSPT1 can inhibit tumor cell proliferation, migration, and invasion, GSPT1 is a promising target protein for anticancer drug development. However, designing traditional small molecule inhibitors for GSPT1 protein has been difficult due to the lack of well-defined binding pockets or active sites. Recently, however, GSPT1 protein degraders have been utilized as a powerful modality that degrades and removes GSPT1 protein through the ubiquitin-proteasome system (UPS) by acting as a molecular glue that induces interactions between GSPT1 protein and E3 ubiquitin ligase. When the GSPT1 protein is degraded, problems occur in the final stage of novel protein translation, which disrupts normal protein synthesis. Consequently, the resulting proteins are misfolded, mislocated, or have altered functions, causing serious homeostatic problems within the cell. This activates the Integrated Stress Response (ISR), and if the resulting changes in the expression of stress response genes exceed an internal threshold, apoptosis occurs.
[0267] That is, in the case of the urea derivative compound of the present invention, by degrading the neo-substrate as described above, the finally degraded neo-substrate induces serious problems in the homeostasis of related proteins, thereby inducing the death of abnormal cells, particularly cancer cells.
[0268] In one aspect of the present invention,
[0269] The above pharmaceutically acceptable salt may be a salt of an inorganic or organic acid selected from the group consisting of hydrochloric acid, hydrobromide, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvate, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid, and toluenesulfonic acid.
[0270] The present invention also relates to a pharmaceutical composition for the prevention, alleviation, or treatment of cancer comprising the above-mentioned compound as an active ingredient.
[0271] In another aspect of the present invention,
[0272] The above pharmaceutical composition may have neo-substrate degrading activity.
[0273] In this specification, the treatment of cancer refers to the treatment of all cancer cells, and cancer includes the angiogenesis of endothelial cells and their mitosis (solid tumors, tumor metastasis, and benign tumors). For example, cancer may include, but is not limited to, breast cancer, ovarian cancer, cervical cancer, prostate cancer, testicular cancer, genitourinary cancer, esophageal cancer, laryngeal cancer, glioblastoma, gastric cancer, skin cancer, keratosquamoma, lung cancer, squamous cell carcinoma, large cell carcinoma, small cell carcinoma, lung adenocarcinoma, bone cancer, colon cancer, adenoma, pancreatic cancer, adenocarcinoma, thyroid cancer, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, sarcoma, bladder cancer, liver cancer and biliary duct cancer, kidney cancer, myeloid disease, lymphoid disease, Hodgkin's disease, hair cell carcinoma, oral cancer, pharyngeal (oral) cancer, lip cancer, tongue cancer, small intestine cancer, colorectal cancer, colon cancer, rectal cancer, brain cancer, central nervous system cancer, leukemia, hemangioma, trachoma or pyogenic sarcoma.
[0274] Depending on the use and method of use of the pharmaceutical composition of the present invention, the content of the compound represented by Chemical Formula 1, the pharmaceutically acceptable salt, or the hydrate thereof, which is the active ingredient, may be appropriately adjusted and used according to the choice of a person skilled in the art.
[0275] For example, the pharmaceutical composition may contain a compound represented by Formula 1, a pharmaceutically acceptable salt or hydrate thereof in an amount of 0.1 to 10 weight%, more preferably 0.5 to 5 weight%, based on the total weight of the composition.
[0276] The compound represented by the above chemical formula 1, its pharmaceutically acceptable salt, or hydrate may be included alone in the above pharmaceutical composition, or may be included together with other pharmacologically acceptable carriers, excipients, diluents, or auxiliary components.
[0277] Examples of the above-mentioned pharmaceutically acceptable carriers, excipients, or diluents include, but are not limited to, one or more selected from the group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, dextrin, calcium carbonate, propylene glycol, liquid paraffin, and physiological saline solution. Any conventional carrier, excipient, or diluent may be used. In addition, the above pharmaceutical composition may further include conventional fillers, extenders, binders, disintegrants, anticoagulants, lubricants, wetting agents, pH adjusters, nutrients, vitamins, electrolytes, alginic acid and its salts, pectic acid and its salts, protective colloids, glycerin, flavorings, emulsifiers, or preservatives.
[0278] The compound of Formula 1 according to the present invention or a pharmaceutically acceptable salt thereof can enhance the therapeutic effect by co-administering it with other anticancer agents or drugs for treating or improving cancer or tumors.
[0279] The method of administration of the above pharmaceutical composition may be oral or parenteral, and may be administered via various routes, such as oral, transdermal, subcutaneous, intravenous, or intramuscularly. In addition, the formulation of the above composition may vary depending on the method of use and may be formulated using methods well known in the art to which the present invention belongs so as to provide rapid, sustained, or delayed release of the active ingredient after administration to mammals. Generally, solid formulations for oral administration include tablets, pills, soft or hard capsules, pills, powders, and granules, and these formulations may be prepared by mixing one or more excipients, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition, lubricants such as magnesium stearate and talc may also be used in addition to simple excipients. Liquid formulations for oral administration include suspensions, oral liquids, emulsions, and syrups. In addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as humectants, sweeteners, flavorings, and preservatives may be included. Forms for parenteral administration may be in the form of creams, lotions, ointments, plasters, liquids and soultions, aerosols, fluid extracts, elixirs, infusions, sachets, patches, or injections. If an injectable formulation is used, it may preferably be in the form of an isotonic aqueous solution or a suspension.
[0280] The above pharmaceutical composition may further contain adjuvants such as sterilizing agents, preservatives, stabilizers, hydrating agents or emulsification promoters, salts and / or buffers for osmotic pressure regulation, and other therapeutically useful substances, and may be formulated according to conventional mixing, granulation, or coating methods, and may also be formulated using appropriate methods known in the art.
[0281] In addition, the dosage of the above pharmaceutical composition may be determined by considering the method of administration, the age and gender of the user, the severity and condition of the patient, the absorption and inactivation rate of the active ingredient in the body, and concomitant drugs, and may be administered once or in divided doses. As an active ingredient of the pharmaceutical composition, it may preferably be administered to mammals, including humans, by an oral or parenteral route in an amount of 0.001 to 100 mg / kg body weight, preferably 0.01 to 35 mg / kg body weight, on a daily basis, once a day or in divided doses.
[0282] Another embodiment of the present invention provides a method for treating cancer, comprising the step of administering a therapeutically effective amount of a urea derivative compound represented by Formula 1.
[0283] Preferably, the above treatment method may additionally include a step of identifying a patient who requires prevention or treatment of the cancer prior to the administration step.
[0284] The “therapeutic effective amount” of the present invention refers to an amount of an active ingredient for mammals that is effective for the prevention or treatment of cancer, and the therapeutic effective amount may be adjusted according to various factors including the type of disease, the severity of the disease, the type and content of the active ingredient and other ingredients contained in the composition, the type of formulation, the patient’s age, body weight, general health condition, gender and diet, time of administration, route of administration and blood clearance of the composition, duration of treatment, and concurrently used drugs, but preferably, as described above, it may be administered orally or parenterally once a day or in divided doses in an amount of 0.001 to 100 mg / kg body weight, preferably 0.01 to 35 mg / kg body weight per day.
[0285] The present invention is also characterized by a method for preparing a compound represented by the above chemical formula 1.
[0286] Various synthesis methods for starting materials for synthesizing the compounds of the present invention are known, and if the starting materials are commercially available, they may be purchased from suppliers. Reagent suppliers include, but are not limited to, companies such as Sigma-Aldrich, TCI, Wako, Kanto, Fluorchem, Acros, Alfa, Fluka, Combi-blocks, and Dae-Jung. Furthermore, unless otherwise specified, all commercially available materials were used without additional purification.
[0287] In addition, the compound represented by Formula 1 of the present invention may be prepared by the following reaction formulas 1 to 9 or by the method described in the examples. However, the following reaction formulas 1 to 9 are merely examples for explaining the method of preparing Formula 1, and the method of preparing Formula 1 of the present invention is not limited to these reaction formulas.
[0288] [Reaction Equation 1]
[0289]
[0290] Compound 1-2 was obtained by reducing Compound 1-1 with borane, and Compound 1-4 was obtained through substitution and reduction reactions, after which Compound 1-5 was obtained by reducing the nitro group with iron. Compound 1-6 was obtained by introducing a protecting group to the amine group using phthalic anhydride, and then Compound 1-7 was obtained by introducing a leaving group using methanesulfonyl chloride, followed by obtaining Compound 1-8 by substituting a hydroxycarbamate. Compound 1-9 was obtained by removing the protecting group using hydrazine, followed by obtaining the urea form of Compound 1-11 using diphosgene, and then Compound 1 was obtained by removing the protecting group under acidic conditions, and Compound 3 was obtained in the same manner.
[0291] [Reaction Equation 2]
[0292]
[0293] Compound 2-3 was obtained in the same manner as in Reaction Scheme 1, compound 2-4 was obtained through Buchwald-Hartwig coupling under a palladium catalyst, then the protecting group was removed under acidic conditions and compound 2-6 in the urea form was obtained using diphosgene, then compound 2 was obtained by removing the protecting group under acidic conditions, and compounds 4 and 5 were obtained in the same manner.
[0294] [Reaction Equation 3]
[0295]
[0296] Compound 3-4 was obtained by introducing a leaving group to Compound 3-1 and substituting Compound 3-3, and then Compound 3-6 was obtained by removing the protecting group using hydrazine. Compound 3-7 was obtained using a water-based solution, and then Compound 7 was obtained in the same manner as in Reaction Scheme 1, and Compounds 6, 8, 9, 10, and 11 were obtained in a similar manner.
[0297] [Reaction Equation 4]
[0298]
[0299] Compound 4-2 was obtained from Compound 4-1 via Stille cross-coupling, and Compound 4-3 was selectively obtained using (R)-2-methylpropane-2-sulfonamide. After removing the sulfonate group under acidic conditions, Compound 4-5 was obtained using a hydrochloric acid. Compound 4-6 was obtained through hydrolysis, and an ester form of Compound 4-6 was obtained using (trimethylsilyl)diazomethane. The hydroxyl group was then substituted with bromine. Compound 4-10 was obtained through a chain substitution and cyclization reaction using Compound 4-9, and Compound 4-11 was obtained by removing the protecting group under acidic conditions. Compound 4-13 was obtained by substituting dimethyl malonate into Compound 4-12, and Compound 4-14 was obtained through a decarboxylation reaction. Compound 4-15 was obtained by substituting a methyl group. After obtaining compound 4-18 through reduction, substitution, and reduction reactions, compound 4-19 was obtained through the Mitsunobu reaction, and then compound 4-20 was obtained by reduction with iron. Compound 4-21 in the urea form was obtained using phenylchloroformate, and then compound 31 was obtained by removing the protecting group with acid, and in a similar manner, compounds 26, compound 0169, compound 32, compound 41, compound 42, compound 45, compound 51, compound 52, compound 23, compound 54, compound 63, compound 66, compound 37, compound 70, compound 72, compound 73, and compound 74 were obtained.
[0300] [Reaction Equation 5]
[0301]
[0302] Compound 5-2 was obtained by introducing a protecting group with benzoyl to Compound 5-1, and Compound 5-3 was obtained through the Mitsunobu reaction, after which the protecting group was removed to obtain Compound 5-4. Compound 5-5 was obtained by the Mitsunobu reaction of Compound 5-4 and Compound 1-4, and Compound 5-6 was obtained by reduction with iron, and then Compound 5-7 in the urea form was obtained using phenylchloroformate, and then Compound 23 was obtained by removing the protecting group with acid, and in a similar manner, Compounds 22, 25, 36, 37, 50, 55, 56, 57, 60, 61, 64, 65, 68, and 69 were obtained.
[0303] [Reaction Equation 6]
[0304]
[0305] Compound 18 was obtained by amide coupling of Compound 1 with glycolic acid, and Compounds 17, 19, 20, 43, and 44 were obtained in a similar manner.
[0306] [Reaction Equation 7]
[0307]
[0308] Compound 7-1 in the form of a thiourea was obtained using thiocarbonyldiimidazole with compounds 1-9 and 1-10, and then the protecting group was removed under acidic conditions to obtain compound 24, and compounds 28, 29, 30, 34, and 49 were obtained in a similar manner.
[0309] [Reaction Equation 8]
[0310]
[0311] Compound 8-1 was obtained by introducing a leaving group into compound 4-19 and compound 8-2 was obtained through a substitution reaction, compound 8-3 was obtained through a reduction reaction using iron, compound 8-4 in the urea form was obtained using phenylchloroformate, and compound 75 was obtained by removing the protecting group with acid, and compounds 58, 59, and 76 were obtained in a similar manner.
[0312] [Reaction Equation 9]
[0313]
[0314] Compound 9-4 was obtained from compound 9-1 through reduction, substitution, and reduction reactions, then compound 9-5 was obtained through the Mitsunobu reaction, and then compound 9-6 was obtained through the Stille cross-coupling reaction. Compound 9-7 was obtained through an oxidation reaction using selenium oxide, then compound 9-8 in the urea form was obtained using phenylchloroformate, and then compound 48 was obtained by removing the protecting group with acid, and compounds 46 and 47 were obtained in a similar manner.
[0315]
[0316] Hereinafter, preferred embodiments of the present invention will be described with reference to the accompanying drawings so that those skilled in the art can easily implement them. Furthermore, in describing the present invention, if it is determined that a detailed description of related known functions or known configurations may unnecessarily obscure the essence of the invention, such detailed description will be omitted. Also, some features presented in the drawings have been enlarged, reduced, or simplified for ease of explanation, and the drawings and their components are not necessarily depicted in appropriate proportions. However, those skilled in the art will easily understand these details.
[0317]
[0318] Example 1: Synthesis of 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea
[0319] Step 1) Synthesis of 2-(2-chloro-4-nitrophenyl)ethanol-1-ol
[0320]
[0321] Borein dimethyl sulfide complex (10.0 M tetrahydrofuran solution, 5.798 mL, 57.980 mmol) was added to a solution of 2-(2-chloro-4-nitrophenyl)acetic acid (5.000 g, 23.192 mmol) dissolved in tetrahydrofuran (100 mL) at 0°C, and the mixture was heated under reflux for 2 hours, after which the temperature was lowered to room temperature to terminate the reaction. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 25 g cartridge; ethyl acetate / hexane = 20% to 70%) to obtain 2-(2-chloro-4-nitrophenyl)ethanol-1-ol (4.100 g, 87.7%) in the form of a light brown solid.
[0322] Step 2) Synthesis of tert-butyl 2-(2-chloro-4-nitropenetoxy)acetate
[0323]
[0324] A mixture of 2-(2-chloro-4-nitrophenyl)ethanol-1-ol (4.100 g, 20.336 mmol), tert-butyl 2-bromoacetate (11.930 mL, 81.345 mmol), and tetrabutylammonium hydrogen sulfate (5.524 g, 16.269 mmol) was mixed in toluene (40 mL) and stirred at room temperature for 30 hours. Then, sodium hydroxide (5.0 M aqueous solution, 366.053 mL, 1.830 mol) was added and stirred for an additional 2 hours at the same temperature. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 25 g cartridge; ethyl acetate / hexane = 0% to 20%) to obtain tert-butyl 2-(2-chloro-4-nitropenetoxy)acetate (4.500 g, 70.1%) in the form of a yellow liquid.
[0325] Step 3) Synthesis of 2-(2-chloro-4-nitropenetoxy)ethanol-1-ol
[0326]
[0327] Diisobutyl aluminum hydride (DIBAL, 1.0 M tetrahydrofuran solution, 31.354 mL, 31.354 mmol) was added to a solution of tert-butyl 2-(2-chloro-4-nitropenetoxy)acetate (4.500 g, 14.252 mmol) dissolved in tetrahydrofuran (100 mL) at 0 °C and stirred at room temperature for 18 hours. Then, water (5.136 mL, 285.036 mmol) was added to the reaction mixture at 0 °C and stirred for 30 minutes to terminate the reaction. The reaction mixture was filtered through a Celite pad to remove the solid, and a saturated aqueous sodium bicarbonate solution was poured into the filtrate and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 25 g cartridge; ethyl acetate / hexane = 20% to 60%) to obtain 2-(2-chloro-4-nitropenetoxy)ethanol-1-ol (2.360 g, 67.4%) in the form of a yellow liquid.
[0328] Step 4) Synthesis of (2-(4-amino-2-chlorophennetoxy)ethanol-1-ol
[0329]
[0330] A mixture of 2-(2-chloro-4-nitropenetoxy)ethanol-1-ol (1.020 g, 4.729 mmol), ammonium chloride (1.518 g, 28.375 mmol), and iron (2.641 g, 47.292 mmol) was mixed in water (3 mL) and ethanol (15 mL) at room temperature and stirred at 80 °C for 1 hour, after which the temperature was lowered to room temperature to terminate the reaction. The reaction mixture was filtered through a Celite pad to remove the solid, and the filtrate was subjected to solvent removal under reduced pressure to obtain a concentrate. A saturated aqueous sodium bicarbonate solution was poured over the concentrate, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The product was used without further purification (2-(4-amino-2-chlorophennetoxy)ethanol-1-ol, 0.715 g, 70.1%, yellow liquid).
[0331] Step 5) Synthesis of (2-(3-chloro-4-(2-(2-hydroxyethoxy)ethyl)phenyl)isoindolin-1,3-dione
[0332]
[0333] A mixture of 2-(4-amino-2-chlorophennetoxy)ethanol-1-ol (0.715 g, 2.911 mmol) and isobenzofuran-1,3-dione (0.431 g, 2.911 mmol) in acetic acid (5 mL) at room temperature was stirred at 120 °C for 1 hour, after which the temperature was lowered to room temperature to terminate the reaction. The reaction mixture was subjected to solvent removal under reduced pressure to obtain a concentrate, to which an aqueous solution of saturated sodium bicarbonate was poured and extracted with ethyl acetate. The organic layer was washed with an aqueous solution of saturated sodium chloride, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The product was used without further purification (2-(3-chloro-4-(2-(2-hydroxyethoxy)ethyl)phenyl)isoindolin-1,3-dione (1.0 g, 99.4%, brown liquid).
[0334] Step 6) Synthesis of 2-(2-chloro-4-(1,3-dioxoisoindolin-2-yl)phennetoxy)ethyl methanesulfonate
[0335]
[0336] Methanesulfonyl chloride (0.336 mL, 4.338 mmol) and N,N-diisopropylethylamine (1.511 mL, 8.676 mmol) were added to a solution of 2-(3-chloro-4-(2-(2-hydroxyethoxy)ethyl)phenyl)isoindoline-1,3-dione (1.000 g, 2.892 mmol) dissolved in dichloromethane (20 mL) at room temperature, and the mixture was stirred at the same temperature for 2 hours. A saturated aqueous sodium bicarbonate solution was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 40%) to obtain 2-(2-chloro-4-(1,3-dioxoisoindolin-2-yl)phennetoxy)ethyl methanesulfonate (0.856 g, 69.8%) in the form of a brown solid.
[0337] Step 7) Synthesis of tert-butyl (2-(2-chloro-4-(1,3-dioxoisoindolin-2-yl)phennetoxy)ethoxy)(methyl)carbamate
[0338]
[0339] Sodium hydride (60.00% phosphorus mineral oil, 0.089 g, 2.221 mmol) was added to a solution of tert-butyl hydroxy(methyl)carbamate (0.357 g, 2.423 mmol) dissolved in N,N-dimethylformamide (15 mL) at 0 °C, and the mixture was stirred for 30 minutes at the same temperature. 2-(2-chloro-4-(1,3-dioxoisoindolin-2-yl)phennetoxy)ethyl methanesulfonate (0.856 g, 2.020 mmol) was added to the reaction mixture, and the mixture was further stirred for 18 hours at room temperature. A saturated aqueous sodium bicarbonate solution was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 10% to 40%) to obtain tert-butyl (2-(2-chloro-4-(1,3-dioxoisoindolin-2-yl)phennetoxy)ethoxy)(methyl)carbamate (0.267 g, 27.8%) in the form of a brown liquid.
[0340] Step 8) Synthesis of tert-butyl (2-(4-amino-2-chlorophennetoxy)ethoxy)(methyl)carbamate
[0341]
[0342] Hydrazine monohydrate (0.055 mL, 1.124 mmol) was added to a solution of tert-butyl (2-(2-chloro-4-(1,3-dioxoisoindolin-2-yl)phennetoxy)ethoxy)(methyl)carbamate (0.267 g, 0.562 mmol) dissolved in ethanol (10 mL) at room temperature, and the mixture was stirred at 60 °C for 1 hour, after which the temperature was lowered to room temperature to terminate the reaction. The reaction mixture was subjected to solvent removal under reduced pressure to obtain a concentrate, to which a saturated aqueous sodium bicarbonate solution was poured and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 40%) to obtain tert-butyl (2-(4-amino-2-chlorophennetoxy)ethoxy)(methyl)carbamate (0.106 g, 54.7%) in the form of a yellow liquid.
[0343] Step 9) Synthesis of tert-butyl (2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)(methyl)carbamate
[0344]
[0345] Trichloromethyl carbonochloridate (0.074 mL, 0.615 mmol) was added to a solution of tert-butyl (2-(4-amino-2-chlorophennetoxy)ethoxy)(methyl)carbamate (0.106 g, 0.307 mmol) dissolved in tetrahydrofuran (5 mL) at room temperature, stirred for 1 hour at the same temperature, and then concentrated. To the reaction mixture, 3-(5-(aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-diionic hydrochloride (0.07 MN,N-dimethylformamide solution, 5.270 mL, 0.369 mmol) and triethylamine (0.428 mL, 3.074 mmol) were added, and the mixture was further stirred for 1 hour at the same temperature. A saturated aqueous sodium bicarbonate solution was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 5g cartridge; methanol / dichloromethane = 0% to 10%) to obtain tert-butyl(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)(methyl)carbamate (0.089 g, 45.0%) as a bright yellow liquid.
[0346]
[0347] A solution of tert-butyl (2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)(methyl)carbamate (0.089 g, 0.138 mmol) dissolved in trifluoroacetic acid (1 mL) / dichloromethane (3 mL) at room temperature was stirred for 30 minutes at the same temperature. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (C18, 10 g cartridge; acetonitrile / 0.1% aqueous formic acid solution = 0% to 70%) to obtain 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea (0.020 g, 26.6%) in the form of a white solid.
[0348] 1 H-NMR (400 MHz, DMSO-d6) δ 10.93 (s, 1H), 8.73 (s, 1H), 7.64 (m, 2H), 7.47 (s, 1H), 7.40 (d, J = 7.6 Hz, 1H), 7.18 (d, J = 8.0 Hz, 1H), 7.11 (dd, J = 8.4, 2.0 Hz, 1H), 6.76 (t, J = 6.0 Hz, 1H), 6.45 (bs, 1H), 5.06 (dd, J = 13.2, 4.8 Hz, 1H), 4.43 - 4.25 (m, 4H), 3.60 (t, J) = 4.8 Hz, 2H), 3.52 - 3.46 (m, 4H), 2.87 - 2.58 (m, 6H), 2.36 (m, 2H), 1.96 (m, 1H); LRMS (ES) m / z 544.2 [M+H] + .
[0349]
[0350] Example 2: Synthesis of 1-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl))-3-(4-(((methylamino)oxy)methyl)phenyl)urea
[0351] Step 1) Synthesis of 4-Bromobenzyl Methanesulfonate
[0352]
[0353] (4-Bromophenyl)methanol (1 g, 5.3 mmol) was dissolved in dichloromethane (10 mL), and after lowering the temperature to 0 °C, triethylamine (1.5 mL, 10.6 mmol) and methanesulfonyl chloride (0.67 g, 5.8 mmol) were slowly added dropwise. After stirring for 1 hour, ice was added to the reaction mixture. The mixture was extracted three times with dichloromethane, washed with a saturated aqueous sodium chloride solution, and dried with anhydrous sodium sulfate. After removing the solvent by vacuum distillation, 0.97 g of brown solid was obtained.
[0354] Step 2) Synthesis of tert-butyl (4-bromobenzyl)oxy(methyl)carbamate
[0355]
[0356] Tert-butyl hydroxy(methyl)carbamate (0.31 g, 2.08 mmol) was dissolved in N,N-dimethylformamide (4 mL), and after lowering the temperature to 0 °C, sodium hydride (60% phosphorus mineral oil, 83 mg, 2.08 mmol) was added dropwise. After stirring for 30 minutes, 4-bromobenzyl methanesulfonate (0.5 g, 1.89 mmol) was added dropwise. After raising the temperature to room temperature and stirring for 16 hours, and then stirring for 1 hour, ice was added to the reaction mixture. It was extracted three times with dichloromethane, washed with a saturated aqueous sodium chloride solution, and dried with anhydrous sodium sulfate. After removing the solvent by vacuum distillation, the concentrate was purified by column chromatography (SiO2) and concentrated to obtain 0.5 g.
[0357] 1 H-NMR (400 MHz, CDCl3) δ 7.48 (d, 2H), 7.26 (d, 2H), 4.76 (s, 2H), 3.03 (s, 3H), 1.32 (s, 9H).
[0358] Step 3) Synthesis of tert-butyl (4-((tert-butoxycarbonyl)amino)benzyl)oxy(methyl)carbamate
[0359]
[0360] tert-butyl (4-bromobenzyl)oxy(methyl)carbamate (0.17 g, 0.53 mmol), tert-butylcarbamate (0.19 g, 1.58 mmol), tris(dibenzylideneacetone)dipalladium (0.024 g, 0.026 mmol), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (0.050 g, 0.10 mmol), and cesium carbonate (0.86 g, 2.64 mmol) were added to dioxane (5 mL) and stirred at 100 °C under nitrogen for 1.5 hours. Distilled water was added to the reaction mixture, extracted three times with ethyl acetate, washed with a saturated aqueous sodium chloride solution, and dried with anhydrous sodium sulfate. After removing the solvent by vacuum distillation, the concentrate was purified and concentrated by column chromatography (SiO2) to obtain 0.19 g.
[0361] LRMS (ES) m / z 375 [M+Na] + .
[0362] Step 4) Synthesis of tert-butyl (4-aminobenzyl)oxy(methyl)carbamate
[0363]
[0364] Tert-butyl (4-((tert-butoxycarbonyl)amino)benzyl)oxy(methyl)carbamate (0.18 g, 0.51 mmol) was dissolved in dichloromethane (5.3 mL), hydrogen chloride (4.0 M 1,4-dioxane solution, 1.3 mL, 5.1 mmol) was added dropwise at room temperature, and the mixture was stirred for 1 hour. After adding hydrogen chloride (4.0 M 1,4-dioxane solution, 1.3 mL, 5.1 mmol) and stirring for 30 minutes, the solvent was removed by vacuum distillation to obtain a concentrate.
[0365] The concentrate was dissolved in dichloromethane (5 mL) and cooled to 0 °C. Then, triethylamine (0.22 mL, 1.53 mmol) and di-tert-butyl dicarbonate (0.11 g, 0.51 mmol) were added dropwise, and the mixture was stirred for 30 minutes. The temperature was raised to room temperature and stirred for 1.5 hours. Distilled water was added to the reaction mixture, extracted three times with dichloromethane, washed with a saturated aqueous sodium chloride solution, and dried with anhydrous sodium sulfate. After removing the solvent by vacuum distillation, the concentrate was purified by column chromatography (SiO2) and concentrated to obtain 0.05 g.
[0366] 1 H-NMR (400 MHz, CDCl3) δ 7.23 (d, 2H), 6.83 (d, 2H), 5.22 (br, 2H), 4.70 (s, 2H), 3.00 (s, 3H), 1.47 (s, 9H).
[0367] Step 5) Synthesis of tert-butyl (4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy(methyl)carbamate
[0368]
[0369] Trichloromethyl carbonochloridate (0.019 mL, 0.15 mmol) was added to a solution of tert-butyl (4-aminobenzyl)oxy(methyl)carbamate (0.020 g, 0.08 mmol) dissolved in tetrahydrofuran (1 mL) at room temperature, stirred for 1 hour at the same temperature, and then concentrated by vacuum distillation. The concentrate was dissolved in N,N-dimethylformamide (1 mL), and 3-(5-(aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-diionic hydrochloride (29 mg, 0.09 mmol) and triethylamine (0.11 mL, 0.79 mmol) were added at room temperature and stirred for 1.5 hours. Ice was placed on the reaction mixture, extracted three times with ethyl acetate, washed with a saturated aqueous sodium chloride solution, and dried with anhydrous sodium sulfate. After removing the solvent by vacuum distillation, the concentrate was purified and concentrated by column chromatography (SiO2) to obtain 0.03 g.
[0370] LRMS (ES) m / z 574 [M+Na] + .
[0371] Step 6) Synthesis of 1-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl))-3-(4-(((methylamino)oxy)methyl)phenyl)urea
[0372]
[0373] tert-butyl (4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy(methyl)carbamate (0.03 g, 0.06 mmol) was treated with hydrogen chloride (4.0 M 1,4-dioxane solution, 0.15 mL, 0.59 mmol) at room temperature and stirred for 2 hours. After removing the solvent by vacuum distillation, the concentrate was purified by column chromatography (SiO2) and concentrated to obtain 0.02 g.
[0374] LRMS (ES) m / z 456 [M+H] + .
[0375]
[0376] Example 3: Synthesis of 1-(4-(2-(2-(aminooxy)ethoxy)ethyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride
[0377]
[0378] It was synthesized in a manner similar to Example 1.
[0379] 1 H-NMR (400 MHz, DMSO-d6)δ 10.97 (s, 1H), 10.68 (s, 1H), 9.01 (s, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.65 (d, J = 2.0 Hz, 1H), 7.51 (s, 1H), 7.44 (d, J = 8.0 Hz, 1H), 7.22 (d, J = 8.4 Hz, 1H), 7.18 (dd, J = 8.4, 2.0 Hz, 1H), 6.95 (t, J = 6.0 Hz, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.47 - 4.29 (m, 4H), 4.12 - 4.07 (m, 2H), 3.66 - 3.63 (m, 2H), 3.57 (t, J = 3.5 Hz, 2H), 2.96 - 2.88 (m, 1H), 2.86 (t, J = 7.2 Hz, 2H), 2.69 - 2.56 (m, 1H), 2.44 - 2.30 (m, 1H), 2.06 - 1.95 (m, 1H); LRMS (ES) m / z 530.2 [M+H] + .
[0380]
[0381] Example 4: Synthesis of 1-(3-chloro-4-(((methylamino)oxy)methyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea
[0382]
[0383] It was synthesized in a manner similar to Example 2.
[0384] 1 H NMR (400 MHz, Methanol-d4)δ 7.77 (d, J = 7.9 Hz, 1H), 7.61 (d, J = 2.2 Hz, 1H), 7.56 (dq, J = 1.6, 0.8 Hz, 1H), 7.49 (ddt, J = 7.9, 1.4, 0.7 Hz, 1H), 7.34 (d, J = 8.3 Hz, 1H), 7.23 (dd, J = 8.4, 2.2 Hz, 1H), 5.14 (dd, J = 13.3, 5.2 Hz, 1H), 4.73 (s, 2H), 4.54 - 4.42 (m, 4H), 2.97 - 2.86 (m, 1H), 2.78 (ddd, J = 17.7, 4.7, 2.5 Hz, 1H), 2.66 (d, J = 3.1 Hz, 3H), 2.49 (qd, J = 13.3, 4.7 Hz, 1H), 2.21 - 2.12 (m, 1H); LRMS (ES) m / z 485.2 [M+H] + .
[0385]
[0386] Example 5: Synthesis of 1-(4-((aminooxy)methyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride
[0387]
[0388] It was synthesized in a manner similar to Example 2.
[0389] 1H NMR (400 MHz, DMSO-d6)δ 10.93 (br, 1H), 10.75 (s, 2H), 9.23 (s, 1H), 7.74 (dd, J = 2.2, 0.9 Hz, 1H), 7.66 (d, J = 7.7 Hz, 1H), 7.48 (s, 1H), 7.40 (d, J = 7.9 Hz, 1H), 7.34 (d, J = 8.5 Hz, 1H), 7.26 (dd, J = 8.4, 2.2 Hz, 1H), 7.02 (t, J = 6.0 Hz, 1H), 5.07 (dd, J = 13.3, 5.1 Hz, 1H), 4.97 (s, 2H), 4.45 - 4.23 (m, 4H), 2.93 - 2.81 (m, 1H), 2.64 - 2.51 (m, 1H), 2.41 - 2.27 (m, 1H), 2.00 - 1.91 (m, 1H); LRMS (ES) m / z 472.1 [M+H] + .
[0390]
[0391] Example 6: Synthesis of 2-amino-N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)acetamide
[0392]
[0393] It was synthesized in a manner similar to Example 7.
[0394] 1H-NMR (400 MHz, Methanol-d4) δ 11.04 (s, 1H), 9.43 (d, J = 32.9 Hz, 1H), 8.30 (s, 1H), 7.75 (s, 1H), 7.69 (d, J = 7.7 Hz, 1H), 7.51 (s, 1H), 7.44 (d, J = 7.8 Hz, 1H), 7.40 - 7.22 (m, 2H), 5.10 (dd, J = 13.3, 5.0 Hz, 1H), 4.81 (d, J = 6.8 Hz, 2H), 4.39 (dt, J = 45.9, 17.7 Hz, 6H), 2.96 - 2.85 (m, 1H), 2.59 (d, J = 17.6 Hz, 1H), 2.42 - 2.34 (m, 1H), 2.00 (d, J = 7.3 Hz, 1H); LRMS (ES) m / z 529.1 [M+H] + .
[0395]
[0396] Example 7: Synthesis of N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-2-(methylamino)acetamide
[0397] Step 1) Synthesis of 2-chloro-4-nitrobenzyl methanesulfonate
[0398]
[0399] A solution of (2-chloro-4-nitrophenyl)methanol (2.000 g, 10.662 mmol), methanesulfonyl chloride (0.908 mL, 11.728 mmol), and triethylamine (1.626 mL, 11.728 mmol) dissolved in dichloromethane (50 mL) was stirred at room temperature for 1 hour and then stirred for an additional 1 hour at the same temperature. Water was added to the reaction mixture and extracted with dichloromethane. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was used without further purification (2-chloro-4-nitrobenzyl methanesulfonate, 2.900 g, 102.4%, brown liquid).
[0400] Step 2) Synthesis of 2-((2-chloro-4-nitrobenzyl)oxy)isoindolin-1,3-dione
[0401]
[0402] A solution of 2-chloro-4-nitrobenzyl methanesulfonate (2.900 g, 10.916 mmol), N,N-diisopropylethylamine (9.533 mL, 54.581 mmol), and 2-hydroxyisoindolin-1,3-dione (3.562 g, 21.832 mmol) dissolved in dichloromethane (10 mL) was stirred at room temperature for 1 hour and further stirred at the same temperature for 18 hours. Water was added to the concentrate obtained by removing the solvent from the reaction mixture under reduced pressure, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 50%) to obtain 2-((2-chloro-4-nitrobenzyl)oxy)isoindolin-1,3-dione (2.422 g, 66.7%) in the form of a deep orange liquid.
[0403] Step 3) Synthesis of O-(2-chloro-4-nitrobenzyl)hydroxylamine
[0404]
[0405] A solution of 2-((2-chloro-4-nitrobenzyl)oxy)isoindolin-1,3-dione (2.420 g, 7.274 mmol) and hydrazine hydrate (0.728 g, 14.548 mmol) dissolved in ethanol (20 mL) was stirred at room temperature for 0.1 hours and then further stirred at 80 °C for 0.5 hours, after which the temperature was lowered to room temperature to terminate the reaction. Water was added to the concentrate obtained by removing the solvent from the reaction mixture under reduced pressure, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 50%) to obtain O-(2-chloro-4-nitrobenzyl)hydroxylamine (1.550 g, 105.2%) in the form of a brown liquid.
[0406] Step 4) Synthesis of tert-butyl ((2-chloro-4-nitrobenzyl)oxy)carbamate
[0407]
[0408] A solution of O-(2-chloro-4-nitrobenzyl)hydroxylamine (1.500 g, 7.404 mmol), di-tert-butyl dicarbonate (0.889 g, 4.072 mmol), and triethylamine (5.132 mL, 37.021 mmol) dissolved in dichloromethane (10 mL) was stirred at room temperature for 1 hour and further stirred at the same temperature for 18 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 30%) to obtain tert-butyl ((2-chloro-4-nitrobenzyl)oxy)carbamate (1.030 g, 46.0%).
[0409] Step 5) Synthesis of tert-butyl ((4-amino-2-chlorobenzyl)oxy)carbamate
[0410]
[0411] A solution of tert-butyl ((2-chloro-4-nitrobenzyl)oxy)carbamate (1.050 g, 3.469 mmol), iron (0.969 g, 17.343 mmol), and ammonium chloride (0.742 g, 13.875 mmol) dissolved in ethanol (10 mL) and water (2 mL) was stirred at room temperature for 1 hour and then further stirred at 80 °C for 1 hour, after which the temperature was lowered to room temperature to terminate the reaction. Water was added to the concentrate obtained by removing the solvent from the reaction mixture under reduced pressure, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 50%) to obtain tert-butyl ((4-amino-2-chlorobenzyl)oxy)carbamate (0.589 g, 62.3%) in the form of a yellow solid.
[0412] LRMS (ES) m / z 295.1 [M+Na] + .
[0413] Step 6) Synthesis of tert-butyl((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)carbamate
[0414]
[0415] A solution dissolved in tetrahydrofuran (5 mL) / N,N-dimethylformamide (5 mL) was stirred at room temperature for 1 hour, and the mixture was added and stirred for an additional hour at the same temperature. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; methanol / dichloromethane = 0% to 10%) to obtain tert-butyl((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)carbamate (0.196 g, 15.8%).
[0416] LRMS (ES) m / z 594.2 [M+Na] + .
[0417] Step 7) Synthesis of 1-(4-((aminooxy)methyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea
[0418]
[0419] A solution of tert-butyl ((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)carbamate (0.200 g, 0.350 mmol) and hydrogen chloride (4.0 M 1,4-dioxane solution, 0.874 mL, 3.496 mmol) dissolved in dichloromethane (10 mL) was stirred at room temperature for 1 hour and then further stirred at the same temperature for 18 hours. After removing the solvent from the reaction mixture under reduced pressure, the precipitated solid was filtered, washed with hexane, and dried to obtain 1-(4-((aminooxy)methyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea (0.179 g, 108.5%) in the form of a white solid.
[0420] LRMS (ES) m / z 493.2 [M+Na] + .
[0421] Step 8) Synthesis of tert-butyl (2-(((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)amino)-2-oxoethyl)(methyl)carbamate
[0422]
[0423] 1-(4-((aminooxy)methyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea (0.025 g, 0.053 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, 0.012 g, 0.079 mmol), 1H-benzo[d][1,2,3]triazole-1-ol (HOBt, 0.011 g, 0.079 mmol), N,N-diisopropylethylamine (0.037 mL, 0.212 mmol) and N-(tert-butoxycarbonyl)-N-methylglycine (0.012 g, 0.064 mmol) to N,N-dimethylformamide (1 The solution dissolved in mL was stirred at room temperature for 1 hour and further stirred at the same temperature for 18 hours. A saturated aqueous sodium bicarbonate solution was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; methanol / dichloromethane = 0% to 10%) to obtain tert-butyl(2-(((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)amino)-2-oxoethyl)(methyl)carbamate (0.022 g, 64.6%) as a white solid.
[0424] LRMS (ES) m / z 665.2 [M+Na] + .
[0425] Step 9) Synthesis of N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-2-(methylamino)acetamide
[0426]
[0427] A solution of tert-butyl (2-(((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)amino)-2-oxoethyl)(methyl)carbamate (0.020 g, 0.031 mmol) and hydrogen chloride (4.0 M 1,4-dioxane solution, 0.078 mL, 0.311 mmol) dissolved in dichloromethane (1 mL) was stirred at room temperature for 1 hour and further stirred at the same temperature for 18 hours. Water was added to the concentrate obtained by removing the solvent from the reaction mixture under reduced pressure, and the mixture was extracted with dichloromethane. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (C18, 10 g cartridge; acetonitrile / 0.1% aqueous formic acid solution = 0% to 50%) to obtain N-((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-2-(methylamino)acetamide (0.003 g, 18.9%).
[0428] 1H-NMR (400 MHz, Methanol-d4) δ 10.98 (s, 1H), 9.29 (s, 1H), 7.75 (s, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.52 (s, 1H), 7.44 (d, J = 7.8 Hz, 1H), 7.35 (d, J = 8.4 Hz, 1H), 7.27 (d, J = 8.9 Hz, 2H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.84 - 4.80 (m, 2H), 4.48 - 4.26 (m, 6H), 3.79 (d, J = 7.9 Hz, 1H), 2.95 - 2.87 (m, 2H), 2.59 (dd, J = 15.3, 2.3 Hz, 1H), 2.54 - 2.54 (m, 3H), 2.38 (dd, J = 13.2, 4.3 Hz, 1H), 1.98 (d, J = 5.0 Hz, 1H) LRMS (ES) m / z 543.2 [M+H] + .
[0429]
[0430] Example 8: Synthesis of N-((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)azetidine-3-carboxamide
[0431]
[0432] It was synthesized in a manner similar to Example 7.
[0433] 1H-NMR (400 MHz, Methanol-d4) δ 8.52 (s, 1H), 7.77 (d, J = 8.0 Hz, , 1H), 7.66 (d, J = 2.1 Hz, 1H), 7.55 (s, 1H), 7.50 (d, J = 8.1 Hz, 1H), 7.39 (d, J = 8.3 Hz, 1H), 7.27 (dd, J = 8.3, 2.0 Hz, 1H), 5.14 (dd, J = 13.2, 5.1 Hz, 1H), 4.95 (s, 2H), 4.52 (s, 1H), 4.48 (d, J = 7.7 Hz, 1H), 4.18 - 4.14 (m, 3H), 3.47 (dd, J = 15.9, 8.0 Hz, 1H), 2.98 - 2.85 (m, 1H), 2.78 (ddd, J = 17.6, 4.6, 2.4 Hz, 1H), 2.48 (qd, J = 13.2, 4.7 Hz, 1H), 2.17 (dtd, J = 12.7, 5.2, 2.4 Hz, 1H); LRMS (ES) m / z 693.2 [M+H] + .
[0434]
[0435] Example 9: Synthesis of 3-amino-N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)propanamide hydrochloride
[0436]
[0437] It was synthesized in a manner similar to Example 7.
[0438] 1H-NMR (400 MHz, Methanol-d4) δ 7.77 (d, J = 7.9 Hz, 1H), 7.66 (d, J = 1.9 Hz, 1H), 7.56 (s, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.43 - 7.37 (m, 1H), 7.28 (dd, J = 8.3, 2.2 Hz, 1H), 5.14 (dd, J = 13.4, 5.2 Hz, 1H), 4.95 (s, 2H), 4.52 (s, 2H), 4.48 (d, J = 7.7 Hz, 2H), 2.97 - 2.85 (m, 1H), 2.80 - 2.74 (m, 1H), 2.53 - 2.43 (m, 3H), 2.17 (dtd, J = 12.7, 5.2, 2.3 Hz, 1H), 1.27 - 1.21 (m, 2H); LRMS (ES) m / z 543.1 [M+H] + .
[0439]
[0440] Example 10: Synthesis of N-((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-3-(methylamino)propanamide hydrochloride
[0441]
[0442] It was synthesized in a manner similar to Example 7.
[0443] 1H-NMR (400 MHz, Methanol-d4) δ 7.77 (d, J = 7.7 Hz, 1H), 7.66 (s, 1H), 7.56 (s, 1H), 7.50 (d, J = 8.2 Hz, 1H), 7.40 (d, J = 8.6 Hz, 1H), 7.28 (dd, J = 8.4, 2.2 Hz, 1H), 5.15 (dd, J = 13.4, 5.2 Hz, 1H), 4.98 (d, J = 10.7 Hz, 2H), 4.83 - 4.40 (m, 4H), 3.59 (ddd, J = 9.9, 8.7, 5.2 Hz, 1H), 3.35 (s, 3H), 3.27 (d, J = 5.8 Hz, 2H), 2.97 - 2.84 (m, 1H), 2.82 - 2.76 (m, 1H), 2.55 - 2.47 (m, 1H), 2.24 - 2.12 (m, 1H). LRMS (ES) m / z 557.2 [M+H] + .
[0444]
[0445] Example 11: Synthesis of 4-amino-N-((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)butanamide hydrochloride
[0446]
[0447] It was synthesized in a manner similar to Example 7.
[0448] 1H-NMR (400 MHz, Methanol-d4) δ 7.77 (d, J = 7.8 Hz, 1H), 7.65 (s, 1H), 7.56 (s, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.39 (d, J = 8.5 Hz, 1H), 7.28 (dd, J = 8.4, 2.1 Hz, 1H), 5.18 - 5.12 (m, 1H), 4.93 (s, 2H), 4.61 - 4.47 (m, 4H), 2.95 (dd, J = 19.6, 13.8 Hz, 3H), 2.88 (dd, J = 13.4, 5.3 Hz, 1H), 2.84 - 2.74 (m, 1H), 2.55 - 2.43 (m, 1H), 2.28 - 2.19 (m, 2H), 2.19 - 2.11 (m, 1H), 1.92 (dd, J = 14.7, 7.5 Hz, 2H). LRMS (ES) m / z 557.2 [M+H] + .
[0449]
[0450] Example 12: Synthesis of N-((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-4-(methylamino)butanamide hydrochloride
[0451] Step 1)
[0452]
[0453] 1-(4-((aminooxy)methyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea (0.025 g, 0.053 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, 0.012 g, 0.079 mmol), 1H-benzo[d][1,2,3]triazole-1-ol (HOBt, 0.011 g, 0.079 mmol), N,N-diisopropylethylamine (0.037 mL, 0.212 mmol), and 4-((tert-butoxycarbonyl)(methyl)amino)butanoic acid (0.014 g, 0.064 mmol) A solution dissolved in N,N-dimethylformamide (0.5 mL) was stirred at room temperature for 1 hour and further stirred at the same temperature for 18 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; methanol / dichloromethane = 0% to 10%) to obtain tert-butyl (4-(((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)amino)-4-oxobutyl)(methyl)carbamate (0.009 g, 25.3%) in the form of a transparent solid.
[0454] LRMS (ES) m / z 693.2 [M+Na] + .
[0455] Step 2)
[0456]
[0457] A solution of tert-butyl (4-(((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)amino)-4-oxobutyl)(methyl)carbamate (0.009 g, 0.013 mmol) and hydrogen chloride (4.0 M 1,4-dioxane solution, 0.034 mL, 0.134 mmol) dissolved in tetrahydrofuran (0.5 mL) was stirred at room temperature for 1 hour and further stirred at the same temperature for 18 hours. After removing the solvent from the reaction mixture under reduced pressure, the precipitated solid was filtered, washed with hexane, and dried to obtain N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-4-(methylamino)butanamide hydrochloride (0.003 g, 34.4%) in the form of a white solid.
[0458] 1 H-NMR (400 MHz, Methanol-d4) δ 7.78 (s, 1H), 7.66 (s, 1H), 7.56 (s, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.40 (d, J = 8.3 Hz, 1H), 7.30 (dd, J = 15.5, 13.4 Hz, 1H), 5.17 - 5.13 (m, 1H), 4.94 (s, 2H), 4.61 - 4.47 (m, 4H), 3.73 (t, J = 6.7 Hz, 1H), 3.36 (s, 3H), 3.00 (d, J = 4.6 Hz, 2H), 2.90 (dd, J = 11.4, 6.3 Hz, 1H), 2.83 - 2.77 (m, 1H), 2.49 (dd, J = 13.2, 4.6 Hz, 1H), 2.31 - 2.20 (m, 2H), 2.20 - 2.14 (m, 1H), 1.97 - 1.90 (m, 2H); LRMS (ES) m / z 571.2 [M+H] +
[0459]
[0460] Example 13: Synthesis of 2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-N-(2-((methylamino)oxy)ethyl)acetamide
[0461] Step 1) Synthesis of tert-butyl (2-(2-(2-chloro-4-nitrophenyl)acetamido)ethoxy)(methyl)carbamate
[0462]
[0463] A solution of 2-(2-chloro-4-nitrophenyl)acetic acid (0.100 g, 0.464 mmol), tert-butyl (2-aminoethoxy)(methyl)carbamate (0.124 g, 0.649 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (0.247 g, 0.649 mmol), and N,N-diisopropylethylamine (0.243 mL, 1.392 mmol) dissolved in N,N-dimethylformamide (2 mL) was stirred at 0 °C for 1 hour and further stirred at room temperature for 1 hour. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 5g cartridge; methanol / dichloromethane = 0% to 5%) to obtain tert-butyl (2-(2-(2-chloro-4-nitrophenyl)acetamido)ethoxy)(methyl)carbamate (0.235 g, 130.7%) in the form of a white solid.
[0464] LRMS (ES) m / z 410.1 [M+Na] + .
[0465] Step 2) Synthesis of tert-butyl (2-(2-(4-amino-2-chlorophenyl)acetamido)ethoxy)(methyl)carbamate
[0466]
[0467] A solution of tert-butyl (2-(2-(2-chloro-4-nitrophenyl)acetamido)ethoxy)(methyl)carbamate (0.235 g, 0.606 mmol), iron (0.169 g, 3.031 mmol), and ammonium chloride (0.162 g, 3.031 mmol) dissolved in ethanol (3 mL) and water (1 mL) at 80 °C was stirred at the same temperature for 3 hours, after which the temperature was lowered to room temperature to terminate the reaction. The reaction mixture was filtered through Celite to remove the solid, water was added to the filtrate, and the mixture was extracted with dichloromethane. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 5g cartridge; ethyl acetate / hexane = 0% to 80%) to obtain tert-butyl (2-(2-(4-amino-2-chlorophenyl)acetamido)ethoxy)(methyl)carbamate (0.151 g, 69.7%) in the form of a yellow oil.
[0468] LRMS (ES) m / z 358.2 [M+Na] + .
[0469] Step 3) Synthesis of tert-butyl (2-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)acetamido)ethoxy)(methyl)carbamate
[0470]
[0471] tert-butyl (2-(2-(4-amino-2-chlorophenyl)acetamido)ethoxy)(methyl)carbamate (0.272 g, 0.761 mmol) and trichloromethyl chloroformate (0.184 mL, 1.521 mmol) were dissolved in tetrahydrofuran (3 mL) and reacted at 0 °C for 1 hour. After removing all solvent, at room temperature
[0472]
[0473] A solution of tert-butyl (2-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)acetamido)ethoxy)(methyl)carbamate (0.112 g, 0.170 mmol) dissolved in trifluoroacetic acid (1 mL) / dichloromethane (2 mL) at 0 °C was stirred at the same temperature for 2 hours. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (C18, 5 g cartridge; acetonitrile / 0.1% aqueous formic acid solution = 0% to 60%) to obtain 2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-N-(2-((methylamino)oxy)ethyl)acetamide (0.013 g, 13.5%) in the form of a white solid.
[0474] 1 H NMR (400 MHz, Methanol-d4)δ 7.73 (d, J = 7.9 Hz, 1H), 7.61 (d, J = 2.0 Hz, 1H), 7.52 (s, 1H), 7.46 (dd, J = 7.9, 1.4 Hz, 1H), 7.21 - 7.13 (m, 2H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.49 - 4.39 (m, 6H), 4.20 - 4.07 (m, 2H), 3.92 - 3.72 (m, 2H), 2.87 (ddd, J = 18.4, 13.5, 5.4 Hz, 1H), 2.78 - 2.70 (m, 1H), 2.63 (d, J = 0.6 Hz, 3H), 2.44 (qd, J = 13.2, 4.7 Hz, 1H), 2.13 (dtd, J = 12.9, 5.5, 2.5 Hz, 1H); LRMS (ES) m / z 543.2 [M+H] + .
[0475]
[0476] Example 14: Synthesis of 2-(aminooxy)-N-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethyl)acetamide
[0477] Step 1) Synthesis of 2-(2-chloro-4-nitrophenyl)acetamide
[0478]
[0479] A solution of 2-(2-chloro-4-nitrophenyl)acetic acid (1.000 g, 4.638 mmol), oxalyl chloride (0.648 g, 5.102 mmol), and N,N-dimethylformamide (0.017 mL, 0.464 mmol) dissolved in dichloromethane (10 mL) was stirred at 0 °C for 1 hour and further stirred at room temperature for 1 hour. After removing all the solvent, the reaction mixture was suspended in dichloromethane (2 mL) and the temperature was lowered to 0 °C. After adding ammonium hydroxide and removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 40%) to obtain 2-(2-chloro-4-nitrophenyl)acetamide (0.760 g, 76.3%) in the form of an ivory solid.
[0480] LRMS (ES) m / z 215.0 [M+H] + .
[0481] Step 2) Synthesis of 2-(2-chloro-4-nitrophenyl)ethane-1-amine
[0482]
[0483] A solution of 2-(2-chloro-4-nitrophenyl)acetamide (0.400 g, 1.864 mmol) and borane-tetrahydrofuran somplex (1.0 M tetrahydrofuran solution, 2.050 mL, 2.050 mmol) dissolved in tetrahydrofuran (7 mL) at 70 °C was stirred at the same temperature for 16 hours, after which the temperature was lowered to room temperature to terminate the reaction. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; methanol / dichloromethane = 0% to 15%) to obtain 2-(2-chloro-4-nitrophenyl)ethane-1-amine (0.167 g, 44.7%) in the form of an orange oil.
[0484] LRMS (ES) m / z 201.0 [M+H] + .
[0485] Step 3) Synthesis of tert-butyl (2-((2-chloro-4-nitropenethyl)amino)-2-oxoethoxy)carbamate
[0486]
[0487] A solution of 2-(2-chloro-4-nitrophenyl)ethane-1-amine (0.080 g, 0.399 mmol), 2-(((tert-butoxycarbonyl)amino)oxy)acetic acid (0.084 g, 0.439 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (0.227 g, 0.598 mmol), and N,N-diisopropylethylamine (0.104 mL, 0.598 mmol) dissolved in N,N-dimethylformamide (2.5 mL) at 0 °C was stirred for 1 hour at the same temperature. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, and the mixture was filtered and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; methanol / dichloromethane = 0% to 3%) to obtain tert-butyl (2-((2-chloro-4-nitropenethyl)amino)-2-oxoethoxy)carbamate (0.190 g, 127.7%) as an orange oil.
[0488] LRMS (ES) m / z 396.1 [M+Na] + .
[0489] Step 4) Synthesis of tert-butyl (2-((4-amino-2-chlorophenethyl)amino)-2-oxoethoxy)carbamate
[0490]
[0491] A solution of tert-butyl (2-((2-chloro-4-nitropenethyl)amino)-2-oxoethoxy)carbamate (0.399 mmol, 0.399 mmol), iron (0.134 g, 2.394 mmol), and ammonium chloride (0.128 g, 2.394 mmol) dissolved in ethanol (2 mL) and water (1 mL) at 80 °C was stirred at the same temperature for 2 hours, after which the temperature was lowered to room temperature to terminate the reaction. The reaction mixture was filtered through Celite to remove the solid, water was added to the filtrate, and the mixture was extracted with dichloromethane. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; methanol / dichloromethane = 0% to 5%) to obtain tert-butyl (2-((4-amino-2-chlorophenethyl)amino)-2-oxoethoxy)carbamate (0.055 g, 40.1%) in the form of an orange oil.
[0492] LRMS (ES) m / z 366.1 [M+Na] + .
[0493] Step 5) Synthesis of tert-butyl (2-((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethyl)amino)-2-oxoethoxy)carbamate
[0494]
[0495] tert-butyl (2-((4-amino-2-chlorophenethyl)amino)-2-oxoethoxy)carbamate (0.056 g, 0.162 mmol) and trichloromethyl chloroformate (0.064 g, 0.325 mmol) were dissolved in tetrahydrofuran (3 mL) / N,N-dimethylformamide (2 mL) and reacted at 0 °C for 1 hour. After removing all the solvent, a solution of 3-(5-(aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-diionic hydrochloride (0.060 g, 0.195 mmol) and triethylamine (0.225 mL, 1.623 mmol) mixed in N,N-dimethylformamide (2 mL) was added at room temperature and stirred at the same temperature for 1 hour. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; methanol / dichloromethane = 0% to 3%) to obtain tert-butyl (2-((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethyl)amino)-2-oxoethoxy)carbamate (0.014 g, 13.0%) in the form of an ivory solid.
[0496] LRMS (ES) m / z 665.2 [M+Na] + .
[0497] Step 6) Synthesis of 2-(aminooxy)-N-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethyl)acetamide
[0498]
[0499] A solution of tert-butyl (2-((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethyl)amino)-2-oxoethoxy)carbamate (0.014 g, 0.021 mmol) dissolved in trifluoroacetic acid (1 mL) / dichloromethane (2 mL) at 0 °C was stirred at the same temperature for 2 hours. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (C18, 5 g cartridge; acetonitrile / 0.1% aqueous formic acid solution = 0% to 60%) to obtain 2-(aminooxy)-N-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethyl)acetamide (0.011 g, 95.8%) in the form of a white solid.
[0500] 1 H NMR (400 MHz, DMSO-d6)δ 10.93 (s, 1H), 8.76 (s, 1H), 7.81 (t, J = 5.9 Hz, 1H), 7.65 (d, J = 7.8 Hz, 1H), 7.63 (s, 1H), 7.47 (s, 1H), 7.40 (d, J = 7.8 Hz, 1H), 7.12 (s, 1H), 7.12 (s, 1H), 6.79 (t, J = 6.0 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.46 - 4.22 (m, 4H), 3.88 (s, 2H), 2.95 - 2.80 (m, 1H), 2.74 (t, J = 7.3 Hz, 2H), 2.67 - 2.51 (m, 1H), 2.43 - 2.25 (m, 1H), 2.02 - 1.89 (m, 3H); LRMS (ES) m / z 543.2 [M+H] + .
[0501]
[0502] Example 15: Synthesis of N-(2-aminoethoxy)-2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)acetamide hydrochloride
[0503] Step 1) Synthesis of tert-butyl (2-((tert-butoxycarbonyl)amino)ethoxy)(2-(2-chloro-4-nitrophenyl)acetyl)carbamate
[0504]
[0505] A solution of 2-(2-chloro-4-nitrophenyl)acetic acid (0.150 g, 0.696 mmol), tert-butyl (2-(aminooxy)ethyl)carbamate (0.123 g, 0.696 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.160 g, 0.835 mmol), 1-hydroxybenzotriazole hydrate (0.047 g, 0.348 mmol), and triethylamine (0.289 mL, 2.087 mmol) dissolved in dichloromethane (4 mL) was stirred at 0 °C for 1 hour, and then di-tert-butyl dicarbonate (0.759 g, 3.479 mmol) was added and stirred for an additional 18 hours at room temperature. Water was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 10%) to obtain tert-butyl (2-((tert-butoxycarbonyl)amino)ethoxy)(2-(2-chloro-4-nitrophenyl)acetyl)carbamate (0.262 g, 79.6%) in the form of a yellow oil.
[0506] LRMS (ES) m / z 496.1 [M+Na] + .
[0507] Step 2) Synthesis of tert-butyl (2-((2-(4-amino-2-chlorophenyl)acetamido)oxy)ethyl)carbamate
[0508]
[0509] A solution of tert-butyl (2-((tert-butoxycarbonyl)amino)ethoxy)(2-(2-chloro-4-nitrophenyl)acetyl)carbamate (0.262 g, 0.554 mmol), iron (0.186 g, 3.322 mmol), and ammonium chloride (0.178 g, 3.322 mmol) dissolved in ethanol (3 mL) and water (1 mL) at 80 °C was stirred at the same temperature for 3 hours, after which the temperature was lowered to room temperature to terminate the reaction. Water was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; methanol / dichloromethane = 0% to 3%) to obtain tert-butyl (2-((2-(4-amino-2-chlorophenyl)acetamido)oxy)ethyl)carbamate (0.096 g, 50.4%) in the form of a yellow solid.
[0510] LRMS (ES) m / z 366.1 [M+Na] + .
[0511] Step 3) Synthesis of tert-butyl (2-((2-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)acetamido)oxy)ethyl)carbamate
[0512]
[0513] tert-butyl (2-((2-(4-amino-2-chlorophenyl)acetamido)oxy)ethyl)carbamate (0.094 g, 0.273 mmol), phenyl chloroformate (0.038 mL, 0.301 mmol), and pyridine (0.024 mL, 0.301 mmol) were reacted in ethyl acetate (2 mL) at 0 °C for 30 minutes. Once all the starting materials had reacted, the solvent was concentrated. The reaction mixture was dissolved in N,N-dimethylformamide, and 3-(5-(aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dionic cellulose (0.102 g, 0.328 mmol) and triethylamine (0.189 mL, 1.367 mmol) were added at room temperature and stirred at the same temperature for 5 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 5g cartridge; methanol / dichloromethane = 0% to 5%) to obtain tert-butyl(2-((2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)acetamido)oxy)ethyl)carbamate)0.114 g, 64.8%) as an ivory solid.
[0514] LRMS (ES) m / z 665.2 [M+Na] + .
[0515] Step 4) Synthesis of N-(2-aminoethoxy)-2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)acetamide hydrochloride
[0516]
[0517] A solution of tert-butyl (2-((2-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)acetamido)oxy)ethyl)carbamate (0.114 g, 0.177 mmol) and hydrogen chloride (4.0 M 1,4-dioxane solution, 0.900 mL, 3.545 mmol) dissolved in dichloromethane (2 mL) was stirred at 0 °C for 1 hour and further stirred at room temperature for 1 hour. After removing the solvent from the reaction mixture under reduced pressure, hexane (10 mL) was added to the concentrate and stirred to filter the precipitated solid, wash with hexane, and dry to obtain N-(2-aminoethoxy)-2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)acetamide hydrochloride (0.077 g, 74.5%) in the form of an ivory solid.
[0518] 1 H NMR (400 MHz, DMSO-d6)δ 11.62 (s, 1H), 10.97 (s, 1H), 9.12 (s, 1H), 7.93 (s, 2H), 7.70 (d, J = 4.0 Hz, 1H), 7.69 (d, J = 1.8 Hz, 1H), 7.52 (s, 1H), 7.44 (d, J = 8.0 Hz, 1H), 7.25 - 7.18 (m, 2H), 7.01 (t, J = 5.9 Hz, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.50 - 4.27 (m, 4H), 3.97 (t, J = 5.1 Hz, 2H), 3.47 (s, 2H), 3.03 - 2.96 (m, 2H), 2.95 - 2.86 (m, 1H), 2.66 - 2.57 (m, 1H), 2.43 - 2.32 (m, 1H), 2.04 - 1.95 (m, 1H); LRMS (ES) m / z 543.2 [M+H] + .
[0519]
[0520] Example 16: Synthesis of 2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-N-(2-(methylamino)ethoxy)acetamide
[0521]
[0522] It was synthesized in a manner similar to Example 15.
[0523] 1 H NMR (400 MHz, DMSO-d6)δ 10.97 (s, 1H), 8.87 (s, 1H), 7.70 (s, 1H), 7.69 (d, J = 5.3 Hz, 1H), 7.51 (s, 1H), 7.44 (d, J = 8.5 Hz, 1H), 7.24 (d, J = 8.4 Hz, 1H), 7.19 (dd, J = 8.3, 2.1 Hz, 1H), 6.87 (t, J = 6.0 Hz, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.50 - 4.26 (m, 4H), 3.70 (s, 2H), 3.61 (s, 3H), 3.31 - 3.28 (m, 2H), 2.98 - 2.83 (m, 1H), 2.70 - 2.54 (m, 1H), 2.52 - 2.50 (m, 2H), 2.44 - 2.29 (m, 1H), 2.04 - 1.94 (m, 1H); LRMS (ES) m / z 557.2 [M+H] + .
[0524]
[0525] Example 17: Synthesis of N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-2-hydroxyacetamide
[0526]
[0527] It was synthesized in a manner similar to Example 18.
[0528] 1H NMR (400 MHz, Methanol-d4)δ 7.76 (s, 1H), 7.64 (d, J = 1.8 Hz, 1H), 7.53 (s, 1H), 7.47 (d, J = 7.9 Hz, 1H), 7.41 (d, J = 8.4 Hz, 1H), 7.23 (dd, J = 8.7, 1.8 Hz, 1H), 5.12 (dd, J = 13.3, 5.2 Hz, 1H), 4.93 (s, 2H), 4.55 - 4.39 (m, 6H), 2.95 - 2.80 (m, 1H), 2.81 - 2.69 (m, 1H), 2.55 - 2.38 (m, 1H), 2.21 - 2.10 (m, 1H); LRMS (ES) m / z 530.1 [M+H] + .
[0529]
[0530] Example 18: Synthesis of N-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)-2-hydroxy-N-methylacetamide
[0531]
[0532] A solution of 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride (0.040 g, 0.069 mmol), 2-hydroxyacetic acid (0.010 g, 0.138 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (0.052 g, 0.138 mmol), and N,N-diisopropylethylamine (0.060 mL, 0.345 mmol) dissolved in N,N-dimethylformamide (1 mL) at room temperature, at the same temperature 1 The mixture was stirred for a period of time. The reaction mixture was purified and concentrated by column chromatography (C18, 10 g cartridge; acetonitrile / 0.1% aqueous formic acid solution = 0% to 60%) to obtain N-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)-2-hydroxy-N-methylacetamide (0.024 g, 56.6%) in the form of a white solid.
[0533] 1H NMR (400 MHz, DMSO-d6)δ 10.96 (s, 1H), 8.86 (s, 1H), 7.70 - 7.64 (m, 2H), 7.51 (s, 1H), 7.43 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 8.3 Hz, 1H), 7.15 (dd, J = 8.3, 2.2 Hz, 1H), 6.89 (t, J = 6.0 Hz, 1H), 5.10 (dd, J = 13.3, 5.0 Hz, 1H), 4.47 - 4.27 (m, 4H), 4.19 - 4.14 (m, 2H), 3.98 - 3.94 (m, 2H), 3.60 - 3.54 (m, 4H), 3.07 (s, 3H), 2.92 - 2.83 (m, 3H), 2.65 - 2.60 (m, 1H), 2.43 - 2.30 (m, 1H), 2.04 - 1.97 (m, 1H); LRMS (ES) m / z 602.1 [M+H] + .
[0534]
[0535] Example 19: Synthesis of (2R)-N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-2-hydroxypropanamide
[0536]
[0537] It was synthesized in a manner similar to Example 18.
[0538] 1H NMR (400 MHz, DMSO-d6)δ 10.94 (s, 1H), 8.93 (s, 1H), 7.69 (d, J = 2.1 Hz, 1H), 7.66 (d, J = 7.8 Hz, 1H), 7.48 (s, 1H), 7.41 (dd, J = 7.8, 1.4 Hz, 1H), 7.33 (d, J = 8.4 Hz, 1H), 7.20 (dd, J = 8.4, 2.1 Hz, 1H), 6.89 (t, J = 6.0 Hz, 1H), 5.28 (d, J = 5.5 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.77 (s, 2H), 4.46 - 4.22 (m, 4H), 3.90 (p, J = 6.5 Hz, 1H), 2.98 - 2.79 (m, 1H), 2.66 - 2.52 (m, 1H), 2.40 - 2.25 (m, 1H), 2.01 - 1.90 (m, 1H), 1.15 (d, J = 6.7 Hz, 3H); LRMS (ES) m / z 544.1 [M+H] + .
[0539]
[0540] Example 20: Synthesis of (2R)-N-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)-2-hydroxy-N-methylpropanamide
[0541]
[0542] It was synthesized in a manner similar to Example 18.
[0543] 1H NMR (400 MHz, DMSO-d6)δ 10.93 (s, 1H), 8.78 (s, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.63 (d, J = 2.2 Hz, 1H), 7.47 (s, 1H), 7.40 (d, J = 8.0) Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 7.12 (dd, J = 8.4, 2.2 Hz, 1H), 6.81 (t, J = 6.0 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.52 - 4.44 (m, 1H), 4.44 - 4.23 (m, 4H), 4.03 - 3.86 (m, 2H), 3.57 - 3.52 (m, 4H), 3.06 (s, 3H), 2.92 - 2.87 (m, 1H), 2.82 (t, J = 6.9 Hz, 2H), 2.63 - 2.53 (m, 1H), 2.41 - 2.26 (m, 1H), 2.01 - 1.91 (m, 1H), 1.13 (d, J = 6.6 Hz, 3H); LRMS (ES) m / z 616.3 [M+H] + .
[0544]
[0545] Example 21: Synthesis of 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)urea
[0546] Step 1) Synthesis of tert-butyl (2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)(methyl)carbamate
[0547]
[0548] A solution of tert-butyl (2-(4-amino-2-chlorophennetoxy)ethoxy)(methyl)carbamate (0.040 g, 0.116 mmol), phenylchloroformate (0.016 mL, 0.128 mmol), and triethylamine (0.032 mL, 0.232 mmol) dissolved in tetrahydrofuran (1.5 mL) was stirred at 0 °C for 1 hour, and then the reaction mixture was concentrated under reduced pressure. To the concentrated reaction mixture, 5-(aminomethyl)-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-diionic hydrochloride (0.10 MN,N-dimethylformamide solution, 1.740 mL, 0.174 mmol) and triethylamine (0.081 mL, 0.580 mmol) were added and stirred at room temperature for 18 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 5g cartridge; ethyl acetate / hexane = 30% to 100%) to obtain tert-butyl (2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)(methyl)carbamate (0.059 g, 77.3%) in ivory solid form.
[0549] LRMS (ES) m / z 680.2 [M+Na] + .
[0550] Step 2) Synthesis of 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)urea hydrochloride
[0551]
[0552] Hydrogen chloride (4.0 M 1,4-dioxane solution, 0.186 mL, 0.745 mmol) was added to a solution of tert-butyl (2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)(methyl)carbamate (0.025 g, 0.037 mmol) dissolved in dichloromethane (1 mL) at room temperature, and the mixture was stirred for 30 minutes at the same temperature. After removing the solvent from the reaction mixture under reduced pressure, the product was used without further purification (1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)urea hydrochloride, 0.016 g, 72.3%, yellow solid).
[0553] 1 H-NMR (400 MHz, DMSO-d6) δ 11.11 (s, 1H), 9.14 (s, 1H), 7.89 (d, J = 7.6 Hz, 1H), 7.85 - 7.76 (m, 2H), 7.64 (d, J = 1.7 Hz, 1H), 7.23 (d, J = 8.4 Hz, 1H), 7.19 (dd, J = 8.4, 1.9 Hz, 1H), 7.12 - 7.06 (m, 1H), 5.14 (dd, J = 12.9, 5.2 Hz, 1H), 4.46 (d, J = 5.7 Hz, 2H), 4.20 - 4.14 (m, 2H), 3.67 - 3.62 (m, 2H), 3.58 (t, J = 7.1 Hz, 2H), 2.94 - 2.88 (m, 1H), 2.86 (t, J = 7.1 Hz, 2H), 2.82 (s, 3H), 2.65 - 2.53 (m, 2H), 2.07 - 2.02 (m, 1H); LRMS (ES) m / z 558.1 [M+H] + .
[0554]
[0555] Example 22: Synthesis of 1-(3-chloro-4-(2-(2-((ethylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride
[0556]
[0557] It was synthesized in a manner similar to Example 23.
[0558] 1 H-NMR (400 MHz, DMSO-d6)δ 12.03 (s, 1H), 10.97 (s, 1H), 9.20 (s, 1H), 7.67 (dd, J = 7.8, 4.9 Hz, 2H), 7.51 (s, 1H), 7.44 (d, J = 7.9 Hz, 1H), 7.19 (dt, J = 8.4, 5.2 Hz, 2H), 7.07 (s, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.32 (ddd, J = 32.0, 14.8, 11.0 Hz, 6H), 3.66 (d, J = 4.3 Hz, 2H), 3.20 (q, J = 7.2 Hz, 2H), 2.96 - 2.88 (m, 1H), 2.85 (t, J = 7.2 Hz, 2H), 2.65 - 2.56 (m, 1H), 2.38 (dd, J = 13.1, 4.6 Hz, 1H), 2.05 - 1.94 (m, 1H), 1.18 (t, J = 7.2 Hz, 3H); LRMS (ES) m / z 558.0 [M+H] + .
[0559]
[0560] Example 23: Synthesis of 1-(3-chloro-4-(2-(2-((isopropylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride
[0561] Step 1) Synthesis of tert-butyl (benzoyloxy)carbamate
[0562]
[0563] Benzoyl chloride (4.799 mL, 41.307 mmol) was added to a solution of tert-butyl N-hydroxycarbamate (5.000 g, 37.552 mmol) and triethylamine (6.804 mL, 48.817 mmol) dissolved in diethyl ether (180 mL) at room temperature, and the mixture was stirred at 0 °C for 1 hour at the same temperature. The reaction mixture was filtered through a paper filter to remove the solid, and the solvent was removed from the filtrate under reduced pressure. Then, diethyl ether (30 mL) and hexane (100 mL) were added to the concentrate and stirred. The precipitated solid was filtered, washed with hexane, and dried to obtain tert-butyl (benzoyloxy)carbamate (7.840 g, 88.0%) in the form of a white solid.
[0564] LRMS (ES) m / z 260.1 [M+Na] + .
[0565] Step 2) Synthesis of tert-butyl (benzoyloxy)(isopropyl)carbamate
[0566]
[0567] A solution of tert-butyl (benzoyloxy)carbamate (0.237 g, 0.999 mmol), propan-2-ol (0.114 mL, 1.498 mmol), diisopropyl azodicarboxylate (0.303 g, 1.498 mmol), and triphenylphosphine (0.393 g, 1.498 mmol) dissolved in tetrahydrofuran (8 mL) was stirred at 0 °C for 1 hour and further stirred at room temperature for 16 hours. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 20%) to obtain tert-butyl (benzoyloxy)(isopropyl)carbamate (0.170 g, 60.9%) in the form of a clear oil.
[0568] LRMS (ES) m / z 302.0 [M+Na]+ .
[0569] Step 3) Synthesis of tert-butyl hydroxy(isopropyl)carbamate
[0570]
[0571] Tert-butyl (benzoyloxy)(isopropyl)carbamate (0.170 g, 0.609 mmol) was dissolved in methanol (2 mL), and potassium carbonate (0.084 g, 0.609 mmol) was added at room temperature and stirred for 1 hour at the same temperature. Water was added to the concentrate obtained by removing the solvent from the reaction mixture under reduced pressure, and the mixture was extracted with dichloromethane. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was used without further purification (tert-butyl hydroxy(isopropyl)carbamate, 0.100 g, 93.8%, clear liquid).
[0572] LRMS (ES) m / z 198.0 [M+Na] + .
[0573] Step 4) Synthesis of tert-butyl (2-(2-chloro-4-nitropenetoxy)ethoxy)(isopropyl)carbamate
[0574]
[0575] Diisopropyl azodicarboxylate (0.438 mL, 2.035 mmol) was added to a solution prepared by dissolving 2-(2-chloro-4-nitropenetoxy)ethanol-1-ol (0.250 g, 1.018 mmol), tert-butylhydroxy(isopropyl)carbamate (0.357 g, 2.035 mmol), and triphenylphosphine (0.534 g, 2.035 mmol) in tetrahydrofuran (6 mL) at room temperature, and the mixture was stirred at 0 °C for 5 hours, followed by stirring at room temperature for 16 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 20%) to obtain tert-butyl (2-(2-chloro-4-nitropenenetoxy)ethoxy)(isopropyl)carbamate (0.058 g, 14.1%) in the form of a clear liquid.
[0576] LRMS (ES) m / z 425.1 [M+Na] + .
[0577] Step 5) Synthesis of tert-butyl (2-(4-amino-2-chlorophennetoxy)ethoxy)(isopropyl)carbamate
[0578]
[0579] A solution of tert-butyl (2-(2-chloro-4-nitropenetoxy)ethoxy)(isopropyl)carbamate (0.058 g, 0.144 mmol), iron (0.040 g, 0.720 mmol), and ammonium chloride (0.031 g, 0.576 mmol) dissolved in ethanol (5 mL) and water (1 mL) at room temperature was stirred at 80 °C for 1 hour, after which the temperature was lowered to room temperature to terminate the reaction. The reaction mixture was filtered through a Celite pad to remove the solid, water was added to the filtrate, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 40%) to obtain tert-butyl (2-(4-amino-2-chlorophennetoxy)ethoxy)(isopropyl)carbamate (0.047 g, 87.5%) in the form of a clear liquid.
[0580] LRMS (ES) m / z 395.0 [M+Na] + .
[0581] Step 6) Synthesis of tert-butyl (2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)(isopropyl)carbamate
[0582]
[0583] tert-butyl (2-(4-amino-2-chlorophennetoxy)ethoxy)(isopropyl)carbamate (0.047 g, 0.126 mmol) and pyridine (0.011 mL, 0.139 mmol) were dissolved in ethyl acetate (3 mL), phenyl chloroformate (0.018 mL, 0.139 mmol) was added, and the mixture was stirred at 0 °C for 0.5 hours and concentrated. The residue was dissolved in N,N-dimethylformamide (2 mL), triethylamine (0.087 mL, 0.630 mmol) and 3-(5-(aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dionic cellulose (0.041 g, 0.132 mmol) were added, and the mixture was further stirred at room temperature for 3 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; methanol / dichloromethane = 1% to 10%) to obtain tert-butyl (2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)(isopropyl)carbamate (0.063 g, 74.4%) as a white solid.
[0584] LRMS (ES) m / z 694.1 [M+Na] + .
[0585] Step 7) Synthesis of 1-(3-chloro-4-(2-(2-((isopropylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride
[0586]
[0587] Hydrogen chloride (4.0 M 1,4-dioxane solution, 0.469 mL, 1.874 mmol) was added to a solution of tert-butyl (2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)(isopropyl)carbamate (0.063 g, 0.094 mmol) dissolved in dichloromethane (5 mL) at room temperature, and the mixture was stirred at the same temperature for 3 hours. After removing the solvent from the reaction mixture under reduced pressure, diethyl ether (5 mL) and hexane (2 mL) were added to the concentrate and stirred to filter the precipitated solid, wash it with hexane, and dry it to obtain 1-(3-chloro-4-(2-(2-((isopropylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride (0.055 g, 96.4%) in the form of a white solid.
[0588] 1 H-NMR (400 MHz, DMSO-d6)δ 11.82 (s, 1H), 10.97 (s, 1H), 9.09 (s, 1H), 7.67 (dd, J = 10.2, 4.9 Hz, 2H), 7.51 (s, 1H), 7.44 (d, J = 7.9 Hz, 1H), 7.19 (dt, J = 8.4, 5.3 Hz, 2H), 7.00 (t, J = 5.8 Hz, 1H), 5.12 (d, J = 5.1 Hz, 1H), 4.48 - 4.20 (m, 6H), 3.66 (d, J = 4.3 Hz, 1H), 3.60 (t, J = 7.1 Hz, 2H), 2.98 - 2.88 (m, 1H), 2.86 (t, J = 7.1 Hz, 2H), 2.60 (d, J = 16.5 Hz, 1H), 2.45 - 2.29 (m, 1H), 2.05 - 1.95 (m, 1H), 1.22 (d, J = 6.5 Hz, 6H); LRMS (ES) m / z 571.2 [M+H] + .
[0589]
[0590] Example 24: Synthesis of 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)thiourea hydrochloride
[0591] Step 1) Synthesis of tert-butyl (2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)thiouredo)phennetoxy)ethoxy)(methyl)carbamate
[0592]
[0593] tert-butyl (2-(4-amino-2-chlorophennetoxy)ethoxy)(methyl)carbamate (0.050 g, 0.145 mmol) and di(1H-imidazole-1-yl)methanethio (0.026 g, 0.145 mmol) were dissolved in dichloromethane (2 mL) and N,N-dimethylformamide (2 mL), stirred at room temperature for 90 minutes, and then triethylamine (0.040 mL, 0.290 mmol) and 3-(6-(aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (0.040 g, 0.145 mmol) were added and stirred for an additional 2 hours at the same temperature. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (SiO2, 5 g cartridge; methanol / ethyl acetate = 0% to 10%), the resulting product was crystallized with diethyl ether (5 mL) at 25 °C, filtered, and dried to obtain tert-butyl (2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)thiouredo)phennetoxy)ethoxy)(methyl)carbamate (0.046 g, 48.2%) in the form of white crystals.
[0594] LRMS (ES) m / z 682.21 [M+Na] + .
[0595] Step 2) Synthesis of 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)thiourea hydrochloride
[0596]
[0597] tert-butyl (2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)thiouredo)phennetoxy)ethoxy)(methyl)carbamate (0.046 g, 0.070 mmol) and hydrogen chloride (4.0 M 1,4-dioxane solution, 0.88 mL, 3.491 mmol) were dissolved in dichloromethane (2 mL), stirred at 0 °C for 30 minutes, and then further stirred at room temperature for 2 hours. After removing the solvent from the reaction mixture under reduced pressure, an aqueous diethyl ether solution (10 mL) was poured over the concentrate to suspend it and filter the resulting solid, which was then washed with hexane and dried to obtain 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)thiourea hydrochloride (0.040 g, 96.0%) in the form of ivory crystals.
[0598] 1H-NMR (400 MHz, DMSO-d6)δ 10.74 (s, 1H), 9.68 (br, 1H), 8.29 (br, 1H), 7.47 (d, J = 7.8 Hz, 2H), 7.31 (s, 1H), 7.23 (d, J = 7.8 Hz, 2H), 7.09 (s, 1H), 4.87 (dd, J = 13.1, 5.3 Hz, 1H), 4.63 (d, J = 5.3 Hz, 2H), 4.15 (dd, J = 55.0, 17.4 Hz, 2H), 3.89 (br, 2H), 3.47 - 3.36 (m, 3H), 3.17 - 3.06 (m, 2H), 2.73 - 2.61 (m, 2H), 2.59 (d, J = 2.0 Hz, 3H), 2.44 - 2.15 (m, 2H), 2.12 - 1.71 (m, 2H), 1.82 - 1.73 (m, 1H); LRMS (ES) m / z 560.2 [M+H] + .
[0599]
[0600] Example 25: Synthesis of 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea hydrochloride
[0601]
[0602] It was synthesized in a manner similar to Example 23.
[0603] 1H-NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.97 (d, J = 3.9 Hz, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.61 (d, J = 2.0 Hz, 1H), 7.56 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.20 (d, J = 8.4 Hz, 1H), 7.13 (dd, J = 8.4, 1.9 Hz, 1H), 7.10 (dd, J = 8.6, 2.0 Hz, 1H), 5.10 (dd, J = 13.2, 4.9 Hz, 1H), 4.90 (p, J = 6.8 Hz, 1H), 4.45 (dd, J = 17.4, 3.0 Hz, 1H), 4.31 (d, J = 17.1 Hz, 1H), 4.21 - 4.13 (m, 2H), 3.67 - 3.61 (m, 2H), 3.59 - 3.55 (m, 2H), 2.97 - 2.87 (m, 1H), 2.84 (t, J = 7.3 Hz, 2H), 2.81 (s, 3H), 2.64 - 2.55 (m, 1H), 2.46 - 2.31 (m, 1H), 2.04 - 1.95 (m, 1H), 1.40 (d, J = 6.9 Hz, 3H); LRMS (ES) 558.1 m / z [M+H] + .
[0604]
[0605] Example 26: Synthesis of 1-(3-chloro-4-(1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride
[0606]
[0607] It was synthesized in a manner similar to Example 31.
[0608] LRMS (ES) 558.1 m / z [M+H] + .
[0609]
[0610] Example 27: Synthesis of 1-(3-chloro-4-(1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea hydrochloride
[0611]
[0612] It was synthesized in a manner similar to Example 31.
[0613] 1 H-NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.81 (d, J = 3.7 Hz, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.60 (dd, J = 5.1, 2.2 Hz, 1H), 7.56 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 8.6 Hz, 1H), 7.19 - 7.13 (m, 1H), 6.99 (dd, J = 7.7, 2.7 Hz, 1H), 5.10 (dd, J = 13.2, 5.1 Hz, 1H), 4.96 - 4.85 (m, 1H), 4.51 - 4.26 (m, 2H), 4.10 (t, J = 4.1 Hz, 2H), 3.64 - 3.58 (m, 2H), 3.53 (dd, J = 6.3, 1.6 Hz, 1H), 3.43 (d, J = 7.3 Hz, 1H), 2.91 (ddd, J = 17.4, 13.9, 5.4 Hz, 1H), 2.80 (s, 3H), 2.68 - 2.53 (m, 1H), 2.46 - 2.31 (m, 1H), 1.99 (ddd, J = 10.2, 5.2, 2.6 Hz, 1H), 1.41 (d, J = 6.8 Hz, 3H), 1.15 (d, J = 6.8 Hz, 3H); LRMS(ES) m / z 572.2 [M+H] + .
[0614]
[0615] Example 28: Synthesis of 1-(3-chloro-4-(1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)thiourea hydrochloride
[0616]
[0617] It was synthesized in a manner similar to Example 24.
[0618] 1 H-NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 10.01 (s, 1H), 8.58 (t, J = 5.5 Hz, 1H), 7.70 (d, J = 7.9 Hz, 2H), 7.54 (s, 1H), 7.47 (d, J = 7.9 Hz, 1H), 7.38 - 7.33 (m, 2H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.86 (d, J = 5.6 Hz, 2H), 4.39 (dd, J = 55.1, 17.4 Hz, 2H), 4.12 (t, J = 4.4 Hz, 2H), 3.66 - 3.55 (m, 4H), 3.51 - 3.46 (m, 2H), 2.80 (s, 3H), 2.62 (t, J = 18.0 Hz, 1H), 2.43 - 2.32 (m, 1H), 2.00 (ddd, J = 10.4, 5.2, 3.1 Hz, 1H), 1.18 (d, J = 6.8 Hz, 3H); LRMS(ES) m / z 574.2 [M+H] + .
[0619]
[0620] Example 29: Synthesis of 1-(3-chloro-4-(1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)thiourea hydrochloride
[0621]
[0622] It was synthesized in a manner similar to Example 24.
[0623] 1 H-NMR (400 MHz, DMSO-d 6) δ 10.98 (s, 1H), 9.94 (s, 1H), 8.72 (d, J = 7.8 Hz, 1H), 7.75 (d, J = 6.1 Hz, 1H), 7.71 (d, J = 7.9 Hz, 1H), 7.58 (s, 1H), 7.50 (d, J = 7.9 Hz, 1H), 7.36 (dd, J = 7.1, 3.2 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 5.58 (s, 1H), 5.11 (dd, J = 13.2, 5.1 Hz, 1H), 4.46 (dd, J = 17.4, 4.7 Hz, 1H), 4.32 (dd, J = 17.5, 2.9 Hz, 1H), 4.12 (t, J = 4.4 Hz, 2H), 3.64 - 3.58 (m, 3H), 3.47 (dd, J = 9.5, 7.2 Hz, 2H), 3.01 - 2.85 (m, 1H), 2.80 (s, 3H), 2.63 (dd, J = 26.6, 9.1 Hz, 1H), 2.43 - 2.30 (m, 1H), 2.05 - 1.95 (m, 1H), 1.49 (d, J = 7.0 Hz, 3H), 1.18 (d, J = 6.8 Hz, 3H); LRMS(ES) m / z 588.2 [M+H] + .
[0624]
[0625] Example 30: Synthesis of 1-(4-(2-(2-(aminooxy)ethoxy)ethyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)thiourea hydrochloride
[0626]
[0627] It was synthesized in a manner similar to Example 24.
[0628] 1H-NMR (400 MHz, DMSO-d6)δ 10.99 (s, 1H), 9.83 (s, 1H), 8.49 (s, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.66 (d, J = 1.6 Hz, 1H), 7.55 (s, 1H), 7.48 (d, J = 7.0 Hz, 1H), 7.39 - 7.26 (m, 2H), 5.12 (dd, J = 13.3, 5.2 Hz, 1H), 4.87 (d, J = 4.9 Hz, 2H), 4.40 (dd, J = 55.3, 17.3 Hz, 2H), 3.70 - 3.51 (m, 6H), 2.90 (t, J = 7.0 Hz, 2H), 2.72 - 2.54 (m, 1H), 2.48 - 2.30 (m, 2H), 2.08 - 1.97 (m, 1H); LRMS (ES) m / z 547.1 [M+H] + .
[0629]
[0630] Example 31: Synthesis of 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea
[0631] Step 1) Synthesis of 5-acetylisobenzofuran-1(3H)-one
[0632]
[0633] Tributyl(1-ethoxyvinyl)stanneine (11.894 mL, 35.206 mmol) was added to a solution of 5-bromoisobenzofuran-1(3H)-one (5.000 g, 23.471 mmol) and bis(triphenylphosphine)palladium(II) dichloride (1.647 g, 2.347 mmol) dissolved in 1,4-dioxane (200 mL) at 80 °C, and stirred at the same temperature for 18 hours. After lowering the temperature to room temperature, 1.0 M aqueous hydrochloric acid solution was added to the reaction mixture at room temperature and stirred for 30 minutes to terminate the reaction. The reaction mixture was filtered through a Celite pad to remove the solid, water was added to the filtrate, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 50 g cartridge; ethyl acetate / hexane = 20% to 70%) to obtain 5-acetylisobenzofuran-1(3H)-one (3.960 g, 95.8%) in the form of a yellow solid.
[0634] 1 H-NMR (400 MHz, CDCl3) δ 8.10 (ddd, J = 2.1, 1.4, 0.7 Hz, 1H), 8.08 (dq, J = 1.7, 0.9 Hz, 1H), 8.04 - 8.00 (m, 1H), 5.39 (s, 2H), 2.69 (s, 3H).
[0635] Step 2) Reaction of (R)-2-methyl-N-((S)-1-(1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)propane-2-sulfinamide
[0636]
[0637] 5-acetylosobenzofuran-1(3H)-one (0.905 g, 5.137 mmol) and (S)-2-methylpropane-2-sulfinamide (0.685 g, 5.651 mmol) were dissolved in tetrahydrofuran (17 mL), titanium ethoxide (2.154 mL, 10.274 mmol) was added, and the mixture was heated under reflux for 18 hours at 0 °C, after which the temperature was lowered to room temperature. The reaction mixture was added at -60 °C to a turbid solution of sodium borohydride (0.777 g, 20.548 mmol) dissolved in tetrahydrofuran (10 mL), stirred to raise the temperature to room temperature, and then methanol (10 mL) and a saturated aqueous sodium chloride solution were added to terminate the reaction. The reaction mixture was filtered through a Celite pad to remove the solid, water was poured into the filtrate, and the mixture was extracted with ethyl acetate. The organic layer was dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 25 g cartridge; ethyl acetate / hexane = 50% to 100%) to obtain (R)-2-methyl-N-((S)-1-(1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)propane-2-sulfinamide (1.089 g, 75.3%) in the form of an ivory solid.
[0638] 1 H-NMR (400 MHz, DMSO-d6) δ 7.82 (d, J = 8.0 Hz, 1H), 7.68 (s, 1H), 7.64 (dd, J = 8.3, 1.0 Hz, 1H), 5.86 (d, J = 7.5 Hz, 1H), 5.41 (s, 2H), 4.54 (p, J = 6.9 Hz, 1H), 1.43 (d, J = 6.8 Hz, 3H), 1.12 (s, 9H).
[0639] Step 3) Synthesis of (S)-5-(1-aminoethyl)isobenzofuran-1(3H)-one dihydrochloride
[0640]
[0641] (R)-2-methyl-N-((S)-1-(1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)propane-2-sulfinamide (1.080 g, 3.838 mmol) was dissolved in 1,4-dioxane (10 mL), and at 0 °C, hydrogen chloride (4.0 M 1,4-dioxane solution, 9.596 mL, 38.384 mmol) was added and stirred at room temperature for 1 hour. After removing the solvent from the reaction mixture under reduced pressure, the product was used without further purification ((S)-5-(1-aminoethyl)isobenzofuran-1(3H)-one dihydrochloride, 0.911 g, 94.8%, white solid).
[0642] 1 H-NMR (400 MHz, DMSO-d6) δ 8.73 (brs, 3H), 7.93 (d, J = 8.0 Hz, 1H), 7.82 (s, 1H), 7.76 (dd, J = 8.0, 1.3 Hz, 1H), 5.45 (s, 2H), 4.58 (p, J = 6.4 Hz, 1H), 1.55 (d, J = 6.8 Hz, 3H).
[0643] Step 4) Synthesis of tert-butyl (S)-(1-(1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)carbamate
[0644]
[0645] (S)-5-(1-aminoethyl)isobenzofuran-1(3H)-one hydrochloride (0.950 g, 4.446 mmol) was dissolved in tetrahydrofuran (15 mL) / water (10 mL), and di-tert-butyl dicarbonate (1.456 g, 6.669 mmol) and sodium bicarbonate (1.868 g, 22.232 mmol) were added at 0 °C and stirred at room temperature for 12 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with water, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 50%) to obtain tert-butyl(S)-(1-(1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)carbamate (0.974 g, 79.0%) in the form of white amorphous crystals.
[0646] 1 H-NMR (400 MHz, CDCl3) δ 7.88 (d, J = 8.0 Hz, 1H), 7.47 dd, J = 8.0 Hz, 1H), 7.42 (s, 1H), 5.29 (s, 2H), 5.00 - 4.77 (m, 2H), 1.46 (d, J = 6.9 Hz, 3H), 1.41 (brs, 9H); LRMS (ES) m / z 300.1 [M+Na] + .
[0647] Step 5) Synthesis of (S)-4-(1-((tert-butoxycarbonyl)amino)ethyl)-2-(hydroxymethyl)benzoic acid
[0648]
[0649] tert-butyl (S)-(1-(1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)carbamate (0.838 g, 3.022 mmol) was dissolved in tetrahydrofuran (3 mL) / water (12 mL), sodium hydroxide (0.181 g, 4.533 mmol) was added at 0 °C and stirred at room temperature for 1 hour. Then, at 0 °C, 1.0 M aqueous hydrochloric acid solution was added to the reaction mixture to adjust the pH to 2 and stirred for 30 minutes to terminate the reaction. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was used without further purification ((S)-4-(1-((tert-butoxycarbonyl)amino)ethyl)-2-(hydroxymethyl)benzoic acid, 0.885 g, 99.2%, white solid).
[0650] 1 H-NMR (400 MHz, DMSO-d6) δ 7.79 (d, J = 8.0 Hz, 1H), 7.64 (s, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.24 (dd, J = 8.0, 1.1 Hz, 1H), 4.81 (s, 2H), 4.63 (p, J = 7.0 Hz, 1H), 1.36 (s, 9H), 1.30 (d, J = 7.1 Hz, 3H); LRMS (ES) m / z 318.1 [M+Na] + .
[0651] Step 6) Synthesis of methyl(S)-4-(1-((tert-butoxycarbonyl)amino)ethyl)-2-(hydroxymethyl)benzoate
[0652]
[0653] (S)-4-(1-((tert-butoxycarbonyl)amino)ethyl)-2-(hydroxymethyl)benzoic acid (0.880 g, 2.980 mmol) was dissolved in methanol (6 mL) / ethyl acetate (6 mL), and (diazomethyl)trimethylsilane (4.740 mL, 29.796 mmol) was added at 0 °C and stirred for 3 hours at the same temperature. Cold water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was used without further purification (methyl (S)-4-(1-((tert-butoxycarbonyl)amino)ethyl)-2-(hydroxymethyl)benzoate, 0.901 g, 97.7%, clear, viscous liquid).
[0654] 1 H-NMR (400 MHz, CDCl3) δ 7.98 (d, J = 8.1 Hz, 1H), 7.37 (d, J = 1.7 Hz, 1H), 7.31 (dd, J = 8.1, 1.8 Hz, 1H), 4.86 - 4.80 (m, 1H), 4.78 (d, J = 1.1 Hz, 2H), 3.93 (s, 3H), 1.44 (d, J = 6.9 Hz, 3H), 1.41 (s, 9H); LRMS (ES) m / z 332.0 [M+Na] + .
[0655] Step 7) Synthesis of methyl(S)-2-(bromomethyl)-4-(1-((tert-butoxycarbonyl)amino)ethyl)benzoate
[0656]
[0657] Methyl (S)-4-(1-((tert-butoxycarbonyl)amino)ethyl)-2-(hydroxymethyl)benzoate (0.920 g, 2.974 mmol) was dissolved in tetrahydrofuran (15 mL), and triphenylphosphine (1.560 g, 5.948 mmol) and carbon sabromide (1.972 g, 5.948 mmol) were added at 0 °C and stirred at room temperature for 2 hours. Cold water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 50%) to obtain methyl (S)-2-(bromomethyl)-4-(1-((tert-butoxycarbonyl)amino)ethyl)benzoate (0.773 g, 69.8%) in the form of a white solid.
[0658] 1 H-NMR (400 MHz, CDCl3) δ 7.94 (d, J = 8.1 Hz, 1H), 7.38 (d, J = 1.8 Hz, 1H), 7.30 (dd, J = 8.1, 1.8 Hz, 1H), 4.95 (dd, J = 16.0, 8.0 Hz, 2H), 4.81 (brs, 1H), 3.93 (s, 3H), 1.44 (d, J = 6.8 Hz, 3H), 1.41 (s, 9H); LRMS (ES) m / z 396.0 [M+Na] + .
[0659] Step 8) Synthesis of tert-butyl ((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)carbamate
[0660]
[0661] N,N-diisopropylethylamine (1.432 mL, 8.199 mmol) was added to a solution of methyl (S)-2-(bromomethyl)-4-(1-((tert-butoxycarbonyl)amino)ethyl)benzoate (0.763 g, 2.050 mmol) and 3-aminopiperidin-2,6-diionic hydrochloride (0.506 g, 3.074 mmol) dissolved in N,N-dimethylformamide (15 mL) at room temperature, and the mixture was stirred at 80 °C for 13 hours, after which the temperature was lowered to room temperature to terminate the reaction. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 25 g cartridge; ethyl acetate / hexane = 30% to 100%) to obtain tert-butyl ((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)carbamate (0.628 g, 79.1%) in the form of a purple solid.
[0662] 1 H-NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 7.67 (d, J = 7.8 Hz, 1H), 7.53 - 7.47 (m, 2H), 7.44 (d, J = 7.9 Hz, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.71 (p, J = 6.8 Hz, 1H), 4.44 (dd, J = 17.3, 3.4 Hz, 1H), 4.30 (dd, J = 17.3, 4.0 Hz, 1H), 2.97 - 2.84 (m, 1H), 2.64 - 2.55 (m, 1H), 2.45 - 2.34 (m, 1H), 2.04 - 1.95 (m, 1H), 1.36 (s, 9H), 1.33 (d, J = 7.1 Hz, 3H); LRMS (ES) m / z 410.0 [M+Na] + .
[0663] Step 9) Synthesis of (3-(5-((S)-1-aminoethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride
[0664]
[0665] Hydrogen chloride (4.0 M 1,4-dioxane solution, 10.002 mL, 40.006 mmol) was added to a solution of tert-butyl ((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)carbamate (0.620 g, 1.600 mmol) dissolved in 1,4-dioxane (10 mL) at room temperature, and the mixture was stirred at the same temperature for 3 hours. After removing the solvent from the reaction mixture under reduced pressure, the product was used without further purification (3-(5-((S)-1-aminoethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dionic hydrochloride, 0.456 g, 88.0%, light gray solid).
[0666] 1 H-NMR (400 MHz, DMSO-d6) δ 10.99 (s, 1H), 8.64 (brs, 3H), 7.80 - 7.74 (m, 2H), 7.70 - 7.64 (m, 1H), 5.12 (dd, J = 13.3, 5.1 Hz, 1H), 4.57 - 4.44 (m, 2H), 4.35 (dd, J = 17.5, 8.1 Hz, 1H), 2.97 - 2.86 (m, 1H), 2.65 - 2.56 (m, 1H), 2.48 - 2.35 (m, 1H), 2.05 - 1.98 (m, 1H), 1.55 (d, J = 6.8 Hz, 3H); LRMS (ES) m / z 288.2 [M+H] + .
[0667] Step 10) Synthesis of dimethyl 2-(2-chloro-4-nitrophenyl)malonate
[0668]
[0669] Sodium hydroxide (0.971 g, 24.285 mmol) was added to a solution of 2-chloro-1-fluoro-4-nitrobenzene (2.030 g, 11.564 mmol) and dimethyl malonate (1.721 mL, 15.034 mmol) dissolved in 1-methylylrolidine-2-one (50 mL) at room temperature, and the mixture was stirred at 80 °C for 2 hours. After lowering the temperature to room temperature, a 1.0 M aqueous hydrochloric acid solution was added to the reaction mixture at 0 °C to adjust the pH to 2, and the reaction was terminated by stirring for 30 minutes. The reaction mixture was filtered through a paper filter to obtain a precipitated solid. The solid was then dissolved in dichloromethane and dried to obtain dimethyl 2-(2-chloro-4-nitrophenyl)malonate (3.220 g, 96.8%) in the form of an orange solid.
[0670] 1 H-NMR (400 MHz, CDCl3) δ 8.30 (d, J = 2.3 Hz, 1H), 8.17 - 8.13 (m, 1H), 7.77 - 7.70 (m, 1H), 5.31 (s, 1H), 3.81 (s, 6H).
[0671] Step 11) Synthesis of Methyl 2-(2-chloro-4-nitrophenyl)acetate
[0672]
[0673] A solution of dimethyl 2-(2-chloro-4-nitrophenyl)malonate (3.220 g, 11.194 mmol) and sodium chloride (1.178 g, 20.149 mmol) dissolved in dimethyl sulfoxide (50 mL) / water (0.2 mL) was stirred at room temperature for 10 minutes and further stirred at 110 °C for 8 hours, after which the temperature was lowered to room temperature to terminate the reaction. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 50 g cartridge; ethyl acetate / hexane = 0% to 20%) to obtain methyl 2-(2-chloro-4-nitrophenyl)acetate (1.680 g, 65.4%) in the form of a pale yellow solid.
[0674] 1 H-NMR (400 MHz, CDCl3) δ 8.28 (d, J = 2.3 Hz, 1H), 8.11 (dd, J = 8.5, 2.3 Hz, 1H), 7.50 (d, J = 8.5 Hz, 1H), 3.88 (s, 2H), 3.74 (s, 3H).
[0675] Step 12) Synthesis of Methyl 2-(2-chloro-4-nitrophenyl)-2-methylpropanoate
[0676]
[0677] Methyl 2-(2-chloro-4-nitrophenyl)acetate (1.650 g, 7.186 mmol) and iodomethane (1.789 mL, 28.743 mmol) were dissolved in N,N-dimethylformamide (15 mL), and sodium hydride (60.00% phosphorus mineral oil, 0.719 g, 17.964 mmol) was added at 0 °C and stirred at room temperature for 4 hours. A saturated aqueous ammonium chloride solution was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 25 g cartridge; ethyl acetate / hexane = 0% to 20%) to obtain methyl 2-(2-chloro-4-nitrophenyl)-2-methylpropanoate (1.550 g, 83.7%) in the form of a yellow oil.
[0678] 1 H-NMR (400 MHz, CDCl3) δ 8.24 (d, J = 2.4 Hz, 1H), 8.14 (dd, J = 8.7, 2.4 Hz, 1H), 7.60 (d, J = 8.7 Hz, 1H), 3.68 (s, 3H), 1.65 (s, 6H); LRMS (ES) m / z 258.0 [M+H] + .
[0679] Step 13) Synthesis of 2-(2-chloro-4-nitrophenyl)-2-methylpropan-1-ol
[0680]
[0681] Methyl 2-(2-chloro-4-nitrophenyl)-2-methylpropanoate (3.690 g, 14.321 mmol) was dissolved in tetrahydrofuran (70 mL), and diisobutylaluminum hydride (1.0 M tetrahydrofuran solution, 42.962 mL, 42.962 mmol) was added at 0 °C and stirred at the same temperature for 3 hours. Then, at 0 °C, 2.0 M aqueous sodium hydroxide solution was added to the reaction mixture and stirred for 30 minutes to terminate the reaction. The reaction mixture was filtered through a Celite pad to remove the solid, water was added to the filtrate, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 50 g cartridge; ethyl acetate / hexane = 0% to 30%) to obtain 2-(2-chloro-4-nitrophenyl)-2-methylpropan-1-ol (2.722 g, 82.8%) in the form of an orange solid.
[0682] 1 H-NMR (400 MHz, CDCl3) δ 8.23 (d, J = 2.5 Hz, 1H), 8.06 (dd, J = 8.8, 2.5 Hz, 1H), 7.67 (d, J = 8.8 Hz, 1H), 4.03 (s, 2H), 1.52 (s, 6H).
[0683] Step 14) Synthesis of tert-butyl 2-(2-(2-chloro-4-nitrophenyl)-2-methylpropoxy)acetate
[0684]
[0685] 2-(2-chloro-4-nitrophenyl)-2-methylpropan-1-ol (2.720 g, 11.844 mmol), tert-butyl 2-bromoacetate (13.895 mL, 94.749 mmol), and tetrabutylammonium hydrogen sulfate (3.217 g, 9.475 mmol) were dissolved in toluene (50 mL), and 5.0 M aqueous sodium hydroxide solution (59.218 mL, 296.090 mmol) was added at 0 °C and stirred for 2 hours at the same temperature. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 50 g cartridge; ethyl acetate / hexane = 0% to 30%) to obtain tert-butyl 2-(2-(2-chloro-4-nitrophenyl)-2-methylpropoxy)acetate (3.903 g, 95.9%) in the form of a yellow oil.
[0686] 1 H-NMR (400 MHz, CDCl3) δ 8.20 (d, J = 2.5 Hz, 1H), 8.06 (dd, J = 8.9, 2.5 Hz, 1H), 7.82 (d, J = 8.9 Hz, 1H), 3.93 (s, 2H), 3.88 (s, 2H), 1.53 (s, 6H), 1.48 (s, 9H); LRMS (ES) m / z 366.1 [M+Na] + .
[0687] Step 15) Synthesis of 2-(2-(2-chloro-4-nitrophenyl)-2-methylpropoxy)ethanol-1-ol
[0688]
[0689] Diisobutyl aluminum hydride (1.0 M tetrahydrofuran solution, 34.031 mL, 34.031 mmol) was added to a solution of tert-butyl 2-(2-(2-chloro-4-nitrophenyl)-2-methylpropoxy)acetate (3.900 g, 11.344 mmol) dissolved in tetrahydrofuran (60 mL) at 0 °C and stirred for 2 hours at the same temperature. Then, at 0 °C, 2.0 M aqueous sodium hydroxide solution was added to the reaction mixture and stirred for 30 minutes to terminate the reaction. The reaction mixture was filtered through a Celite pad to remove the solid, water was added to the filtrate, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 50 g cartridge; ethyl acetate / hexane = 0% to 30%) to obtain 2-(2-(2-chloro-4-nitrophenyl)-2-methylpropoxy)ethanol-1-ol (2.722 g, 87.7%) in the form of a yellow oil.
[0690] 1 H-NMR (400 MHz, CDCl3) δ 8.21 (d, J = 2.5 Hz, 1H), 8.05 (dd, J = 8.8, 2.5 Hz, 1H), 7.61 (d, J = 8.9 Hz, 1H), 3.86 (s, 2H), 3.68 - 3.60 (m, 2H), 3.57 - 3.47 (m, 2H), 1.52 (s, 6H); LRMS (ES) m / z 296.0 [M+Na] + .
[0691] Step 16) Synthesis of tert-butyl (2-(2-(2-chloro-4-nitrophenyl)-2-methylpropoxy)ethoxy)(methyl)carbamate
[0692]
[0693] 2-(2-(2-chloro-4-nitrophenyl)-2-methylpropoxy)ethanol-1-ol (0.295 g, 1.078 mmol), tert-butyl hydroxy(methyl)carbamate (0.219 mL, 1.617 mmol), and triphenylphosphine (0.424 g, 1.617 mmol) were dissolved in tetrahydrofuran (10 mL), and diisopropyl azodicarboxylate (0.318 mL, 1.617 mmol) was added at 0 °C and stirred at room temperature for 18 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 30%) to obtain tert-butyl (2-(2-(2-chloro-4-nitrophenyl)-2-methylpropoxy)ethoxy)(methyl)carbamate (0.367 g, 84.5%) in the form of a yellow oil.
[0694] 1 H-NMR (400 MHz, CDCl3) δ 8.19 (d, J = 2.4 Hz, 1H), 8.03 (dd, J = 8.8, 2.5 Hz, 1H), 7.65 (d, J = 8.9 Hz, 1H), 3.95 - 3.91 (m, 2H), 3.82 (s, 2H), 3.64 - 3.59 (m, 2H), 3.01 (s, 3H), 1.51 (s, 6H), 1.47 (s, 9H); LRMS (ES) m / z 425.1 [M+Na] + .
[0695] Step 17) Synthesis of tert-butyl (2-(2-(4-amino-2-chlorophenyl)-2-methylpropoxy)ethoxy)(methyl)carbamate
[0696]
[0697] A solution of tert-butyl (2-(2-(2-chloro-4-nitrophenyl)-2-methylpropoxy)ethoxy)(methyl)carbamate (0.330 g, 0.819 mmol), iron (2.287 g, 40.956 mmol), and ammonium chloride (0.131 g, 2.457 mmol) dissolved in ethanol (10 mL) and water (2 mL) was stirred at room temperature for 15 minutes and then further stirred at 80 °C for 30 minutes, after which the temperature was lowered to room temperature to terminate the reaction. The reaction mixture was filtered through a Celite pad to remove the solid, and the solvent was removed from the filtrate under reduced pressure. The concentrate was then purified and concentrated by column chromatography (SiO2, 5g cartridge; ethyl acetate / hexane = 0% to 50%) to obtain tert-butyl (2-(2-(4-amino-2-chlorophenyl)-2-methylpropoxy)ethoxy)(methyl)carbamate (0.260 g, 85.1%) in the form of a yellow oil.
[0698] 1 H-NMR (400 MHz, DMSO-d6) δ 7.05 (d, J = 8.6 Hz, 1H), 6.56 (dd, J = 2.5 Hz, 1H), 6.43 (dd, J = 8.6, 2.5 Hz, 1H), 5.16 (s, 2H), 3.88 - 3.83 (m, 2H), 3.64 (s, 2H), 3.54 - 3.49 (m, 2H), 2.94 (s, 3H), 1.40 (s, 9H), 1.33 (s, 6H); LRMS (ES) m / z 395.1 [M+Na] + .
[0699] Step 18) Synthesis of tert-butyl (2-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenyl)-2-methylpropoxy)ethoxy)(methyl)carbamate
[0700]
[0701] A solution of tert-butyl (2-(2-(4-amino-2-chlorophenyl)-2-methylpropoxy)ethoxy)(methyl)carbamate (0.090 g, 0.241 mmol), phenyl chloroformate (0.033 mL, 0.265 mmol), and N,N-diisopropylethylamine (0.084 mL, 0.483 mmol) dissolved in tetrahydrofuran (2.5 mL) was stirred at 0 °C for 1 hour, and then the reaction mixture was concentrated under reduced pressure. To the concentrated reaction mixture, 3-(5-((S)-1-aminoethyl)-1-oxoisoindolin-2-yl)piperidin-2,6-diionic hydrochloride (0.10 MN,N-dimethylformamide solution, 3.620 mL, 0.362 mmol) and N,N-diisopropylethylamine (0.169 mL, 0.965 mmol) were added and stirred at room temperature for 15 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 5g cartridge; ethyl acetate / hexane = 70% to 100%) to obtain tert-butyl (2-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenyl)-2-methylpropoxy)ethoxy)(methyl)carbamate (0.142 g, 85.9%) in the form of a pale blue oil.
[0702] LRMS (ES) m / z 708.2 [M+Na] + .
[0703] Step 19) Synthesis of 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea
[0704]
[0705] Trifluoroacetic acid (1.036 mL, 4.145 mmol) was added to a solution of tert-butyl (2-(2-(2-2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenyl)-2-methylpropoxy)ethoxy)(methyl)carbamate (0.142 g, 0.207 mmol) dissolved in dichloromethane (2 mL) at room temperature, and the mixture was stirred for 15 minutes at the same temperature. After removing the solvent from the reaction mixture under reduced pressure, it was washed three times with hexane, and then repeatedly washed with the addition of an aqueous solution of saturated sodium bicarbonate to obtain a solid compound. The precipitated solid was filtered and dried to obtain 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea (0.092 g, 75.7%) in the form of a pale gray solid.
[0706] 1H-NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.54 (d, J = 2.9 Hz, 1H), 7.70 (d, J = 7.9 Hz, 1H), 7.57 (d, J = 1.6 Hz, 1H), 7.55 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.26 (d, J = 8.7 Hz, 1H), 7.09 (dd, J = 8.5, 1.7 Hz, 1H), 6.80 (dd, J = 7.5, 1.9 Hz, 1H), 5.10 (dd, J = 13.1, 4.9 Hz, 1H), 4.91 (p, J = 6.8 Hz, 1H), 4.45 (d, J = 17.2 Hz, 1H), 4.31 (d, J = 17.2 Hz, 1H), 3.67 (s, 2H), 3.64 - 3.59 (m, 2H), 3.51 - 3.43 (m, 2H), 2.97 - 2.84 (m, 1H), 2.64 - 2.55 (m, 1H), 2.43 (s, 3H), 2.42 - 2.32 (m, 1H), 2.04 - 1.94 (m, 1H), 1.42 (d, J = 6.7 Hz, 3H), 1.35 (s, 6H); LRMS (ES) m / z 586.2 [M+H] + .
[0707]
[0708] Example 32: Synthesis of 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea
[0709]
[0710] It was synthesized in a manner similar to Example 31.
[0711] 1H-NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 9.08 (s, 1H), 7.69 (d, J = 7.7 Hz, 1H), 7.61 (d, J = 2.4 Hz, 1H), 7.51 (s, 1H), 7.44 (dd, J = 7.8, 1.5 Hz, 1H), 7.27 (d, J = 8.8 Hz, 1H), 7.19 (dd, J = 8.7, 2.4 Hz, 1H), 7.00 (t, J = 6.0 Hz, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.47 - 4.38 (m, 3H), 4.31 (d, J = 17.3 Hz, 1H), 4.17 - 4.10 (m, 2H), 3.71 (s, 2H), 3.62 - 3.56 (m, 2H), 2.96 - 2.85 (m, 1H), 2.79 (s, 3H), 2.64 - 2.56 (m, 1H), 2.41 - 2.32 (m, 1H), 2.04 - 1.96 (m, 1H), 1.37 (s, 6H); LRMS (ES) m / z 572.2 [M+H] + .
[0712]
[0713] Example 33: Synthesis of 1-(3-chloro-4-(2-(methyl(2-((methylamino)oxy)ethyl)amino)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride
[0714] Step 1) Synthesis of 2-(2-chloro-4-nitrophenyl)-N-methylacetamide
[0715]
[0716] To a solution in which 2-(2-chloro-4-nitrophenyl)acetic acid (1.000 g, 4.638 mmol), methylamine hydrochloride (0.626 g, 9.277 mmol), and N,N-diisopropylethylamine (4.051 mL, 23.192 mmol) were dissolved in N,N-dimethylformamide (10 mL) at room temperature, 1H-benzo[d][1,2,3]triazole-1-ol (HOBt, 0.940 g, 6.958 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC-HCl, 1.334 g, 6.958 mmol) were added and stirred at the same temperature for 3 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, and then filtered and concentrated under reduced pressure. Diethyl ether (20 mL) and hexane (20 mL) were added to the concentrate and stirred to precipitate the solid, which was then filtered, washed with hexane, and dried to obtain 2-(2-chloro-4-nitrophenyl)-N-methylacetamide (0.555 g, 52.3%) in the form of a white solid.
[0717] 1 H-NMR (400 MHz, DMSO-d6)δ 8.26 (t, J = 1.8 Hz, 1H), 8.16 (dt, J = 8.5, 1.7 Hz, 1H), 8.05 (s, 1H), 7.69 - 7.64 (m, 1H), 3.72 (s, 3H), 2.60 (s, 2H); LRMS (ES) m / z 229.0 [M+Na] + .
[0718] Step 2) Synthesis of 2-(2-chloro-4-nitrophenyl)-N-methylethane-1-amine
[0719]
[0720] Borein-tetrahydrozomplex (1.0 M tetrahydrofuran solution, 9.710 mL, 9.710 mmol) was added to a solution of 2-(2-chloro-4-nitrophenyl)-N-methylacetamide (1.110 g, 4.855 mmol) dissolved in tetrahydrofuran (12 mL) at room temperature, and the mixture was stirred at 70 °C for 16 hours, after which the temperature was lowered to room temperature to terminate the reaction. Water was poured into the reaction mixture, and it was extracted three times with ethyl acetate and once with 10% methanol / dichloromethane. (Target compound ratio, organic layer : water layer = 2 : 8) The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. After concentrating the aqueous layer, the residue was washed with 10% methanol / dichloromethane, and the filtrate was concentrated and combined with the mixture obtained from the organic layer. The mixture was then purified and concentrated by column chromatography (SiO2, 10g cartridge; methanol / dichloromethane = 3% to 10%) to obtain 2-(2-chloro-4-nitrophenyl)-N-methylethane-1-amine (0.360 g, 34.5%) in the form of a brown solid.
[0721] LRMS (ES) m / z 215.0 [M+H] + .
[0722] Step 3) Synthesis of tert-butyl N-(2-chloro-4-nitropenethyl)-N-methylglycinate
[0723]
[0724] 2-(2-chloro-4-nitrophenyl)-N-methylethane-1-amine (0.360 g, 1.677 mmol) and triethylamine (0.349 mL, 2.516 mmol) were dissolved in tetrahydrofuran (5 mL) at room temperature, to which tert-butyl bromoacetate (0.320 mL, 2.180 mmol) was added and stirred at the same temperature for 4 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 5% to 20%) to obtain tert-butyl N-(2-chloro-4-nitropenethyl)-N-methylglycinate (0.233 g, 42.3%) as a light brown liquid.
[0725] 1 H NMR (400 MHz, CDCl3)δ 8.24 (d, J = 2.3 Hz, 1H), 8.07 (dd, J = 8.4, 2.3 Hz, 1H), 7.53 (d, J = 7.8 Hz, 1H), 3.38 (s, 2H), 3.22 - 3.08 (m, 2H), 3.05 - 2.95 (m, 2H), 2.62 (s, 3H), 1.48 (s, 9H); LRMS(ES) m / z 329.1 [M+Na] + .
[0726] Step 4) Synthesis of 2-((2-chloro-4-nitropenethyl)(methyl)amino)ethanol-1-ol
[0727]
[0728] Diisobutylaluminum hydride (DIBAL-H, 1.749 mL, 1.749 mmol) was added to a solution of tert-butyl N-(2-chloro-4-nitropenethyl)-N-methylglycinate (0.230 g, 0.700 mmol) dissolved in tetrahydrofuran (4 mL) at room temperature, and the mixture was stirred at 0 °C for 3 hours. The reaction mixture was filtered through a Celite pad to remove the solid, and the solvent was removed from the filtrate under reduced pressure; the resulting product was used without further purification (2-((2-chloro-4-nitropenethyl)(methyl)amino)ethanol-1-ol, 0.190 g, 105.0 %, orange solid).
[0729] 1 H NMR (400 MHz, CDCl3)δ 8.31 - 8.27 (m, 1H), 8.12 (dd, J = 4.2, 3.2 Hz, 1H), 7.66 (d, J = 8.5 Hz, 1H), 4.08 - 4.00 (m, 2H), 3.54 - 3.45 (m, 2H), 3.27 (d, J = 8.8 Hz, 4H), 2.92 (s, 3H); LRMS (ES) m / z 259.0 [M+H] + .
[0730] Step 5) Synthesis of tert-butyl (2-((2-chloro-4-nitropenethyl)(methyl)amino)ethoxy)(methyl)carbamate
[0731]
[0732] Diisopropyl azodicarboxylate (1.9 M toluene solution, 0.773 mL, 1.469 mmol) was added to a solution of 2-((2-chloro-4-nitropenethyl)(methyl)amino)ethanol-1-ol (0.190 g, 0.734 mmol), tert-butylhydroxy(methyl)carbamate (0.200 mL, 1.469 mmol), and triphenylphosphine (0.385 g, 1.469 mmol) dissolved in tetrahydrofuran (4 mL) at room temperature, and the mixture was stirred at 0 °C for 3 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 40% to 100%) to obtain tert-butyl (2-((2-chloro-4-nitropenethyl)(methyl)amino)ethoxy)(methyl)carbamate (0.975 g, 342.3%) in the form of a yellow solid.
[0733] LRMS (ES) m / z 388.1 [M+H] + .
[0734] Step 6) Synthesis of tert-butyl (2-((4-amino-2-chlorophenethyl)(methyl)amino)ethoxy)(methyl)carbamate
[0735]
[0736] A solution of tert-butyl (2-((2-chloro-4-nitropenethyl)(methyl)amino)ethoxy)(methyl)carbamate (0.280 g, 0.722 mmol), iron (0.202 g, 3.610 mmol), and ammonium chloride (0.154 g, 2.888 mmol) dissolved in ethanol (5 mL) and water (1 mL) at room temperature was stirred at 80 °C for 1 hour, after which the temperature was lowered to room temperature to terminate the reaction. The reaction mixture was filtered through a Celite pad to remove the solid, water was added to the filtrate, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; methanol / dichloromethane = 0% to 7%) to obtain tert-butyl (2-((4-amino-2-chlorophenethyl)(methyl)amino)ethoxy)(methyl)carbamate (0.081 g, 31.4%) in the form of a yellow liquid.
[0737] 1 H NMR (400 MHz, CDCl3)δ 7.03 (d, J = 8.2 Hz, 1H), 6.68 (t, J = 2.0 Hz, 1H), 6.52 (dt, J = 8.1, 3.3 Hz, 1H), 4.09 (s, 2H), 3.10 (s, 2H), 2.92 (d, J = 7.0 Hz, 4H), 2.81 (s, 2H), 2.56 (s, 2H), 1.48 (s, 9H); LRMS(ES) m / z 358.2 [M+H] + .
[0738] Step 7) Synthesis of tert-butyl (2-((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethyl)(methyl)amino)ethoxy)(methyl)carbamate
[0739]
[0740] A solution of tert-butyl (2-((4-amino-2-chlorophenethyl)(methyl)amino)ethoxy)(methyl)carbamate (0.040 g, 0.112 mmol), pyridine (0.010 mL, 0.123 mmol), and phenyl chloroformate (0.016 mL, 0.123 mmol) dissolved in ethyl acetate (3 mL) was stirred and concentrated at 0 °C for 0.5 hours. The residue was dissolved in N,N-dimethylformamide (2 mL), and triethylamine (0.077 mL, 0.559 mmol) and 3-(5-(aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dionic chloroform (0.036 g, 0.117 mmol) were added and further stirred at room temperature for 3 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 5g cartridge; methanol / dichloromethane = 3% to 10%) to obtain tert-butyl (2-((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethyl)(methyl)amino)ethoxy)(methyl)carbamate (0.022 g, 30.0%) as a white solid.
[0741] LRMS(ES) m / z 657.1 [M+H] + .
[0742] Step 8) Synthesis of 1-(3-chloro-4-(2-(methyl(2-((methylamino)oxy)ethyl)amino)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride
[0743]
[0744] Hydrogen chloride (4.0 M 1,4-dioxane solution, 0.167 mL, 0.670 mmol) was added to a solution of tert-butyl (2-((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethyl)(methyl)amino)ethoxy)(methyl)carbamate (0.022 g, 0.033 mmol) dissolved in dichloromethane (3.5 mL) at room temperature, and the mixture was stirred at the same temperature for 3 hours. After removing the solvent from the reaction mixture under reduced pressure, 2-propanol (1 mL), dichloromethane (3 mL) and diethyl ether (10 mL) were added to the concentrate and stirred to filter the precipitated solid, wash it with hexane, and dry it to obtain 1-(3-chloro-4-(2-(methyl(2-((methylamino)oxy)ethyl)amino)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride (0.006 g, 29.2%) in the form of a white solid.
[0745] 1 H NMR (400 MHz, DMSO-d6)δ 10.97 (s, 1H), 9.19 (s, 1H), 7.70 (dd, J = 8.3, 4.9 Hz, 2H), 7.51 (s, 1H), 7.44 (d, J = 7.8 Hz, 1H), 7.32 - 7.22 (m, 2H), 7.05 (t, J = 5.8 Hz, 1H), 5.10 (dd, J = 13.3, 5.0 Hz, 1H), 4.52 - 4.25 (m, 6H), 3.25 (d, J = 4.6 Hz, 3H), 3.06 (dd, J = 10.3, 6.1 Hz, 3H), 2.93 (dd, J = 13.3, 4.9 Hz, 1H), 2.89 (s, 3H), 2.77 (s, 3H), 2.62 (t, J = 18.9 Hz, 1H), 2.42 - 2.31 (m, 1H), 2.04 - 1.95 (m, 1H); LRMS (ES) m / z 557.2 [M+H] + .
[0746]
[0747] Example 34: Synthesis of 1-(4-((aminooxy)methyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)thiourea hydrochloride
[0748]
[0749] It was synthesized in a manner similar to Example 24.
[0750] 1 H-NMR (400 MHz, DMSO-d6)δ 10.96 (s, 1H), 9.94 (br, 1H), 8.54 (br, 1H), 7.82 (s, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.53 (s, 1H), 7.46 (d, J = 8.1 Hz,1H), 7.42 (s, 1H), 5.09 (dd, J = 13.3, 4.8 Hz, 1H), 4.91 (s, 2H), 4.85 (br, 2H), 4.37 (dd, J = 55.2, 17.3 Hz, 2H), 2.99 - 2.52 (m, 2H), 2.22 (ddd, J = 135.2, 11.8, 4.8 Hz, 2H); LRMS (ES) m / z 488.0 [M+H] + .
[0751]
[0752] Example 35: Synthesis of 1-(3-chloro-4-(2-(2-((dimethylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea
[0753]
[0754] A solution of 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride (0.050 g, 0.086 mmol), formaldehyde (0.078 g, 2.584 mmol), and sodium triacetoxyborohydride (0.146 g, 0.689 mmol) dissolved in methanol (3 mL) was stirred at 0 °C for 1 hour and further stirred at room temperature for 1 hour. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; methanol / dichloromethane = 0% to 3%), and the resulting product was further purified and concentrated by column chromatography (C18, 10 g cartridge; acetonitrile / 0.1% formic acid aqueous solution = 20% to 50%) to obtain 1-(3-chloro-4-(2-(2-((dimethylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea (0.011 g, 22.9%) in the form of a white solid.
[0755] 1H NMR (400 MHz, DMSO-d6)δ 10.93 (s, 1H), 8.75 (s, 1H), 7.65 (d, J = 7.8 Hz, 1H), 7.62 (d, J = 1.9 Hz, 1H), 7.47 (s, 1H), 7.40 (d, J = 7.8) Hz, 1H), 7.18 (d, J = 8.3 Hz, 1H), 7.11 (dd, J = 8.3, 2.2 Hz, 1H), 6.78 (t, J = 6.0 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.43 - 4.24 (m, 4H), 3.63 (dd, J = 5.8, 4.0 Hz, 2H), 3.53 - 3.44 (m, 4H), 2.93 - 2.82 (m, 1H), 2.80 (t, J = 7.1 Hz, 2H), 2.64 - 2.50 (m, 1H), 2.44 (s, 6H), 2.36 - 2.25 (m, 1H), 1.99 - 1.90 (m, 1H); LRMS (ES) m / z 558.2 [M+H] + .
[0756]
[0757] Example 36: Synthesis of 1-(3-chloro-4-(2-(2-((cyclopentylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea
[0758]
[0759] It was synthesized in a manner similar to Example 23.
[0760] 1H NMR (400 MHz, DMSO-d6)δ 10.93 (s, 1H), 8.74 (s, 1H), 7.67 - 7.61 (m, 2H), 7.47 (s, 1H), 7.40 (d, J = 7.9 Hz, 1H), 7.17 (d, J = 8.4 Hz, 1H), 7.11 (d, J = 8.3 Hz, 1H), 6.77 (t, J = 5.9 Hz, 1H), 5.06 (dd, J = 13.3, 4.8 Hz, 1H), 4.44 - 4.23 (m, 4H), 3.64 - 3.58 (m, 1H), 3.56 - 3.50 (m, 2H), 3.50 - 3.44 (m, 2H), 2.92 - 2.82 (m, 1H), 2.79 (t, J = 7.3 Hz, 2H), 2.58 (t, J = 19.0 Hz, 1H), 2.39 - 2.27 (m, 1H), 2.24 - 2.19 (m, 2H), 2.00 - 1.91 (m, 3H), 1.65 - 1.57 (m, 2H), 1.55 - 1.48 (m, 2H), 1.43 - 1.37 (m, 2H); LRMS (ES) m / z 598.2 [M+H] + .
[0761]
[0762] Example 37: Synthesis of 1-(3-chloro-4-(2-(2-((cyclobutylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea
[0763]
[0764] It was synthesized in a manner similar to Example 23.
[0765] 1H NMR (400 MHz, DMSO-d6)δ 10.93 (s, 1H), 9.00 (s, 1H), 7.66 - 7.62 (m, 2H), 7.47 (s, 1H), 7.40 (d, J = 7.8 Hz, 1H), 7.21 - 7.09 (m, 2H), 7.04 (t, J = 5.8 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.45 - 4.23 (m, 4H), 3.65 - 3.56 (m, 2H), 3.53 - 3.40 (m, 5H), 2.87 (ddd, J = 17.0, 13.4, 5.3 Hz, 1H), 2.79 (t, J = 7.1 Hz, 2H), 2.63 - 2.52 (m, 1H), 2.37 - 2.26 (m, 1H), 1.98 - 1.87 (m, 3H), 1.79 - 1.71 (m, 2H), 1.65 - 1.50 (m, 2H); LRMS (ES) m / z 584.2 [M+H] + .
[0766]
[0767] Example 38: Synthesis of 1-(3-chloro-4-((4-(((methylamino)oxy)methyl)piperidine-1-yl)methyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea
[0768] Step 1) Synthesis of 1-(bromomethyl)-2-chloro-4-nitrobenzene
[0769]
[0770] A solution of (2-chloro-4-nitrophenyl)methanol (1.000 g, 5.331 mmol) and phosphorus tribromide (2.886 g, 10.662 mmol) dissolved in dichloromethane (20 mL) was stirred at 0 °C for 30 minutes and further stirred at room temperature for 24 hours. Then, at 0 °C, an aqueous solution of saturated sodium bicarbonate was added to the reaction mixture and stirred for 10 minutes to terminate the reaction. The reaction mixture was extracted with dichloromethane. The organic layer was dehydrated with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 25 g cartridge; ethyl acetate / hexane = 0% to 33%) to obtain 1-(bromomethyl)-2-chloro-4-nitrobenzene (0.810 g, 60.7%) in the form of yellow crystals.
[0771] Step 2) Synthesis of (1-(2-chloro-4-nitrobenzyl)piperidine-4-yl)methanol
[0772]
[0773] A solution of 1-(bromomethyl)-2-chloro-4-nitrobenzene (0.100 g, 0.399 mmol), piperidine-4-ylmethanol (0.055 g, 0.479 mmol), and triethylamine (0.111 mL, 0.798 mmol) dissolved in N,N-dimethylformamide (1 mL) at room temperature was stirred at the same temperature for 1 hour. A saturated aqueous sodium bicarbonate solution was poured over the concentrate obtained by removing the solvent from the reaction mixture under reduced pressure, and the mixture was extracted with dichloromethane. The organic layer was washed with a saturated aqueous water solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 80%) to obtain (1-(2-chloro-4-nitrobenzyl)piperidin-4-yl)methanol (0.096 g, 84.5%) in the form of a yellow liquid.
[0774] LRMS (ES) m / z 285.1 [M+H] + .
[0775] Step 3) Synthesis of tert-butyl ((1-(2-chloro-4-nitrobenzyl)piperidin-4-yl)methoxy)(methyl)carbamate
[0776]
[0777] A solution of (1-(2-chloro-4-nitrobenzyl)piperidin-4-yl)methanol (0.096 g, 0.338 mmol), tert-butylhydroxy(methyl)carbamate (0.069 mL, 0.506 mmol), triphenylphosphine (0.133 g, 0.506 mmol), and diisopropyl azodicarboxylate (DIAD, 0.100 mL, 0.506 mmol) dissolved in tetrahydrofuran (3 mL) was stirred at 0 °C for 30 minutes and further stirred at room temperature for 24 hours. A saturated aqueous sodium bicarbonate solution was poured over the concentrate obtained by removing the solvent from the reaction mixture under reduced pressure, and the mixture was extracted with ethyl acetate. The organic layer was dehydrated with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 33%) to obtain tert-butyl ((1-(2-chloro-4-nitrobenzyl)piperidin-4-yl)methoxy)(methyl)carbamate (0.126 g, 90.2%) in the form of yellow crystals.
[0778] LRMS (ES) m / z 414.2 [M+H] + .
[0779] Step 4) Synthesis of (tert-butyl ((1-(4-amino-2-chlorobenzyl)piperidin-4-yl)methoxy)(methyl)carbamate
[0780]
[0781] A mixture of tert-butyl ((1-(2-chloro-4-nitrobenzyl)piperidin-4-yl)methoxy)(methyl)carbamate (0.126 g, 0.304 mmol), iron (0.170 g, 3.044 mmol), and ammonium chloride (0.163 g, 3.044 mmol) in ethanol (4 mL) / water (1 mL) was stirred at 90 °C for 1 hour, after which the temperature was lowered to room temperature to terminate the reaction. The reaction mixture was filtered through a Celite pad to remove the solid, and the solvent was removed from the filtrate under reduced pressure; the resulting product was used without further purification (tert-butyl ((1-(4-amino-2-chlorobenzyl)piperidin-4-yl)methoxy)(methyl)carbamate, 0.104 g, 89.0%, brown liquid).
[0782] LRMS (ES) m / z 384.1 [M+H] + .
[0783] Step 5) Synthesis of tert-butyl ((1-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)piperidine-4-yl)methoxy)(methyl)carbamate
[0784]
[0785] A solution of tert-butyl ((1-(4-amino-2-chlorobenzyl)piperidin-4-yl)methoxy)(methyl)carbamate (0.043 g, 0.112 mmol), 4-nitrophenyl carbonochloridate (0.025 g, 0.123 mmol), and pyridine (0.010 mL, 0.123 mmol) dissolved in ethyl acetate (2 mL) was stirred at room temperature for 1 hour and then concentrated under reduced pressure. The reaction mixture was dissolved in N,N-dimethylformamide (1 mL), and then 3-(5-(aminomethyl)-1-oxoisoindolin-2-yl)piperidin-2,6-dionic cellulose (0.038 g, 0.123 mmol) and triethylamine (0.039 mL, 0.280 mmol) were added and stirred for 18 hours at the same temperature. Water was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 10%) to obtain tert-butyl ((1-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)piperidine-4-yl)methoxy)(methyl)carbamate (0.044 g, 57.5%).
[0786] LRMS (ES) m / z 683.0 [M+H] +
[0787] Step 6) Synthesis of 1-(3-chloro-4-((4-(((methylamino)oxy)methyl)piperidine-1-yl)methyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride
[0788]
[0789] tert-butyl ((1-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)piperidine-4-yl)methoxy)(methyl)carbamate (0.024 g, 0.035 mmol) and hydrogen chloride (4.0 M 1,4-dioxane solution, 0.176 mL, 0.703 mmol) were dissolved in dichloromethane (3 mL), stirred at 0 °C for 30 minutes, and further stirred at room temperature for 1 hour. After removing the solvent from the reaction mixture under reduced pressure, an aqueous diethyl ether solution (8 mL) was poured over the concentrate to suspend it and filter the resulting solid, which was then washed with hexane and dried to obtain 1-(3-chloro-4-((4-(((methylamino)oxy)methyl)piperidin-1-yl)methyl)phenyl)-3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride (0.021 g, 96.5%) in the form of ivory crystals.
[0790] 1 H NMR (400 MHz, DMSO-d6)δ 10.96 (s, 1H), 9.72 (br, 2H), 9.47 (s, 1H), 7.80 (s, 1H), 7.74 - 7.58 (m, 2H), 7.50 (s, 1H), 7.43 (d, J = 7.4 Hz, 1H), 7.33 (d, J = 8.5 Hz, 1H), 7.17 (s, 1H), 5.09 (dd, J = 13.1, 5.5 Hz, 1H), 4.50 - 4.23 (m, 6H), 3.82 (br, 1H), 3.56 (s, 1H), 2.99 - 2.82 (m, 1H), 2.74 (s, 3H), 2.70 - 2.53 (m, 1H), 2.44 - 2.27 (m, 2H), 2.02 - 1.89 (m, 2H), 1.88 - 1.76 (m, 2H), 1.66 - 1.46 (m, 1H); LRMS (ES) m / z 583.1 [M+H] + .
[0791]
[0792] Example 39: Synthesis of 1-(3-chloro-4-(3,6,9-trioxa-2-azaudecane-11-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride
[0793] Step 1) Synthesis of tert-butyl 2-(2-(2-chloro-4-nitropenetoxy)ethoxy)acetate
[0794]
[0795] A solution of 2-(2-chloro-4-nitropenetoxy)ethanol-1-ol (0.567 g, 2.308 mmol), tert-butyl 2-bromoacetate (0.677 mL, 4.616 mmol), and tetrabutylammonium hydrogen sulfate (0.627 g, 1.846 mmol) dissolved in toluene (10 mL) was stirred at room temperature for 1 hour, and sodium hydroxide (5.0 M aqueous solution, 18.465 mL, 92.323 mmol) was added and further stirred at 0 °C for 7 hours. Saturated sodium bicarbonate aqueous solution was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with saturated sodium chloride aqueous solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 25 g cartridge; ethyl acetate / hexane = 0% to 20%) to obtain tert-butyl 2-(2-(2-chloro-4-nitropenetoxy)ethoxy)acetate (0.270 g, 32.5%) in the form of a clear liquid.
[0796] LRMS (ES) m / z 382.1 [M+Na] + .
[0797] Step 2) 2-(2-(2-chloro-4-nitropenetoxy)ethoxy)ethanol-1-ol
[0798]
[0799] A solution of tert-butyl 2-(2-(2-chloro-4-nitropenetoxy)ethoxy)acetate (0.270 g, 0.750 mmol) and diisobutylaluminum hydride (DIBAL-H, 1.0 M tetrahydrofuran solution, 3.002 mL, 3.002 mmol) dissolved in tetrahydrofuran (5 mL) was stirred at 0 °C for 1 hour and further stirred at room temperature for 3 hours. When the reaction was complete, water was added to the reaction mixture at 0 °C and stirred for 30 minutes to terminate the reaction. The reaction mixture was filtered through a Celite pad to remove the solid, water was added to the filtrate, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 100%) to obtain 2-(2-(2-chloro-4-nitropenetoxy)ethoxy)ethanol-1-ol (0.188 g, 86.5%) in the form of a clear liquid.
[0800] LRMS (ES) m / z 312.1 [M+Na] + .
[0801] Step 3) Synthesis of tert-butyl (2-(2-(2-chloro-4-nitropenenetoxy)ethoxy)ethoxy)(methyl)carbamate
[0802]
[0803] 2-(2-(2-chloro-4-nitropenetoxy)ethoxy)ethanol-1-ol (0.188 g, 0.649 mmol), tert-butyl hydroxy(methyl)carbamate (0.131 mL, 0.973 mmol), triphenylphosphine (0.255 g, 0.973 mmol), and diisopropyl azodicarboxylate (DIAD, 0.192 mL, 0.973 mmol) were dissolved in tetrahydrofuran (5 mL) at 0 °C and stirred at room temperature for 18 hours. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (SiO2, 25 g cartridge; ethyl acetate / hexane = 0% to 20%) to obtain tert-butyl (2-(2-(2-chloro-4-nitropenenetoxy)ethoxy)ethoxy)(methyl)carbamate (0.250 g, 92.0%) in the form of a clear liquid.
[0804] LRMS (ES) m / z 441.1 [M+Na] + .
[0805] Step 4) Synthesis of (tert-butyl (2-(2-(4-amino-2-chlorophennetoxy)ethoxy)ethoxy)(methyl)carbamate
[0806]
[0807] Tert-butyl (2-(2-(2-chloro-4-nitropenenetoxy)ethoxy)ethoxy)(methyl)carbamate (0.100 g, 0.239 mmol), iron (0.160 g, 2.865 mmol), and ammonium chloride (0.153 g, 2.865 mmol) were dissolved in ethanol (4 mL) and water (1 mL), and stirred at 80 °C for 1 hour. When the reaction was complete, the temperature was lowered to room temperature to terminate the reaction. The reaction mixture was filtered through a Celite pad to remove the solid, water was added to the filtrate, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The product was used without further purification (tert-butyl (2-(2-(4-amino-2-chlorophennetoxy)ethoxy)ethoxy)(methyl)carbamate, 0.090 g, 96.9%, clear solid).
[0808] LRMS (ES) m / z 411.2 [M+Na] + .
[0809] Step 5) Synthesis of tert-butyl (2-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)ethoxy)(methyl)carbamate
[0810]
[0811] Tert-butyl (2-(2-(4-amino-2-chlorophennetoxy)ethoxy)ethoxy)(methyl)carbamate (0.050 g, 0.129 mmol), phenyl chloroformate (0.018 mL, 0.141 mmol), and pyridine (0.011 mL, 0.141 mmol) were dissolved in ethyl acetate (3 mL) and stirred at 0 °C for 1 hour. Once the formation of the intermediate was confirmed, the organic solvent was removed under reduced pressure. After dissolving the reaction mixture in N,N-dimethylformamide, 3-(5-(aminomethyl)-1-oxoisoindolin-2-yl)piperidin-2,6-dionic cellulose (0.048 g, 0.154 mmol) and triethylamine (0.053 mL, 0.386 mmol) were added, and the mixture was further stirred at room temperature for 18 hours. When the reaction was completed, the solvent was removed from the reaction mixture under reduced pressure, and the concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 10%) to obtain tert-butyl (2-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)ethoxy)(methyl)carbamate (0.028 g, 31.6%) in the form of a white solid.
[0812] LRMS (ES) m / z 688.2 [M+H] + .
[0813] Step 6) Synthesis of 1-(3-chloro-4-(3,6,9-trioxa-2-azaudecane-11-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride
[0814]
[0815] tert-butyl (2-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)ethoxy)(methyl)carbamate (0.028 g, 0.041 mmol) and hydrogen chloride (4.0 M 1,4-dioxane solution, 0.203 mL, 0.814 mmol) were dissolved in dichloromethane (3 mL), stirred at 0 °C for 30 minutes, and then further stirred at room temperature for 1 hour. After removing the solvent from the reaction mixture under reduced pressure, an aqueous diethyl ether solution (5 mL) was poured over the concentrate to suspend it and filter the resulting solid, which was then washed with hexane and dried to obtain 1-(3-chloro-4-(3,6,9-trioxa-2-azaudecane-11-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride (0.021 g, 82.6%) in the form of a white solid.
[0816] 1 H-NMR (400 MHz, DMSO-d6)δ 11.62 (br, 1H), 10.94 (s, 1H), 8.98 (s, 1H), 7.75 - 7.56 (m, 2H), 7.48 (s, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.16 (dd, J = 16.0, 8.3 Hz, 2H), 6.92 (t, J = 5.7 Hz, 1H), 5.07 (dd, J = 13.3, 5.0 Hz, 1H), 4.49 - 4.23 (m, 4H), 4.17 - 4.06 (m, 2H), 3.69 - 3.47 (m, 8H), 2.97 - 2.75 (m, 6H), 2.56 (d, J = 17.6 Hz, 1H), 2.39 - 2.26 (m, 1H), 2.01 - 1.91 (m, 1H); LRMS (ES) m / z 588.2 [M+H] + .
[0817]
[0818] Example 40: Synthesis of 1-(3-chloro-4-(6-methyl-3,7-dioxa-2,6-diazanonnan-9-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea
[0819] Step 1) Synthesis of tert-butyl (2-chloro-4-nitropenethoxy)(methyl)carbamate
[0820]
[0821] 2-(2-chloro-4-nitrophenyl)ethanol-1-ol (0.500 g, 2.480 mmol), tert-butyl hydroxy(methyl)carbamate (0.505 mL, 3.720 mmol), triphenylphosphine (0.976 g, 3.720 mmol), and diisopropyl azodicarboxylate (DIAD, 0.732 mL, 3.720 mmol) were dissolved in tetrahydrofuran (15 mL), stirred at 0 °C for 30 minutes, and further stirred at room temperature for 18 hours. When the reaction was completed, the solvent was removed from the reaction mixture under reduced pressure, and the concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 10%) to obtain tert-butyl (2-chloro-4-nitropenetoxy)(methyl)carbamate (0.240 g, 29.3%) in the form of a clear liquid.
[0822] LRMS (ES) m / z 353.1 [M+Na] + .
[0823] Step 2) Synthesis of O-(2-chloro-4-nitropenethyl)-N-methylhydroxylamine hydrochloride
[0824]
[0825] Tert-butyl (2-chloro-4-nitropenetoxy)(methyl)carbamate (0.240 g, 0.726 mmol) and hydrogen chloride (4.0 M 1,4-dioxane solution, 3.628 mL, 14.512 mmol) were dissolved in dichloromethane (5 mL), stirred at 0 °C for 30 minutes, and further stirred at room temperature for 1 hour. After removing the solvent from the reaction mixture under reduced pressure, diethyl ether (10 mL) was poured over the concentrate to suspend it, and after filtration, the resulting solid was washed with hexane and dried to obtain O-(2-chloro-4-nitropeneethyl)-N-methylhydroxylamine hydrochloride (0.172 g, 88.7%) in the form of a white solid.
[0826] LRMS (ES) m / z 231.05 [M+H] + .
[0827] Step 3) Synthesis of N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-O-(2-chloro-4-nitropenethyl)-N-methylhydroxylamine
[0828]
[0829] O-(2-chloro-4-nitropenethyl)-N-methylhydroxylamine hydrochloride (0.070 g, 0.262 mmol), 2-((tert-butyldimethylsilyl)oxy)acetaldehyde (0.060 mL, 0.314 mmol) and N,N-diisopropylethylamine (0.050 mL, 0.288 mmol) were dissolved in dichloromethane (5 mL), stirred for 30 minutes, and then sodium triacetoxyborohydride (0.111 g, 0.524 mmol) was added and stirred for an additional 12 hours at the same temperature. When the reaction was completed, the solvent was removed from the reaction mixture under reduced pressure, and the concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 5%) to obtain N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-O-(2-chloro-4-nitropenethyl)-N-methylhydroxylamine (0.046 g, 45.1%) in the form of an orange liquid.
[0830] LRMS (ES) m / z 389.1 [M+H] + .
[0831] Step 4) Synthesis of 2-((2-chloro-4-nitropenethoxy)(methyl)amino)ethanol-1-ol
[0832]
[0833] To a solution in which N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-O-(2-chloro-4-nitropenethyl)-N-methylhydroxylamine (0.098 g, 0.252 mmol) was dissolved in tetrahydrofuran (3 mL) at 0 °C, tetrabutylammonium fluoride (0.302 mL, 0.302 mmol) was added and stirred at the same temperature for 5 hours. When the reaction was complete, water was added to the reaction mixture and stirred for 5 minutes to terminate the reaction, after which the reaction mixture was extracted with dichloromethane. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. 2-((2-chloro-4-nitropenetoxy)(methyl)amino)ethanol-1-ol (0.068 g, 98.2%) was obtained in the form of an orange liquid without additional purification of the product.
[0834] LRMS (ES) m / z 275.0 [M+H] + .
[0835] Step 5) Synthesis of tert-butyl (2-((2-chloro-4-nitropenethoxy)(methyl)amino)ethoxy)(methyl)carbamate
[0836]
[0837] 2-((2-chloro-4-nitropenetoxy)(methyl)amino)ethanol-1-ol (0.035 g, 0.127 mmol), triphenylphosphine (0.050 g, 0.191 mmol), tert-butylhydroxy(methyl)carbamate (0.026 mL, 0.191 mmol) and diisopropyl azodicarboxylate (DIAD, 0.038 mL, 0.191 mmol) were dissolved in tetrahydrofuran (2 mL), stirred at 0 °C for 30 minutes, and further stirred at room temperature for 18 hours. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 33%) to obtain tert-butyl (2-((2-chloro-4-nitropenetoxy)(methyl)amino)ethoxy)(methyl)carbamate (0.011 g, 21.4%) in the form of a yellow liquid.
[0838] LRMS (ES) m / z 404.1 [M+H] + .
[0839] Step 6) Synthesis of tert-butyl (2-((4-amino-2-chlorophennetoxy)(methyl)amino)ethoxy)(methyl)carbamate
[0840]
[0841] Tert-butyl (2-((2-chloro-4-nitropenetoxy)(methyl)amino)ethoxy)(methyl)carbamate (0.023 g, 0.057 mmol), iron (0.019 g, 0.342 mmol), and ammonium chloride (0.018 g, 0.342 mmol) were dissolved in ethanol (2 mL) and water (0.5 mL), and stirred at 90 °C for 30 minutes. When the reaction was complete, the temperature was lowered to room temperature to terminate the reaction. The reaction mixture was filtered through a Celite pad to remove the solid, and the filtrate was subjected to solvent removal under reduced pressure. Water was added to the concentrate obtained from the solvent removal, and the mixture was extracted with dichloromethane. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. tert-butyl (2-((4-amino-2-chlorophennetoxy)(methyl)amino)ethoxy)(methyl)carbamate (0.019 g, 87.4%) was obtained as a yellow liquid without further purification of the product.
[0842] LRMS (ES) m / z 374.2 [M+H] + .
[0843] Step 7) Synthesis of tert-butyl (2-((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)(methyl)amino)ethoxy)(methyl)carbamate
[0844]
[0845] A solution of tert-butyl (2-((4-amino-2-chlorophennetoxy)(methyl)amino)ethoxy)(methyl)carbamate (0.019 g, 0.050 mmol), phenylchloroformate (0.007 mL, 0.055 mmol), and pyridine (0.004 mL, 0.055 mmol) dissolved in ethyl acetate (2 mL) was stirred at 0 °C for 1 hour, after which the organic solvent was removed under reduced pressure. The reaction mixture was dissolved in 1 mL of N,N-dimethylformamide, and then 3-(5-(aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dimethylform (0.018 g, 0.060 mmol) and triethylamine (0.021 mL, 0.149 mmol) were added and the mixture was further stirred at room temperature for 18 hours. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; methanol / dichloromethane = 0% to 5%) to obtain tert-butyl (2-((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)(methyl)amino)ethoxy)(methyl)carbamate (0.010 g, 29.9%) in the form of a colorless liquid.
[0846] LRMS (ES) m / z 673.2 [M+H] + .
[0847] Step 8) Synthesis of 1-(3-chloro-4-(6-methyl-3,7-dioxa-2,6-diazanonnan-9-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea
[0848]
[0849] tert-butyl (2-((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)(methyl)amino)ethoxy)(methyl)carbamate (0.010 g, 0.015 mmol) and trifluoroacetic acid (0.568 mL, 7.428 mmol) were dissolved in dichloromethane (2 mL), stirred at 0 °C for 30 minutes, and then further stirred at room temperature for 2 hours. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (C18, 10 g cartridge; acetonitrile / 0.1% aqueous formic acid solution = 20% to 50%) to obtain 1-(3-chloro-4-(6-methyl-3,7-dioxa-2,6-diazanonnan-9-yl)phenyl)-3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)urea (0.003 g, 35.2%) in the form of a white solid.
[0850] 1 H-NMR (400 MHz, DMSO-d6)δ 10.96 (s, 1H), 9.31 (s, 1H), 8.44 (s, 1H), 7.74 - 7.63 (m, 2H), 7.49 (, 1Hs), 7.46 - 7.33 (m, 2H), 7.23 - 7.12 (m, 2H), 5.08 (dd, J = 13.3, 5.1 Hz, 1H), 4.54 - 4.18 (m, 4H), 3.71 (t, J = 7.1 Hz, 2H), 3.61 (t, J = 6.0 Hz, 2H), 2.96 - 2.66 (m, 6H), 2.66 - 2.51 (m, 6H), 2.44 - 2.28 (m, 1H), 2.03 - 1.91 (m, 1H); LRMS (ES) m / z 573.1 [M+H] + .
[0851]
[0852] Example 41: Synthesis of 1-(3-chloro-4-(1-(2-((cyclobutylamino)oxy)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea
[0853]
[0854] It was synthesized in a manner similar to Example 31.
[0855] 1 H NMR (400 MHz, DMSO-d6)δ 10.93 (s, 1H), 8.73 (s, 1H), 7.65 (d, J = 7.8 Hz, 1H), 7.59 (d, J = 2.3 Hz, 1H), 7.47 (s, 1H), 7.40 (d, J = 7.9 Hz, 1H), 7.24 (d, J = 8.7 Hz, 1H), 7.11 (dd, J = 8.8, 2.4 Hz, 1H), 6.75 (t, J = 6.0 Hz, 1H), 5.06 (dd, J = 13.2, 5.0 Hz, 1H), 4.44 - 4.22 (m, 4H), 3.64 (s, 2H), 3.57 (t, J = 4.8 Hz, 2H), 3.44 (t, J = 4.8 Hz, 2H), 3.42 - 3.37 (m, 1H), 2.92 - 2.80 (m, 1H), 2.61 - 2.50 (m, 1H), 2.41 - 2.27 (m, 1H), 2.00 - 1.85 (m, 3H), 1.79 - 1.68 (m, 2H), 1.63 - 1.49 (m, 2H), 1.33 (s, 6H); LRMS (ES) m / z 612.2 [M+H] + .
[0856]
[0857] Example 42: Synthesis of 1-(3-chloro-4-(1-(2-((cyclobutylamino)oxy)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea
[0858]
[0859] It was synthesized in a manner similar to Example 31.
[0860] 1 H NMR (400 MHz, DMSO-d6)δ 10.93 (s, 1H), 8.50 (d, J = 3.5 Hz, 1H), 7.66 (d, J = 7.8 Hz, 1H), 7.55 - 7.49 (m, 2H), 7.44 (d, J = 7.8 Hz, 1H), 7.22 (d, J = 8.7 Hz, 1H), 7.05 (dd, J = 8.7, 2.5 Hz, 1H), 6.75 (dd, J = 7.5, 2.5 Hz, 1H), 5.06 (dd, J = 13.1, 4.8 Hz, 1H), 4.86 (q, J = 7.2 Hz, 1H), 4.45 - 4.36 (m, 1H), 4.30 - 4.24 (m, 1H), 3.63 (s, 2H), 3.56 (t, J = 4.8 Hz, 2H), 3.45 - 3.41 (m, 2H), 3.41 - 3.35 (m, 1H), 2.92 - 2.79 (m, 1H), 2.64 - 2.52 (m, 1H), 2.38 - 2.25 (m, 1H), 2.00 - 1.84 (m, 3H), 1.79 - 1.66 (m, 2H), 1.61 - 1.47 (m, 2H), 1.38 (d, J = 6.9 Hz, 3H), 1.31 (s, 3H); LRMS (ES) m / z 626.3 [M+H] + .
[0861]
[0862] Example 43: Synthesis of N-(2-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenyl)-2-methylpropoxy)ethoxy)-2-hydroxy-N-methylacetamide
[0863]
[0864] It was synthesized in a manner similar to Example 18.
[0865] 1 H-NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.60 (d, J = 3.6 Hz, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.58 (d, J = 2.4 Hz, 1H), 7.55 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.26 (d, J = 8.7 Hz, 1H), 7.10 (dd, J = 8.7, 2.4 Hz, 1H), 6.86 (dd, J = 7.5, 2.7 Hz, 1H), 5.10 (dd, J = 13.2, 4.8 Hz, 1H), 4.90 (p, J = 7.0 Hz, 1H), 4.58 (t, J = 6.1 Hz, 1H), 4.45 (d, J = 17.7 Hz, 1H), 4.31 (d, J = 17.7 Hz, 1H), 4.12 (d, J = 6.0 Hz, 2H), 3.93 - 3.88 (m, 2H), 3.69 (s, 2H), 3.54 - 3.50 (m, 2H), 3.03 (s, 3H), 2.96 - 2.85 (m, 1H), 2.64 - 2.55 (m, 1H), 2.45 - 2.32 (m, 1H), 2.03 - 1.95 (m, 1H), 1.41 (d, J = 6.8 Hz, 3H), 1.38 (s, 6H); LRMS (ES) m / z 644.2 [M+H] + .
[0866]
[0867] Example 44: Synthesis of (2R)-N-(2-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenyl)-2-methylpropoxy)ethoxy)-2-hydroxy-N-methylpropanamide
[0868]
[0869] It was synthesized in a manner similar to Example 18.
[0870] 1H-NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.68 (d, J = 3.6 Hz, 1H), 7.69 (d, J = 7.7 Hz, 1H), 7.58 (d, J = 2.2 Hz, 1H), 7.55 (s, 1H), 7.48 (d, J = 8.1 Hz, 1H), 7.26 (d, J = 8.8 Hz, 1H), 7.10 (dd, J = 8.8, 2.1 Hz, 1H), 6.90 (dd, J = 7.6, 2.6 Hz, 1H), 5.10 (dd, J = 13.4, 4.9 Hz, 1H), 4.90 (p, J = 7.0 Hz, 1H), 4.74 (d, J = 4.0 Hz, 1H), 4.51 - 4.41 (m, 2H), 4.31 (d, J = 17.2 Hz, 1H), 4.01 - 3.95 (m, 1H), 3.92 - 3.86 (m, 1H), 3.70 (s, 2H), 3.56 - 3.52 (m, 2H), 3.05 (s, 3H), 2.96 - 2.84 (m, 1H), 2.64 - 2.56 (m, 1H), 2.45 - 2.31 (m, 1H), 2.03 - 1.94 (m, 1H), 1.41 (d, J = 6.9 Hz, 3H), 1.37 (s, 6H), 1.11 (d, J = 6.5 Hz, 3H); LRMS (ES) m / z 658.2 [M+H] + .
[0871]
[0872] Example 45: Synthesis of 1-(3-chloro-4-(1-(2-(((3,3-difluorocyclobutyl)amino)oxy)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea
[0873]
[0874] It was synthesized in a manner similar to Example 30.
[0875] 1H NMR (400 MHz, DMSO-d6)δ 10.93 (s, 1H), 8.51 (d, J = 3.7 Hz, 1H), 7.66 (dd, J = 7.9, 1.4 Hz, 1H), 7.55 - 7.50 (m, 2H), 7.44 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 8.8 Hz, 1H), 7.05 (dd, J = 8.7, 2.4 Hz, 1H), 6.78 (dd, J = 7.6, 2.9 Hz, 1H), 6.65 (d, J = 6.5 Hz, 1H), 5.07 (dd, J = 13.3, 5.1 Hz, 1H), 4.86 (p, J = 6.9 Hz, 1H), 4.41 (dd, J = 17.4, 2.3 Hz, 1H), 4.27 (d, J = 17.3 Hz, 1H), 3.63 (s, 2H), 3.60 (dd, J = 5.8, 3.7 Hz, 2H), 3.44 (dd, J = 5.8, 3.7 Hz, 2H), 3.41 - 3.33 (m, 1H), 2.87 (ddd, J = 17.3, 13.5, 5.4 Hz, 1H), 2.61 - 2.51 (m, 3H), 2.44 - 2.26 (m, 3H), 1.99 - 1.90 (m, 1H), 1.38 (d, J = 7.9 Hz, 3H), 1.32 (s, 6H); LRMS (ES) m / z 662.2 [M+H] + .
[0876]
[0877] Example 46: Synthesis of 2-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-N-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-oxoacetamide
[0878]
[0879] It was synthesized in a manner similar to Example 48.
[0880] 1H-NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 9.59 (t, J = 5.7 Hz, 1H), 8.61 (s, 1H), 7.92 (ddd, J = 10.1, 7.1, 1.9 Hz, 1H), 7.79 - 7.45 (m, 4H), 7.32 (ddd, J = 22.5, 16.3, 8.1 Hz, 1H), 5.15 - 5.04 (m, 1H), 4.51 (dd, J = 40.3, 11.6 Hz, 2H), 4.27 (dd, J = 46.5, 16.8 Hz, 2H), 3.81 - 3.65 (m, 2H), 3.61 - 3.47 (m, 2H), 3.40 (s, 3H), 3.03 - 2.84 (m, 2H), 2.62 (dt, J = 30.0, 7.6 Hz, 1H), 2.43 - 2.34 (m, 1H), 2.28 (d, J = 8.5 Hz, 1H), 2.00 (d, J = 12.5 Hz, 1H), 1.40 (dt, J = 15.4, 8.5 Hz, 6H); LRMS (ES) m / z 585.1 [M+H] + .
[0881]
[0882] Example 47: Synthesis of N-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-2-oxoacetamide
[0883]
[0884] It was synthesized in a manner similar to Example 48.
[0885] 1H-NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 9.53 (t, J = 5.1 Hz, 1H), 7.92 (d, J = 8.5 Hz, 2H), 7.76 - 7.71 (m, 1H), 7.57 (dd, J = 17.9, 8.3 Hz, 4H), 7.49 (d, J = 7.8 Hz, 1H), 7.36 - 7.20 (m, 1H), 5.11 (dd, J = 13.3, 5.2 Hz, 1H), 4.57 (d, J = 5.9 Hz, 2H), 4.40 (dd, J = 55.6, 17.6 Hz, 2H), 3.60 (dd, J = 9.0, 4.5 Hz, 2H), 3.51 (d, J = 5.8 Hz, 2H), 3.47 (d, J = 5.1 Hz, 2H), 3.40 (s, 3H), 2.31 (dd, J = 12.9, 4.0 Hz, 2H), 2.01 (dd, J = 11.1, 5.8 Hz, 2H), 1.27 (q, J = 6.3 Hz, 6H); LRMS (ES) m / z 551.2 [M+H] + .
[0886]
[0887] Example 48: Synthesis of 2-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-N-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-oxoacetamide
[0888] Step 1) Synthesis of 2-(4-bromo-2-chlorophenyl)ethanol-1-ol
[0889]
[0890] Diisobutylaluminum hydride (DIBAL-H, 1.0 M toluene solution, 28.461 mL, 28.461 mmol) was added to a solution of methyl 2-(4-bromo-2-chlorophenyl)acetate (1.935 mL, 11.384 mmol) dissolved in tetrahydrofuran (20 mL) at room temperature, and the mixture was stirred at 0 °C for 3 hours. The reaction mixture was filtered through a Celite pad to remove the solid, and the solvent was removed from the filtrate under reduced pressure; the resulting product was used without further purification (2-(4-bromo-2-chlorophenyl)ethanol-1-ol, 3.020 g, 112.6%, clear liquid).
[0891] 1 H NMR (400 MHz, CDCl3)δ 7.53 (d, J = 2.0 Hz, 1H), 7.34 (dd, J = 8.2, 2.0 Hz, 1H), 7.16 (d, J = 8.2 Hz, 1H), 3.87 (t, J = 6.6 Hz, 2H), 2.97 (t, J = 6.6 Hz, 2H).
[0892] Step 2) Synthesis of tert-butyl 2-(4-bromo-2-chlorophennetoxy)acetate
[0893]
[0894] Sodium hydroxide (5.0 M aqueous solution, 76.939 mL, 384.697 mmol) was added to a solution of 2-(4-bromo-2-chlorophenyl)ethanol-1-ol (3.020 g, 12.823 mmol), tert-butyl bromoacetate (5.642 mL, 38.470 mmol), and tetrabutylammonium hydrogen sulfate (3.483 g, 10.259 mmol) dissolved in toluene (30 mL) at 0 °C, and the mixture was stirred at the same temperature for 3 hours. Water was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 25 g cartridge; ethyl acetate / hexane = 2% to 10%) to obtain tert-butyl 2-(4-bromo-2-chlorophennetoxy)acetate (3.970 g, 88.5%) in the form of a clear liquid.
[0895] 1 H NMR (400 MHz, CDCl3)δ 7.51 (d, J = 1.9 Hz, 1H), 7.33 (dd, J = 8.2, 1.9 Hz, 1H), 7.22 (d, J = 8.2 Hz, 1H), 3.95 (s, 2H), 3.73 (t, J = 6.9 Hz, 2H), 3.02 (t, J = 6.9 Hz, 2H), 1.47 (s, 9H); LRMS(ES) m / z 371.1 [M+Na] + .
[0896] Step 3) Synthesis of 2-(4-Bromo-2-chlorophennetoxy)ethanol-1-ol
[0897]
[0898] Diisobutylaluminum hydride (DIBAL-H, 1.0 M toluene solution, 28.386 mL, 28.386 mmol) was added to a solution of tert-butyl 2-(4-bromo-2-chlorophennetoxy)acetate (3.970 g, 11.354 mmol) dissolved in tetrahydrofuran (20 mL) at room temperature, and the mixture was stirred at 0 °C for 3 hours. The reaction mixture was filtered through a Celite pad to remove the solid, and the solvent was removed from the filtrate under reduced pressure; the resulting product was used without further purification (2-(4-bromo-2-chlorophennetoxy)ethanol-1-ol, 2.860 g, 90.1%, clear liquid).
[0899] 1 H NMR(400MHz, CDCl3)δ 7.52 (d, J = 2.0 Hz, 1H), 7.32 (dd, J = 8.2, 2.0 Hz, 1H), 7.14 (d, J = 8.2 Hz, 1H), 3.73 - 3.67 (m, 4H), 3.59 - 3.52 (m, 2H), 2.99 (t, J = 6.8 Hz, 2H), 1.80 (s, 2H); LRMS (ES) m / z 295.0 [M+Na] + .
[0900] Step 4) Synthesis of tert-butyl (2-(4-bromo-2-chlorophennetoxy)ethoxy)(methyl)carbamate
[0901]
[0902] Diisopropyl azodicarboxylate (0.169 mL, 0.858 mmol) was added to a solution of 2-(4-bromo-2-chlorophennetoxy)ethanol-1-ol (0.200 g, 0.715 mmol), tert-butyl hydroxy(methyl)carbamate (0.117 mL, 0.858 mmol), and triphenylphosphine (0.225 g, 0.858 mmol) dissolved in tetrahydrofuran (3 mL) at 0 °C, and the mixture was stirred at room temperature for 18 hours. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 2% to 30%) to obtain tert-butyl (2-(4-bromo-2-chlorophennetoxy)ethoxy)(methyl)carbamate (0.255 g, 87.2%) in the form of a clear liquid.
[0903] 1 H NMR (400 MHz, CDCl3)δ 7.50 (d, J = 1.9 Hz, 1H), 7.31 (dd, J = 8.2, 1.9 Hz, 1H), 7.16 (d, J = 8.2 Hz, 1H), 4.02 - 3.95 (m, 2H), 3.66 (dt, J = 9.4, 5.8 Hz, 4H), 3.07 (s, 3H), 2.99 (t, J = 6.9 Hz, 2H), 1.48 (s, 9H); LRMS (ES) m / z 430.2 [M+Na] + .
[0904] Step 5) Synthesis of tert-butyl (2-(4-acetyl-2-chlorophennetoxy)ethoxy)(methyl)carbamate
[0905]
[0906] Tert-butyl (2-(4-bromo-2-chlorophennetoxy)ethoxy)(methyl)carbamate (0.615 g, 1.505 mmol), bis(triphenylphosphine)palladium(ii) dichloride (0.106 g, 0.150 mmol), and tributyl(1-ethoxyvinyl)tin (0.762 mL, 2.257 mmol) were dissolved in 1,4-dioxane (3.5 mL) and stirred at 100 °C for 3 hours. Hydrochloric acid (1.0 M aqueous solution, 2.257 mL, 2.257 mmol) was added to the reaction mixture and stirred further at room temperature for 20 minutes. The reaction mixture was filtered through a Celite pad to remove the solid, and a saturated aqueous sodium bicarbonate solution was poured into the filtrate and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 5% to 30%) to obtain tert-butyl (2-(4-acetyl-2-chlorophennetoxy)ethoxy)(methyl)carbamate (0.447 g, 79.9%) in the form of a clear liquid.
[0907] LRMS (ES) m / z 394.2 [M+Na] +
[0908] Step 6) Synthesis of 2-(3-chloro-4-(2,2,5-trimethyl-4-oxo-3,6,9-trioxa-5-azoundecane-11-yl)phenyl)-2-oxoacetate
[0909]
[0910] Selenium dioxide (0.267 g, 2.404 mmol) was added to a solution of tert-butyl (2-(4-acetyl-2-chlorophennetoxy)ethoxy)(methyl)carbamate (0.447 g, 1.202 mmol) dissolved in pyridine (3 mL) at room temperature, and the mixture was stirred at the same temperature for 2 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a 1 M aqueous hydrochloric acid solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The product was used without further purification (2-(3-chloro-4-(2,2,5-trimethyl-4-oxo-3,6,9-trioxa-5-azaudecane-11-yl)phenyl)-2-oxoacetic acid, 0.506 g, 104.8%, red solid).
[0911] LRMS (ES) m / z 400.0 [MH] - .
[0912] Step 7) Synthesis of tert-butyl (2-(2-chloro-4-(2-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)amino)-2-oxoacetyl)phennetoxy)ethoxy)(methyl)carbamate
[0913]
[0914] 2-(3-chloro-4-(2,2,5-trimethyl-4-oxo-3,6,9-trioxa-5-azaudecane-11-yl)phenyl)-2-oxoacetate (0.500 g, 1.244 mmol), 3-(5-(aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione chloroform (0.578 g, 1.866 mmol), and N,N-diisopropylethylamine (1.087 mL, 6.221 mmol) were dissolved in N,N-dimethylformamide (2 mL) at 0 °C and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU, 0.946 g (2.489 mmol) was added and stirred at room temperature for 16 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. After purifying and concentrating the concentrate by column chromatography (SiO2, 10 g cartridge; methanol / dichloromethane = 1% to 3%), the resulting product was further purified and concentrated by chromatography (C18, 12 g cartridge; acetonitrile / 1% aqueous formic acid = 20% to 60%) to obtain tert-butyl (2-(2-chloro-4-(2-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)amino)-2-oxoacetyl)phennetoxy)ethoxy)(methyl)carbamate (0.250 g, 30.6%) in the form of a white solid.
[0915] LRMS (ES) m / z 679.0 [M+Na] + .
[0916] Step 8) Synthesis of 2-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-N-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-oxoacetamide
[0917]
[0918] Hydrogen chloride (4.0 M 1,4-dioxane solution, 1.902 mL, 7.609 mmol) was added to a solution of tert-butyl (2-(2-chloro-4-(2-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)amino)-2-oxoacetyl)phennetoxy)ethoxy)(methyl)carbamate (0.250 g, 0.380 mmol) dissolved in dichloromethane (3.5 mL) at room temperature, and the mixture was stirred for 20 minutes at the same temperature. After removing the solvent from the reaction mixture under reduced pressure, hexane (3 mL) and a saturated sodium bicarbonate aqueous solution (6 mL) were added to the concentrate and stirred to filter the precipitated solid, wash it with hexane, and dry it. The resulting product was then purified and concentrated by chromatography (C18; acetonitrile / 0.1%-formic acid aqueous solution = 20% to 50%) to obtain 2-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-N-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-oxoacetamide (0.073 g, 34.4%) in the form of a white solid.
[0919] 1H-NMR (400 MHz, DMSO-d6)δ 10.98 (s, 1H), 9.60 (t, J = 6.0 Hz, 1H), 7.96 (ddd, J = 9.6, 5.8, 1.6 Hz, 1H), 7.70 (dd, J = 16.5, 6.4 Hz, 1H), 7.65 - 7.54 (m, 2H), 7.48 (d, J = 7.7 Hz, 1H), 7.38 - 7.23 (m, 1H), 5.15 - 5.04 (m, 1H), 4.57 (d, J = 6.1 Hz, 1H), 4.51 - 4.29 (m, 2H), 4.27 (s, 1H), 3.68 - 3.62 (m, 2H), 3.54 - 3.51 (m, 2H), 3.03 (t, J = 6.7 Hz, 2H), 2.96 - 2.85 (m, 2H), 2.60 (d, J = 15.3 Hz, 1H), 2.48 (s, 3H), 2.37 (dd, J = 17.8, 13.6 Hz, 2H), 2.05 - 1.91 (m, 1H); LRMS (ES) m / z 557.2 [M+H] + .
[0920] Example 49: Synthesis of 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)thiourea
[0921]
[0922] It was synthesized in a manner similar to Example 24.
[0923] 1H-NMR (400 MHz, DMSO-d6)δ 10.98 (s, 1H), 9.64 (s, 1H), 8.54 (s, 1H), 7.86 - 7.44 (m, 4H), 7.33 (s, 2H), 5.59 (br, 1H), 5.26 - 5.02 (m, 1H), 4.38 (dd, J = 56.7, 17.5 Hz, 2H), 3.95 (s, 2H), 3.71 (s, 2H), 3.58 (s, 2H), 2.91 (br, 1H), 2.72 (s, 3H), 2.61 (s, 1H), 2.39 (br, 1H), 2.00 (br, 1H), 1.50 (s, 3H), 1.39 (d, J = 5.5 Hz, 6H); LRMS (ES) m / z 602.2 [M+H] + .
[0924]
[0925] Example 50: Synthesis of 1-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-(3-methyl-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)urea
[0926]
[0927] It was synthesized in a manner similar to Example 23.
[0928] 1H-NMR (400 MHz, DMSO-d6)δ 10.99 (s, 1H), 8.51 (s), 7.77 - 7.60 (m, 1H), 7.51 (s, 1H), 7.44 (d, J = 7.7 Hz, 1H), 7.25 - 7.09 (m. 2H), 7.01 (d, J = 7.7 Hz, 1H), 6.75 (br, 1H), 5.11 (dd, J = 13.0, 4.7 Hz, 1H), 4.59 - 4.19 (m, 4H), 4.04 (br, 2H), 3.74 - 3.35 (m, 4H), 2.95 - 2.83 (m, 1H), 2.84 - 2.68 (m, 5H), 2.66 - 2.52 (m, 1H), 2.44 - 2.30 (m, 1H), 2.20 (s, 3H), 1.98 (br, 1H), 1.26 - 1.09 (m, 1H); LRMS (ES) m / z 524.2 [M+H] + .
[0929]
[0930] Example 51: Synthesis of 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1R)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea
[0931]
[0932] It was synthesized in a manner similar to Example 31.
[0933] 1H-NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.57 (d, J = 3.5 Hz, 1H), 7.70 (dd, J = 8.0, 4.0 Hz, 1H), 7.57 (d, J = 2.4 Hz, 1H), 7.55 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.26 (d, J = 8.8 Hz, 1H), 7.09 (dd, J = 8.7, 2.4 Hz, 1H), 6.83 (dd, J = 7.5, 2.7 Hz, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.90 (p, J = 7.2 Hz, 1H), 4.45 (d, J = 17.5 Hz, 1H), 4.31 (d, J = 17.2 Hz, 1H), 3.66 (s, 2H), 3.61 - 3.57 (m, 2H), 3.49 - 3.45 (m, 2H), 2.96 - 2.85 (m, 1H), 2.64 - 2.56 (m, 1H), 2.45 (s, 3H), 2.43 - 2.32 (m, 1H), 2.03 - 1.95 (m, 1H), 1.41 (d, J = 6.7 Hz, 3H), 1.35 (s, 6H); LRMS (ES) m / z 586.2 [M+H] + .
[0934]
[0935] Example 52: Synthesis of 1-(3-chloro-4-(2-methyl-1-(2-((oxetane-3-ylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea
[0936]
[0937] It was synthesized in a manner similar to Example 31.
[0938] 1H NMR (400 MHz, DMSO-d6)δ 10.97 (s, 1H), 8.52 (s, 1H), 7.68 (dd, J = 7.9, 1.3 Hz, 1H), 7.59 (d, J = 2.3 Hz, 1H), 7.55 (s, 1H), 7.52 - 7.44 (m, 1H), 7.24 (d, J = 8.8 Hz, 1H), 7.15 (dd, J = 8.7, 2.4 Hz, 1H), 7.00 (s, 1H), 6.86 (d, J = 6.6 Hz, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.89 (q, J = 7.1 Hz, 1H), 4.52 (t, J = 6.7 Hz, 2H), 4.37 (t, J = 6.0 Hz, 2H), 4.08 (h, J = 6.4 Hz, 1H), 3.70 - 3.62 (m, 3H), 3.49 (dd, J = 5.8, 3.8 Hz, 2H), 2.98 - 2.83 (m, 1H), 2.70 - 2.54 (m, 1H), 2.44 - 2.26 (m, 1H), 2.00 (d, J = 9.0 Hz, 1H), 1.40 (d, J = 7.0 Hz, 3H), 1.35 (s, 6H); LRMS (ES) m / z 628.3 [M+H] + .
[0939]
[0940] Example 53: Synthesis of 1-(4-(1-(2-(aminooxy)ethoxy)-2-methylpropane-2-yl)-3-chlorophenyl)-3-((1R)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea
[0941]
[0942] It was synthesized in a manner similar to Example 31.
[0943] 1H-NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.57 (d, J = 3.6 Hz, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.57 (d, J = 2.4 Hz, 1H), 7.55 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.25 (d, J = 8.8 Hz, 1H), 7.10 (dd, J = 8.7, 2.4 Hz, 1H), 6.84 (dd, J = 7.5, 2.7 Hz, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.90 (p, J = 7.1 Hz, 1H), 4.45 (d, J = 17.1 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 3.55 (s, 2H), 3.59 - 3.55 (m, 2H), 3.51 - 3.47 (m, 2H), 2.96 - 2.85 (m, 1H), 2.64 - 2.56 (m, 1H), 2.45 - 2.32 (m, 1H), 2.03 - 1.95 (m, 1H), 1.42 (d, J = 6.9 Hz, 3H), 1.35 (s, 6H); LRMS (ES) m / z 572.2 [M+H] + .
[0944]
[0945] Example 54: Synthesis of 1-(4-(1-(2-(aminooxy)ethoxy)-2-methylpropane-2-yl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea
[0946]
[0947] It was synthesized in a manner similar to Example 31.
[0948] 1H-NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.60 (d, J = 3.6 Hz, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.57 (d, J = 2.3 Hz, 1H), 7.55 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.25 (d, J = 8.8 Hz, 1H), 7.10 (dd, J = 8.7, 2.3 Hz, 1H), 6.87 (dd, J = 7.5, 12.8 Hz, 1H), 5.10 (dd, J = 13.2, 5.0 Hz, 1H), 4.90 (p, J = 7.0 Hz, 1H), 4.45 (d, J = 17.2 Hz, 1H), 4.31 (d, J = 17.4 Hz, 1H), 3.66 (s, 2H), 3.60 - 3.55 (m, 2H), 3.51 - 3.46 (m, 2H), 2.96 - 2.85 (m, 1H), 2.64 - 2.55 (m, 1H), 2.45 - 2.31 (m, 1H), 2.04 - 1.95 (m, 1H), 1.41 (d, J = 6.9 Hz, 3H), 1.35 (s, 6H); LRMS (ES) m / z 572.2 [M+H] + .
[0949]
[0950] Example 55: Synthesis of 1-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)-3-(3-methyl-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)urea 2,2,2-trifluoroacetate
[0951]
[0952] It was synthesized in a manner similar to Example 23.
[0953] 1H-NMR (400 MHz, DMSO-d6)δ 10.98 (s, 1H), 8.31 (br, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.55 (s, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.14 (d, J = 2.3) Hz, 1H), 7.10 (dd, J = 8.2, 2.3 Hz, 1H), 6.98 (d, J = 8.2 Hz, 1H), 6.75 (br, 1H), 5.10 (dd, J = 13.5, 4.8 Hz, 1H), 4.89 (t, J = 7.0 Hz, 1H), 4.52 - 4.22 (m, 2H), 4.00 (d, J = 4.3 Hz, 2H), 3.67 - 3.56 (m, 2H), 3.51 (t, J = 7.4 Hz, 2H), 2.91 (ddd, J = 13.5, 12.9, 5.3 Hz, 1H), 2.78 (s, 3H), 2.72 (t, J = 7.3 Hz, 2H), 2.64 - 2.55 (m, 1H), 2.46 - 2.30 (m, 1H), 2.20 (s, 3H), 1.99 (ddd, J = 7.3, 5.3, 2.6 Hz, 1H), 1.41 (d, J = 6.9 Hz, 1H); LRMS (ES) m / z 538.3 [M+H] + .
[0954]
[0955] Example 56: Synthesis of 1-(3-chloro-4-(2-((methylamino)oxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea
[0956]
[0957] It was synthesized in a manner similar to Example 23.
[0958] 1H-NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.58 (d, J = 3.4 Hz, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.61 (d, J = 2.1 Hz, 1H), 7.55 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 7.10 (dd, J = 8.4, 2.2 Hz, 1H), 6.84 (dd, J = 7.5, 2.6 Hz, 1H), 5.10 (dd, J = 13.2, 5.0 Hz, 1H), 4.90 (p, J = 6.6 Hz, 1H), 4.45 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 17.2 Hz, 1H), 3.73 (t, J = 7.0 Hz, H, 2H), 2.96 - 2.86 (m, 1H), 2.84 (t, J = 7.0 Hz, 2H), 2.69 - 2.56 (m, 1H), 2.53 (s, 3H), 2.46 - 2.31 (m, 1H), 1.99 (ddd, J = 9.8, 5.1, 2.5 Hz, 1H), 1.42 (d, J = 7.0 Hz, 3H); LRMS (ES) m / z 514.1 [M+H] + .
[0959]
[0960] Example 57: Synthesis of 1-(3-chloro-4-(2-(2-((isopropylamino)oxy)ethoxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea
[0961]
[0962] It was synthesized in a manner similar to Example 23.
[0963] LRMS (ES) m / z 586.1 [M+H]+.
[0964]
[0965] Example 58: Synthesis of 1-(3-chloro-4-(2-(2-(methoxyamino)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea
[0966]
[0967] It was synthesized in a manner similar to Example 75.
[0968] 1 H NMR (400 MHz, DMSO-d6)δ 10.97 (s, 1H), 8.79 (s, 1H), 7.69 (dd, J = 8.0, 0.7 Hz, 1H), 7.67 (d, J = 2.2 Hz, 1H), 7.51 (s, 1H), 7.44 (d, J = 8.0 Hz, 1H), 7.22 (d, J = 8.4 Hz, 1H), 7.15 (dd, J = 8.4, 2.2 Hz, 1H), 6.82 (t, J = 6.0 Hz, 1H), 6.39 (t, J = 6.3 Hz, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.47 - 4.26 (m, 4H), 3.54 (t, J = 7.1 Hz, 2H), 3.47 (t, J = 5.8 Hz, 2H), 3.36 (s, 3H), 2.96 - 2.81 (m, 5H), 2.64 - 2.55 (m, 1H), 2.44 - 2.31 (m, 1H), 2.04 - 1.95 (m, 1H); LRMS (ES) m / z 544.2 [M+H] + .
[0969]
[0970] Example 59: Synthesis of 1-(3-chloro-4-(2-(2-(methoxyamino)ethoxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea
[0971]
[0972] It was synthesized in a manner similar to Example 75.
[0973] 1 H NMR (400 MHz, DMSO-d6)δ 10.94 (s, 1H), 8.52 (d, J = 3.4 Hz, 1H), 7.66 (d, J = 7.7 Hz, 1H), 7.58 (d, J = 2.2 Hz, 1H), 7.52 (s, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.16 (d, J = 8.4 Hz, 1H), 7.06 (dd, J = 8.4, 2.2 Hz, 1H), 6.79 (dd, J = 7.6, 2.7 Hz, 1H), 5.07 (dd, J = 13.2, 5.2 Hz, 1H), 4.86 (p, J = 7.0 Hz, 1H), 4.41 (d, J = 17.3 Hz, 1H), 4.28 (d, J = 17.3 Hz, 1H), 3.49 (t, J = 7.1 Hz, 2H), 3.42 (t, J = 5.8 Hz, 2H), 3.32 (s, 3H), 2.92 - 2.82 (m, 3H), 2.79 (t, J = 7.1 Hz, 2H), 2.62 - 2.52 (m, 1H), 2.40 - 2.27 (m, 1H), 2.01 - 1.89 (m, 1H), 1.38 (d, J = 7.0 Hz, 3H); LRMS (ES) m / z 558.2 [M+H] + .
[0974]
[0975] Example 60: Synthesis of 1-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-(4-(2-(2-((methylamino)oxy)ethoxy)ethyl)-3-(trifluoromethyl)phenyl)urea
[0976]
[0977] It was synthesized in a manner similar to Example 23.
[0978] 1H NMR (400 MHz, DMSO-d6)δ 10.97 (s, 1H), 9.00 (s, 1H), 7.91 (d, J = 2.3 Hz, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.51 (s, 1H), 7.49 (d, J = 2.2) Hz, 1H), 7.44 (d, J = 7.9 Hz, 1H), 7.36 (d, J = 8.5 Hz, 1H), 6.91 (t, J = 6.1 Hz, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.48 - 4.27 (m, 4H), 3.64 (dd, J = 5.9, 3.8 Hz, 2H), 3.58 - 3.49 (m, 4H), 2.96 - 2.85 (m, 3H), 2.62 - 2.55 (m, 1H), 2.49 (s, 3H), 2.44 - 2.32 (m, 1H), 2.04 - 1.95 (m, 1H); LRMS (ES) m / z 578.2 [M+H] + .
[0979]
[0980] Example 61: Synthesis of 1-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)-3-(4-(2-(2-((methylamino)oxy)ethoxy)ethyl)-3-(trifluoromethyl)phenyl)urea
[0981]
[0982] It was synthesized in a manner similar to Example 23.
[0983] 1H NMR (400 MHz, DMSO-d6)δ 10.97 (s, 1H), 8.74 (d, J = 3.6 Hz, 1H), 7.87 (d, J = 2.3 Hz, 1H), 7.70 (d, J = 7.9 Hz, 1H), 7.56 (s, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.42 (dd, J = 8.5, 2.2 Hz, 1H), 7.35 (d, J = 8.5 Hz, 1H), 6.88 (dd, J = 7.6, 2.4 Hz, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.92 (p, J = 7.0 Hz, 1H), 4.45 (dd, J = 17.3, 2.2 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 3.64 (dd, J = 5.8, 3.9 Hz, 2H), 3.57 - 3.48 (m, 4H), 2.97 - 2.84 (m, 3H), 2.67 - 2.56 (m, 1H), 2.49 (s, 3H), 2.45 - 2.31 (m, 1H), 2.03 - 1.94 (m, 1H), 1.45 - 1.41 (m, 3H); LRMS (ES) m / z 592.2 [M+H] + .
[0984]
[0985] Example 62: Synthesis of 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)methyl)urea
[0986] Step 1) Synthesis of 4-cyano-5-fluoro-2-methylbenzoate
[0987]
[0988] Methyl 4-bromo-5-fluoro-2-methylbenzoate (1.000 g, 4.048 mmol), zinc cyanide (0.951 g, 8.095 mmol), and tetrakis(triphenylphosphine)palladium (0.234 g, 0.202 mmol) were dissolved in a solution of 1,4-dioxane (16 mL) and water (2 mL) at 110 °C. The solution was stirred at the same temperature for 16 hours, after which the temperature was lowered to room temperature to terminate the reaction. The reaction mixture was filtered through a Celite pad to remove the solid, water was added to the filtrate, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 25 g cartridge; ethyl acetate / hexane = 0% to 10%) to obtain methyl 4-cyano-5-fluoro-2-methylbenzoate (0.438 g, 56.0%) in the form of an ivory solid.
[0989] Step 2) Synthesis of 2-(bromomethyl)-4-cyano-5-fluorobenzoate
[0990]
[0991] A solution of methyl 4-cyano-5-fluoro-2-methylbenzoate (0.438 g, 2.267 mmol), azobis-isobutyronitrile (AIBN, 0.112 g, 0.680 mmol), and N-bromosuccinimide (0.605 g, 3.401 mmol) dissolved in acetonitrile (5 mL) at 80 °C was stirred at the same temperature for 16 hours, after which the temperature was lowered to room temperature to terminate the reaction. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 10%) to obtain methyl 2-(bromomethyl)-4-cyano-5-fluorobenzoate (0.393 g, 63.8%) in the form of a white solid.
[0992] Step 3) Synthesis of 2-(2,6-dioxopiperidine-3-yl)-6-fluoro-1-oxoisoindolin-5-carbonitrile
[0993]
[0994] A solution of methyl 2-(bromomethyl)-4-cyano-5-fluorobenzoate (0.393 g, 1.446 mmol), 3-aminopiperidin-2,6-dione (0.370 g, 2.891 mmol), and N,N-diisopropylethylamine (0.505 mL, 2.891 mmol) dissolved in N,N-dimethylformamide (4 mL) at 80 °C was stirred at the same temperature for 2 hours, after which the temperature was lowered to room temperature to terminate the reaction. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 25 g cartridge; methanol / dichloromethane = 0% to 5%) to obtain 2-(2,6-dioxopiperidine-3-yl)-6-fluoro-1-oxoisoindolin-5-carbonitrile (0.210 g, 50.6%) as a dark gray solid.
[0995] LRMS (ES) m / z 288.0 [M+H] + .
[0996] Step 4) Synthesis of ((2-(2,6-dioxopiperidine-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)methyl)carbamate
[0997]
[0998] 2-(2,6-dioxopiperidine-3-yl)-6-fluoro-1-oxoisoindolin-5-carbonitrile (0.210 g, 0.731 mmol), di-tert-butyl dicarbonate (0.319 g, 1.462 mmol) and Raney nickel (0.215 g, 3.655 mmol) were suspended in tetrahydrofuran (5 mL), hydrogen balloons were attached, and the mixture was stirred at 40 °C for 16 hours, after which the temperature was lowered to room temperature to terminate the reaction. The reaction mixture was filtered through Celite to remove the solid, and the solvent was removed from the filtrate under reduced pressure. The concentrate was then purified and concentrated by column chromatography (C18, 10 g cartridge; acetonitrile / 0.1% aqueous formic acid solution = 0% to 80%) to obtain tert-butyl ((2-(2,6-dioxopiperidine-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)methyl)carbamate (0.060 g, 21.0%) in the form of a white solid.
[0999] LRMS (ES) m / z 392.1 [M+H] + .
[1000] Step 5) Synthesis of 3-(5-(aminomethyl)-6-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride
[1001]
[1002] A solution of tert-butyl ((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)methyl)carbamate (0.060 g, 0.153 mmol) and hydrogen chloride (4.0 M 1,4-dioxane solution, 0.383 mL, 1.533 mmol) dissolved in dichloromethane (3 mL) at 0 °C was stirred for 1 hour at the same temperature. After removing the solvent from the reaction mixture under reduced pressure, hexane (5 mL) was added to the concentrate and stirred to filter the precipitated solid, wash with hexane, and dry to obtain 3-(5-(aminomethyl)-6-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride (0.043 g, 85.8%) in the form of an ivory solid.
[1003] LRMS (ES) m / z 292.2 [M+H] + .
[1004] Step 6) Synthesis of tert-butyl (2-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-2-methylpropoxy)ethoxy)(methyl)carbamate
[1005]
[1006] A solution of tert-butyl (2-(2-(4-amino-2-chlorophenyl)-2-methylpropoxy)ethoxy)(methyl)carbamate (0.060 g, 0.161 mmol), phenyl chloroformate (0.024 mL, 0.193 mmol), and pyridine (0.016 mL, 0.193 mmol) dissolved in ethyl acetate (3 mL) was stirred at 0 °C for 1 hour, and the solvent was concentrated. 3-(5-(aminomethyl)-6-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-diionic hydrochloride (0.053 g, 0.161 mmol) and triethylamine (0.112 mL, 0.805 mmol) were added to N,N-dimethylformamide (3 mL), and the mixture was further stirred at room temperature for 18 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; methanol / dichloromethane = 0% to 5%) to obtain tert-butyl (2-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-2-methylpropoxy)ethoxy)(methyl)carbamate) (0.048 g, 43.3%) as a pale yellow oil.
[1007] LRMS (ES) m / z 712.3 [M+Na] + .
[1008] Step 7) Synthesis of 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)methyl)urea
[1009]
[1010] A solution of tert-butyl (2-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-2-methylpropoxy)ethoxy)(methyl)carbamate (0.048 g, 0.070 mmol) dissolved in dichloromethane (3 mL) / trifluoroacetic acid (1 mL) at 0 °C was stirred for 30 minutes at the same temperature. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (C18, 10 g cartridge; acetonitrile / 0.1% aqueous formic acid = 30%) to obtain 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)methyl)urea (0.022 g, 53.6%) in the form of a white solid.
[1011] 1 H NMR (400 MHz, DMSO-d6)δ 10.94 (s, 1H), 8.87 (s, 1H), 7.58 (d, J = 2.4 Hz, 1H), 7.54 (d, J = 6.3 Hz, 1H), 7.47 (d, J = 8.9 Hz, 1H), 7.24 (d, J = 8.8 Hz, 1H), 7.11 (dd, J = 8.7, 2.4 Hz, 1H), 6.86 (t, J = 6.0 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.44 - 4.23 (m, 4H), 3.64 (s, 2H), 3.56 (dd, J = 5.9, 3.9 Hz, 2H), 3.44 (dd, J = 5.9, 3.9 Hz, 2H), 2.86 (ddd, J = 17.3, 13.5, 5.4 Hz, 1H), 2.60 - 2.50 (m, 1H), 2.43 (s, 3H), 2.39 - 2.25 (m, 1H), 2.00 - 1.90 (m, 1H), 1.32 (s, 6H); LRMS (ES) m / z 590.2 [M+H] + .
[1012]
[1013] Example 63: Synthesis of 1-(4-(1-(2-(((2-azapyr[3.3]heptane-6-yl)amino)oxy)ethoxy)-2-methylpropane-2-yl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea
[1014]
[1015] It was synthesized in a manner similar to Example 31.
[1016] 1 H-NMR (400 MHz, DMSO-d6)δ 9.58 (br, 1H), 8.43 (br, 1H), 7.68 (d, J = 7.8 Hz, 1H), 7.60 (d, J = 1.6 Hz, 1H), 7.56 (s), 7.48 (d, J = 7.8 Hz, 1H), 7.24 (d, J = 9.0 Hz, 1H), 7.18 (br, 1H), 6.40 (br, 1H), 5.10 (dd, J = 13.2, 5.3 Hz, 1H), 4.90 (t, J = 6.7 Hz, 1H), 4.50 - 4.26 (m, 2H), 3.90 - 3.71 (m, 4H), 3.66 (s, 2H), 3.62 - 3.56 (m, 2H), 3.49 - 3.43 (m, 2H), 3.36 - 3.26 (m, 2H), 2.91 (ddd, J = 17.5, 13.9, 5.7 Hz, 1H), 2.64 - 2.56 (m, 1H), 2.43 - 2.32 (m, 1H), 2.29 - 2.18 (m, 1H), 2.03 - 1.92 (m, 2H), 1.40 (d, J = 6.9 Hz, 3H), 1.37 (s, 1H), 1.35 (s, 6H); LRMS (ES) m / z 667.3 [M+H] + .
[1017]
[1018] Example 64: Synthesis of 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((1R)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea
[1019]
[1020] It was synthesized in a manner similar to Example 23.
[1021] 1 H-NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.65 (d, J = 3.5 Hz, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.61 (d, J = 2.2 Hz, 1H), 7.55 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.19 (d, J = 8.4 Hz, 1H), 7.10 (dd, J = 8.4, 2.2 Hz, 1H), 6.92 (dd, J = 7.5, 2.8 Hz, 1H), 5.10 (dd, J = 13.2, 5.0 Hz, 1H), 4.90 (p, J = 7.0 Hz, 1H), 4.45 (d, J = 16.7 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 3.65 - 3.61 (m, 2H), 3.55 - 3.48 (m, 4H), 2.96 - 2.85 (m, 1H), 2.82 (t, J = 7.1 Hz, 2H), 2.64 - 2.56 (m, 1H), 2.48 (s, 3H), 2.45 - 2.31 (m, 1H), 2.03 - 1.95 (m, 1H), 1.41 (d, J = 6.9 Hz, 3H); LRMS (ES) m / z 558.2 [M+H] + .
[1022]
[1023] Example 65: Synthesis of 1-(3-chloro-4-(2-(2-((cyclobutylamino)oxy)ethoxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea
[1024]
[1025] It was synthesized in a manner similar to Example 23.
[1026] 1 H-NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.59 (d, J = 3.4 Hz, 1H), 7.70 (d, J = 7.9 Hz, 1H), 7.62 (d, J = 2.2 Hz, 1H), 7.55 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.19 (d, J = 8.4 Hz, 1H), 7.10 (dd, J = 8.4, 2.2 Hz, 1H), 6.85 (dd, J = 7.5, 2.6 Hz, 1H), 5.10 (dd, J = 13.3, 5.0 Hz, 1H), 4.90 (p, J = 7.0 Hz, 1H), 4.45 (dd, J = 17.3, 1.7 Hz, 1H), 4.31 (d, J = 17.2 Hz, 1H), 3.66 - 3.61 (m, 2H), 3.56 - 3.44 (m, 5H), 2.97 - 2.85 (m, 1H), 2.82 (t, J = 7.1 Hz, 2H), 2.64 - 2.55 (m, 1H), 2.46 - 2.31 (m, 1H), 2.03 - 1.91 (m, 3H), 1.84 - 1.73 (m, 2H), 1.69 - 1.54 (m, 2H), 1.42 (d, J = 6.9 Hz, 3H); LRMS (ES) m / z 598.2 [M+H] + .
[1027]
[1028] Example 66: Synthesis of 1-(3-chloro-4-(2-methyl-1-(2-(((1-methylazetidin-3-yl)amino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)urea
[1029]
[1030] It was synthesized in a manner similar to Example 31.
[1031] LRMS (ES) m / z 627.2 [M+H]+.
[1032]
[1033] Example 67: Synthesis of 1-(3-chloro-4-(1-(2-(((1,1-dioxydothiethane-3-yl)amino)oxy)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea
[1034]
[1035] It was synthesized in a manner similar to Example 31.
[1036] 1 H NMR (400 MHz, DMSO-d6)δ 10.97 (s, 1H), 8.83 (s, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.63 (d, J = 2.3 Hz, 1H), 7.44 (dd, J = 7.8, 1.4 Hz, 1H), 7.27 (d, J = 8.8 Hz, 1H), 7.16 (dd, J = 8.8, 2.4 Hz, 1H), 6.91 (d, J = 6.0 Hz, 1H), 6.86 (t, J = 6.0 Hz, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.47 - 4.28 (m, 4H), 4.21 - 4.14 (m, 2H), 3.93 - 3.87 (m, 2H), 3.84 - 3.75 (m, 1H), 3.70 - 3.66 (m, 4H), 3.53 - 3.48 (m, 2H), 2.97 - 2.84 (m, 1H), 2.68 - 2.56 (m, 1H), 2.44 - 2.31 (m, 1H), 2.03 - 1.96 (m, 1H), 1.37 (s, 6H); LRMS (ES) m / z 662.2 [M+H] + .
[1037]
[1038] Example 68: Synthesis of 1-(3-chloro-4-(2-(2-(((cyclopropylmethyl)amino)oxy)ethoxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea
[1039]
[1040] It was synthesized in a manner similar to Example 23.
[1041] 1 H-NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 8.71 (d, J = 3.7 Hz, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.62 (d, J = 2.1 Hz, 1H), 7.55 (s, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.19 (d, J = 8.4 Hz, 1H), 7.10 (dd, J = 8.3, 2.2 Hz, 1H), 6.98 (dd, J = 7.6, 3.0 Hz, 1H), 6.41 (s, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.90 (t, J = 7.1 Hz, 1H), 4.38 (dd, J = 55.1, 16.9 Hz, 1H), 3.67 (dd, J = 5.6, 4.1 Hz, 2H), 3.60 - 3.48 (m, 4H), 3.01 - 2.86 (m, 1H), 2.82 (t, J = 7.0 Hz, 2H), 2.66 (dd, J = 12.3, 10.4 Hz, 1H), 2.58 (d, J = 6.6 Hz, 2H), 2.43 - 2.32 (m, 1H), 1.99 (ddd, J = 9.9, 5.0, 2.5 Hz, 1H), 1.41 (d, J = 7.0 Hz, 3H), 0.85 (ddt, J = 8.0, 6.9, 2.9 Hz, 1H), 0.42 - 0.34 (m, 2H), 0.14 - 0.06 (m, 2H); LRMS (ES) m / z 598.3 [M+H] + .
[1042]
[1043] Example 69: Synthesis of 1-(3-chloro-4-(2-((((cyclopropylmethyl)amino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea
[1044]
[1045] It was synthesized using a method similar to Example 23.
[1046] 1 H-NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.91 (s, 1H), 7.68 (dd, J = 8.3, 5.0 Hz, 2H), 7.51 (s, 1H), 7.44 (d, J = 7.9 Hz, 1H), 7.21 (d, J) = 8.4 Hz, 1H), 7.18 - 7.14 (m, 1H), 6.94 (dd, J = 7.5, 4.1 Hz, 1H), 6.42 (s, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.39 (dt, J = 45.0, 17.4 Hz, 4H), 3.68 (dd, J = 5.7, 4.1 Hz, 2H), 3.59 - 3.51 (m, 4H), 2.96 - 2.87 (m, 1H), 2.83 (t, J = 7.1 Hz, 2H), 2.64 - 2.59 (m, 1H), 2.58 (s, 2H), 2.38 (qd, J = 13.0, 4.2 Hz, 1H), 2.00 (ddd, J = 10.3, 5.3, 3.1 Hz, 1H), 0.94 - 0.78 (m, 1H), 0.43 - 0.33 (m, 2H), 0.14 - 0.07 (m, 2H); LRMS (ES) m / z 584.2 [M+H] + .
[1047]
[1048] Example 70: Synthesis of 1-(4-(1-(2-(((2-oxaspyr[3.3]heptane-6-yl)amino)oxy)ethoxy)-2-methylpropane-2-yl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea
[1049]
[1050] It was synthesized in a manner similar to Example 31.
[1051] 1 H-NMR (400 MHz, DMSO-d6)δ 10.98 (s, 1H), 9.10 (s, 1H), 8.45 (s, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.62 - 7.54 (m, 2H), 7.49 (d, J = 8.0 Hz, 1H), 7.37 (br, 1H), 7.25 (dd, J = 8.4, 5.1 Hz, 1H), 7.17 - 7.08 (m, 1H), 5.11 (dd, J = 13.7, 5.2 Hz, 1H), 4.97 - 4.84 (m, 1H), 4.57 - 4.28 (m, 4H), 3.77 - 3.41 (m, 10H), 2.99 - 2.84 (m, 1H), 2.70 - 2.55 (m, 1H), 2.42 - 2.30 (m, 1H), 2.28 - 2.19 (m, 1H), 2.05 - 1.89 (m, 2H), 1.41 (d, J = 6.6 Hz, 3H), 1.35 (s, 6H); LRMS (ES) m / z 668.2 [M+H] + .
[1052]
[1053] Example 71: Synthesis of 1-(4-(2-(4-aminopiperazine-1-yl)ethyl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea 2,2,2-trifluoroacetate
[1054] Step 1) Synthesis of 2-chloro-4-nitropenethyl methanesulfonate
[1055]
[1056] A solution of 2-(2-chloro-4-nitrophenyl)ethanol-1-ol (0.200 g, 0.992 mmol), methanesulfonyl chloride (0.115 mL, 1.488 mmol), and N,N-diisopropylethylamine (0.520 mL, 2.976 mmol) dissolved in dichloromethane (4 mL) was stirred at 0 °C for 30 minutes and further stirred at room temperature for 2 hours. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 40%) to obtain 2-chloro-4-nitrophenethyl methanesulfonate (0.204 g, 73.5%) in the form of a yellow liquid.
[1057] LRMS (ES) m / z 301.2 [M+Na]+.
[1058] Step 2) Synthesis of tert-butyl (4-(2-chloro-4-nitropenethyl)piperazine-1-yl)carbamate
[1059]
[1060] A solution of 2-chloro-4-nitropene ethyl methanesulfonate (0.200 g, 0.715 mmol), tert-butyl piperazine-1-ylcarbamate (0.173 g, 0.858 mmol), and potassium carbonate (K2CO3, 0.198 g, 1.430 mmol) dissolved in N,N-dimethylformamide (4 mL) / dichloromethane (4 mL) was stirred at room temperature for 1 hour and further stirred at the same temperature for 18 hours. Water was added to the concentrate obtained by removing the solvent from the reaction mixture under reduced pressure, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 70%) to obtain tert-butyl (4-(2-chloro-4-nitropenethyl)piperazine-1-yl)carbamate (0.124 g, 45.1%) in the form of yellow crystals.
[1061] LRMS (ES) m / z 385.1 [M+H]+.
[1062] Step 3) Synthesis of tert-butyl (4-(4-amino-2-chlorophenethyl)piperazine-1-yl)carbamate
[1063]
[1064] A solution of tert-butyl (4-(2-chloro-4-nitropenethyl)piperazine-1-yl)carbamate (0.085 g, 0.221 mmol), iron (0.247 g, 4.417 mmol), and ammonium chloride (NH4Cl, 0.236 g, 4.417 mmol) dissolved in ethanol (2 mL) and water (0.5 mL) at 90 °C was stirred at the same temperature for 1 hour, after which the temperature was lowered to room temperature to terminate the reaction. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The product was used without further purification (tert-butyl (4-(4-amino-2-chlorophenethyl)piperazine-1-yl)carbamate, 0.070 g, 89.8%, clear liquid).
[1065] LRMS (ES) m / z 355.2 [M+H]+ .
[1066] Step 4) Synthesis of tert-butyl (4-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenethyl)piperazine-1-yl)carbamate
[1067]
[1068] A solution of tert-butyl (4-(4-amino-2-chlorophenethyl)piperazine-1-yl)carbamate (0.070 g, 0.198 mmol), phenyl chloroformate (0.028 mL, 0.218 mmol), pyridine (0.018 mL, 0.218 mmol), 3-(5-((S)-1-aminoethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride (0.077 g, 0.238 mmol) and triethylamine (0.083 mL, 0.595 mmol) dissolved in ethyl acetate (5 mL) was stirred at 0 °C for 1 hour, and the organic solvent was concentrated under reduced pressure. The reaction mixture was dissolved in N,N-dimethylformamide (1 mL) and further stirred at room temperature for 18 hours. After concentrating the reaction mixture under reduced pressure, it was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 10%) to obtain tert-butyl (4-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenethyl)piperazine-1-yl)carbamate (0.100 g, 75.4%) in the form of a colorless liquid.
[1069] LRMS (ES) m / z 668.2 [M+H]+ .
[1070] Step 5) Synthesis of 1-(4-(2-(4-aminopiperazine-1-yl)ethyl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea 2,2,2-trifluoroacetate
[1071]
[1072] A solution of tert-butyl (4-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenethyl)piperazine-1-yl)carbamate (0.100 g, 0.150 mmol) and trifluoroacetic acid (0.573 mL, 7.483 mmol) dissolved in dichloromethane (2 mL) was stirred at 0 °C for 30 minutes and further stirred at room temperature for 1 hour. After removing the solvent from the reaction mixture under reduced pressure, diethyl ether (5 mL) was poured over the concentrate to suspend it and filtered. The resulting solid was then washed with hexane and dried to obtain 1-(4-(2-(4-aminopiperazine-1-yl)ethyl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea 2,2,2-trifluoroacetate (0.099 g, 97.2%) in the form of ivory crystals.
[1073] 1H NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 9.70 (br, 2H), 8.91 (br, 1H), 7.73 - 7.64 (m, 2H), 7.55 (s, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.23 - 7.18 (m, 2H), 7.10 (br, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.90 (p, J = 6.5 Hz, 1H), 4.38 (ddd, J = 19.7, 17.5, 3.2 Hz, 2H), 3.19 (br, 4H), 3.09 (ddd, J = 14.5, 7.3, 5.0 Hz, 4H), 3.04 - 2.94 (m, 4H), 2.91 - 2.85 (m, 1H), 2.65 - 2.55 (m, 1H), 2.38 (ddd, J = 18.3, 10.5, 3.7 Hz, 1H), 2.05 - 1.95 (m, 1H), 1.41 (d, J = 7.0 Hz, 3H); LRMS (ES) m / z 568.3 [M+H]+
[1074]
[1075] Example 72: Synthesis of 1-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)-3-(4-(1-(2-((methylamino)oxy)ethoxy)propane-2-yl)-3-(trifluoromethyl)phenyl)urea
[1076]
[1077] It was synthesized in a manner similar to Example 31.
[1078] 1 H NMR (400 MHz, DMSO-d6)δ 10.93 (s, 1H), 8.80 (s, 1H), 7.81 (s, 1H), 7.66 (d, J = 7.9 Hz, 1H), 7.52 (s, 1H), 7.46 - 7.37 (m, 3H), 6.94 (dd, J = 7.8, 2.6 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.88 (p, J = 7.1 Hz, 1H), 4.41 (dd, J = 17.7, 2.5 Hz, 1H), 4.27 (d, J = 17.3 Hz, 1H), 3.93 (t, J = 4.6 Hz, 1H), 3.57 (t, J = 4.9 Hz, 1H), 3.53 - 3.37 (m, 4H), 3.21 - 3.12 (m, 1H), 2.92 - 2.81 (m, 1H), 2.65 - 2.51 (m, 1H), 2.43 (s, 3H), 2.39 - 2.24 (m, 1H), 1.99 - 1.91 (m, 1H), 1.38 (d, J = 6.9 Hz, 3H), 1.14 (dd, J = 6.8, 3.8 Hz, 3H); LRMS (ES) m / z 606.3 [M+H] + .
[1079]
[1080] Example 73: Synthesis of 1-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)-3-(4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)-3-(trifluoromethyl)phenyl)urea
[1081]
[1082] It was synthesized in a manner similar to Example 31.
[1083] LRMS (ES) m / z 620.3 [M+H] + .
[1084]
[1085] Example 74: Synthesis of 1-(3-chloro-4-(1-(2-(((cyclopropylmethyl)amino)oxy)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea
[1086]
[1087] It was synthesized in a manner similar to Example 31.
[1088] 1H NMR (400 MHz, DMSO-d6)δ 10.94 (s, 1H), 8.56 (d, J = 3.8 Hz, 1H), 7.66 (dd, J = 8.2, 1.2 Hz, 1H), 7.54 (d, J = 2.4 Hz, 1H), 7.51 (s, 1H), 7.44 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 8.8 Hz, 1H), 7.05 (dd, J = 8.7, 2.3 Hz, 1H), 6.82 (dd, J = 7.6, 3.0 Hz, 1H), 5.07 (dd, J = 13.2, 5.1 Hz, 1H), 4.86 (p, J = 7.1 Hz, 1H), 4.45 - 4.38 (m, 1H), 4.27 (d, J = 17.2 Hz, 1H), 3.63 (s, 2H), 3.59 (dd, J = 5.8, 3.9 Hz, 2H), 3.45 (dd, J = 5.8, 3.9 Hz, 2H), 2.92 - 2.81 (m, 1H), 2.62 - 2.54 (m, 1H), 2.52 (d, J = 6.9 Hz, 2H), 2.41 - 2.28 (m, 1H), 2.00 - 1.90 (m, 1H), 1.38 (d, J = 6.9 Hz, 3H), 1.31 (s, 6H), 0.84 - 0.71 (m, 1H), 0.35 - 0.29 (m, 2H), 0.07 - 0.01 (m, 2H); LRMS (ES) m / z 626.3 [M+H] + .
[1089]
[1090] Example 75: Synthesis of 1-(3-chloro-4-(1-(2-(methoxyamino)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea
[1091] Step 1) Synthesis of 2-(2-(2-chloro-4-nitrophenyl)-2-methylpropoxy)ethyl methanesulfonate
[1092]
[1093] A solution of 2-(2-(2-chloro-4-nitrophenyl)-2-methylpropoxy)ethanol-1-ol (0.300 g, 1.096 mmol), methanesulfonyl chloride (0.127 mL, 1.644 mmol), and N,N-diisopropylethylamine (0.382 mL, 2.192 mmol) dissolved in dichloromethane (6 mL) at 0 °C was stirred at the same temperature for 1 hour. Water was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 25%) to obtain 2-(2-(2-chloro-4-nitrophenyl)-2-methylpropoxy)ethyl methanesulfonate (0.368 g, 95.4%) in the form of a pale yellow oil.
[1094] LRMS (ES) m / z 352.1 [M+Na] + .
[1095] Step 2) Synthesis of tert-butyl (2-(2-(2-chloro-4-nitrophenyl)-2-methylpropoxy)ethyl)(methoxy)carbamate
[1096]
[1097] A solution of 2-(2-(2-chloro-4-nitrophenyl)-2-methylpropoxy)ethyl methanesulfonate (0.100 g, 0.284 mmol), tert-butyl methoxycarbamate (0.126 g, 0.853 mmol), and cesium carbonate (0.278 g, 0.853 mmol) dissolved in N,N-dimethylformamide (3 mL) at 70 °C was stirred at the same temperature for 16 hours, after which the temperature was lowered to room temperature to terminate the reaction. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 15%) to obtain tert-butyl (2-(2-(2-chloro-4-nitrophenyl)-2-methylpropoxy)ethyl)(methoxy)carbamate (0.176 g, 153.8%) in the form of a pale yellow oil.
[1098] LRMS (ES) m / z 425.1 [M+Na] + .
[1099] Step 3) Synthesis of tert-butyl (2-(2-(4-amino-2-chlorophenyl)-2-methylpropoxy)ethyl)(methoxy)carbamate
[1100]
[1101] A solution of tert-butyl (2-(2-(2-chloro-4-nitrophenyl)-2-methylpropoxy)ethyl)(methoxy)carbamate (0.284 mmol, 0.284 mmol), iron (0.095 g, 1.704 mmol), and ammonium chloride (0.152 g, 2.840 mmol) dissolved in ethanol (3 mL) and water (1 mL) at 90 °C was stirred at the same temperature for 1 hour, after which the temperature was lowered to room temperature to terminate the reaction. The reaction mixture was filtered through Celite to remove the solid, water was added to the filtrate, and the mixture was extracted with dichloromethane. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 35%) to obtain tert-butyl (2-(2-(4-amino-2-chlorophenyl)-2-methylpropoxy)ethyl)(methoxy)carbamate (0.101 g, 95.4%) in the form of a clear oil.
[1102] LRMS (ES) m / z 395.1 [M+Na] + .
[1103] Step 4) Synthesis of tert-butyl (2-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenyl)-2-methylpropoxy)ethyl)(methoxy)carbamate
[1104]
[1105] A solution of tert-butyl (2-(2-(4-amino-2-chlorophenyl)-2-methylpropoxy)ethyl)(methoxy)carbamate (0.062 g, 0.166 mmol), phenyl chloroformate (0.025 mL, 0.200 mmol), and pyridine (0.016 mL, 0.200 mmol) dissolved in ethyl acetate (3 mL) was stirred at 0 °C for 1 hour and the solvent was concentrated. 3-(5-((S)-1-aminoethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-diionic hydrochloride (0.054 g, 0.166 mmol) and triethylamine (0.115 mL, 0.831 mmol) were suspended in N,N-dimethylformamide (3 mL) at room temperature and further stirred for 18 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; methanol / dichloromethane = 0% to 5%) to obtain tert-butyl (2-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenyl)-2-methylpropoxy)ethyl)(methoxy)carbamate (0.051 g, 44.7%) as a pale yellow solid.
[1106] LRMS (ES) m / z 708.3 [M+Na] + .
[1107] Step 5) Synthesis of 1-(3-chloro-4-(1-(2-(methoxyamino)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea
[1108]
[1109] A solution of tert-butyl (2-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenyl)-2-methylpropoxy)ethyl)(methoxy)carbamate (0.051 g, 0.074 mmol) dissolved in dichloromethane (3 mL) / trifluoroacetic acid (1 mL) was stirred at 0 °C for 30 minutes and further stirred at room temperature for 1 hour. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (C18, 10 g cartridge; acetonitrile / 0.1% aqueous formic acid solution = 0% to 80%) to obtain 1-(3-chloro-4-(1-(2-(methoxyamino)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea (0.035 g, 81.3%) in the form of a white solid.
[1110] 1H NMR (400 MHz, DMSO-d6)δ 10.94 (s, 1H), 8.51 (d, J = 3.5 Hz, 1H), 7.66 (d, J = 7.9 Hz, 1H), 7.54 (d, J = 2.3 Hz, 1H), 7.51 (s, 1H), 7.44 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 8.7 Hz, 1H), 7.06 (dd, J = 8.7, 2.4 Hz, 1H), 6.77 (dd, J = 7.6, 2.7 Hz, 1H), 5.07 (dd, J = 13.3, 5.1 Hz, 1H), 4.86 (p, J = 7.0 Hz, 1H), 4.41 (d, J = 17.6 Hz, 1H), 4.28 (d, J = 17.3 Hz, 1H), 3.62 (s, 2H), 3.39 (t, J = 5.8 Hz, 2H), 3.30 (s, 3H), 2.92 - 2.84 (m, 1H), 2.81 (t, J = 5.9 Hz, 2H), 2.63 - 2.52 (m, 1H), 2.42 - 2.27 (m, 1H), 1.99 - 1.91 (m, 1H), 1.38 (dd, J = 6.9, 1.1 Hz, 3H), 1.31 (s, 6H); LRMS (ES) m / z 586.3 [M+H] + .
[1111]
[1112] Example 76: Synthesis of 1-(3-chloro-4-(1-(2-(isopropoxyamino)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea
[1113]
[1114] It was synthesized in a manner similar to Example 75.
[1115] 1H NMR (400 MHz, DMSO-d6)δ 10.93 (s, 1H), 8.63 (d, J = 3.9 Hz, 1H), 7.65 (d, J = 7.8 Hz, 1H), 7.58 - 7.48 (m, 2H), 7.44 (d, J = 8.0 Hz, 1H), 7.21 (d, J = 8.7 Hz, 1H), 7.06 (dd, J = 8.7, 2.5 Hz, 1H), 6.88 (dd, J = 7.4, 3.4 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.86 (t, J = 7.1 Hz, 1H), 4.41 (dd, J = 17.4, 2.7 Hz, 1H), 4.27 (d, J = 17.2 Hz, 1H), 3.64 - 3.56 (m, 3H), 3.38 (t, J = 5.8 Hz, 2H), 2.92 - 2.81 (m, 1H), 2.77 (t, J = 5.8 Hz, 2H), 2.64 - 2.53 (m, 1H), 2.41 - 2.26 (m, 1H), 2.00 - 1.90 (m, 1H), 1.37 (d, J = 7.0 Hz, 3H), 1.31 (s, 6H), 0.97 (d, J = 6.1 Hz, 6H); LRMS (ES) m / z 614.3 [M+H] + .
[1116]
[1117] Example 77: Synthesis of 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)propyl)urea
[1118] Step 1) Synthesis of 1-oxo-1,3-dihydroisobenzofuran-5-carbaldehyde
[1119]
[1120] Raney nickel (2.0 g) was added to a mixture of 1-oxo-1,3-dihydroisobenzofuran-5-carbonitrile (10.000 g, 62.838 mmol) mixed with water (50 mL) and formic acid (150 mL) at room temperature, and the mixture was stirred at 95 °C for 18 hours, after which the temperature was lowered to room temperature to terminate the reaction. The reaction mixture was filtered through a Celite pad to remove the solid, and the filtrate was subjected to solvent removal under reduced pressure to obtain a concentrate. A saturated aqueous sodium bicarbonate solution was poured over the concentrate, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. Ethyl acetate and hexane were added to the concentrate and stirred to precipitate the solid, which was then filtered, washed with hexane, and dried to obtain 1-oxo-1,3-dihydroisobenzofuran-5-carbaldehyde (9.720 g, 95.4%) in the form of a pale yellow solid.
[1121] Step 2) Synthesis of 5-(1-hydroxypropyl)isobenzofuran-1(3H)-one
[1122]
[1123] Ethyl magnesium bromide (1.0 M tetrahydrofuran solution, 33.921 mL, 33.921 mmol) was added to a solution of 1-oxo-1,3-dihydroisobenzofuran-5-carbaldehyde (5.000 g, 30.838 mmol) dissolved in tetrahydrofuran (150 mL) at 0 °C and stirred for 1 hour at the same temperature. Then, hydrochloric acid (1.0 M aqueous solution, 37.005 mL, 37.005 mmol) was added to the reaction mixture at 0 °C and stirred for 30 minutes to terminate the reaction. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 25 g cartridge; ethyl acetate / hexane = 10% to 40%) to obtain 5-(1-hydroxypropyl)isobenzofuran-1(3H)-one (3.720 g, 62.8%) in the form of a yellow liquid.
[1124] Step 3) Synthesis of 5-propionylisobenzofuran-1(3H)-one
[1125]
[1126] 1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one (des-martine periodinane, 9.850 g, 23.225 mmol) was added to a solution of 5-(1-hydroxypropyl)isobenzofuran-1(3H)-one (3.720 g, 19.354 mmol) dissolved in dichloromethane (100 mL) at 0 °C, and the mixture was stirred at room temperature for 1 hour. A saturated aqueous sodium bicarbonate solution was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 25 g cartridge; ethyl acetate / hexane = 0% to 30%) to obtain 5-propionylisobenzofuran-1(3H)-one (2.740 g, 74.4%) in the form of a white solid.
[1127] Step 4) Synthesis of (R)-2-methyl-N-((S)-1-(1-oxo-1,3-dihydroisobenzofuran-5-yl)propyl)propane-2-sulfinamide
[1128]
[1129] Titanium ethoxide (6.041 mL, 28.812 mmol) was added to a mixture of 5-propionylisobenzofuran-1(3H)-one (2.740 g, 14.406 mmol) and (S)-2-methylpropane-2-sulfinamide (1.921 g, 15.846 mmol) mixed in tetrahydrofuran (50 mL) at 0 °C and heated under reflux for 18 hours. After lowering the temperature to -78 °C, sodium borohydride (2.0 M tetrahydrofuran suspension, 28.812 mL, 57.624 mmol) was added to the mixture and stirred at room temperature for 1 hour, after which methanol (17.484 mL, 432.177 mmol) was added to the reaction mixture at 0 °C and stirred for 30 minutes to terminate the reaction. A saturated aqueous sodium bicarbonate solution was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 25 g cartridge; ethyl acetate / hexane = 20% to 70%) to obtain (R)-2-methyl-N-((S)-1-(1-oxo-1,3-dihydroisobenzofuran-5-yl)propyl)propane-2-sulfinamide (2.940 g, 69.1%) as a bright yellow solid.
[1130] Step 5) Synthesis of (S)-5-(1-aminopropyl)isobenzofuran-1(3H)-one hydrochloride
[1131]
[1132] Hydrogen chloride (4.0 M 1,4-dioxane solution, 24.882 mL, 99.526 mmol) was added to a solution of (R)-2-methyl-N-((S)-1-(1-oxo-1,3-dihydroisobenzofuran-5-yl)propyl)propane-2-sulfinamide (2.940 g, 9.953 mmol) dissolved in 1,4-dioxane (20 mL) at room temperature, and the mixture was stirred at the same temperature for 2 hours. After removing the solvent from the reaction mixture under reduced pressure, the product was used without further purification ((S)-5-(1-aminopropyl)isobenzofuran-1(3H)-one hydrochloride, 2.250 g, 99.3%, white solid).
[1133] Step 6) Synthesis of tert-butyl(S)-(1-(1-oxo-1,3-dihydroisobenzofuran-5-yl)propyl)carbamate
[1134]
[1135] Di-tert-butyl dicarbonate (3.405 mL, 14.823 mmol) was added to a mixture of (S)-5-(1-aminopropyl)isobenzofuran-1(3H)-one hydrochloride (2.250 g, 9.882 mmol) and sodium bicarbonate (4.151 g, 49.409 mmol) mixed in water (30 mL) and tetrahydrofuran (40 mL) at 0 °C, and the mixture was stirred at room temperature for 6 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 25 g cartridge; ethyl acetate / hexane = 0% to 30%) to obtain tert-butyl(S)-(1-(1-oxo-1,3-dihydroisobenzofuran-5-yl)propyl)carbamate (2.460 g, 85.4%) in the form of a white solid.
[1136] Step 7) Synthesis of (S)-4-(1-((tert-butoxycarbonyl)amino)propyl)-2-(hydroxymethyl)benzoic acid
[1137]
[1138] Sodium hydroxide (0.50 M aqueous solution, 33.774 mL, 16.887 mmol) was added to a solution of tert-butyl (S)-(1-(1-oxo-1,3-dihydroisobenzofuran-5-yl)propyl)carbamate (2.460 g, 8.443 mmol) dissolved in tetrahydrofuran (10 mL) at 0 °C and stirred at room temperature for 3 hours. Then, hydrochloric acid (1.0 M aqueous solution, 18.576 mL, 18.576 mmol) was added to the reaction mixture at room temperature and stirred for 30 minutes to terminate the reaction. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The product was used without further purification ((S)-4-(1-((tert-butoxycarbonyl)amino)propyl)-2-(hydroxymethyl)benzoic acid, 2.260 g, 86.5%, white solid).
[1139] Step 8) Synthesis of methyl(S)-4-(1-((tert-butoxycarbonyl)amino)propyl)-2-(hydroxymethyl)benzoate
[1140]
[1141] (S)-4-(1-((tert-butoxycarbonyl)amino)propyl)-2-(hydroxymethyl)benzoic acid (2.260 g, 7.305 mmol) was dissolved in methanol (12 mL) / ethyl acetate (12 mL) at 0 °C. (Diazomethyl)trimethylsilane (5.795 mL, 36.527 mmol) was added to the solution and stirred for 2 hours at the same temperature. (Diazomethyl)trimethylsilane (0.658 g, 36.527 mmol) was added to the reaction mixture and stirred for an additional 1 hour at the same temperature. Then, water was added to the reaction mixture at 0 °C and stirred for 30 minutes to terminate the reaction. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The product was used without further purification (methyl (S)-4-(1-((tert-butoxycarbonyl)amino)propyl)-2-(hydroxymethyl)benzoate, 2.350 g, 99.5%, pale yellow liquid).
[1142] Step 9) Synthesis of methyl(S)-2-(bromomethyl)-4-(1-((tert-butoxycarbonyl)amino)propyl)benzoate
[1143]
[1144] Triphenylphosphine (3.812 g, 14.534 mmol) was added to a solution prepared by dissolving methyl (S)-4-(1-((tert-butoxycarbonyl)amino)propyl)-2-(hydroxymethyl)benzoate (2.350 g, 7.267 mmol) and carbon sabromide (4.820 g, 14.534 mmol) in tetrahydrofuran (40 mL) at 0 °C, and the mixture was stirred at room temperature for 1 hour. Subsequently, water was added to the reaction mixture at room temperature and stirred for 30 minutes to terminate the reaction. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dehydrated with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was subjected to column chromatography (SiO2, 25 g cartridge; ethyl acetate / hexane = 0 %). Methyl (S)-2-(bromomethyl)-4-(1-((tert-butoxycarbonyl)amino)propyl)benzoate (2.760 g, 98.3%) was obtained in the form of a pale yellow liquid by purification and concentration to 20%).
[1145] Step 10) Synthesis of tert-butyl ((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)propyl)carbamate
[1146]
[1147] Methyl (S)-2-(bromomethyl)-4-(1-((tert-butoxycarbonyl)amino)propyl)benzoate (2.760 g, 7.145 mmol) and 3-aminopiperidine-2,6-diionic hydrochloride (1.764 g, 10.717 mmol) were mixed in N,N-dimethylformamide (40 mL) at room temperature. To this mixture, N,N-diisopropylethylamine (4.978 mL, 28.580 mmol) was added and stirred at 80 °C for 18 hours, after which the temperature was lowered to room temperature to terminate the reaction. The reaction mixture was subjected to solvent removal under reduced pressure to obtain a concentrate, to which a saturated aqueous sodium bicarbonate solution was poured and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was dissolved in dichloromethane and passed through a silica gel plug (ethyl acetate), then concentrated. After adding ethyl acetate and hexane to the product and stirring, the precipitated solid was filtered, washed with hexane, and dried to obtain tert-butyl ((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)propyl)carbamate (2.470 g, 86.1%) in the form of a purple solid.
[1148] Step 11) Synthesis of 3-(5-((S)-1-aminopropyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride
[1149]
[1150] Hydrogen chloride (4.0 M 1,4-dioxane solution, 12.143 mL, 48.573 mmol) was added to a solution of tert-butyl ((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)propyl)carbamate (0.650 g, 1.619 mmol) dissolved in 1,4-dioxane (30 mL) at room temperature, and the mixture was stirred at the same temperature for 3 hours. After removing the solvent from the reaction mixture under reduced pressure, ethyl acetate was added to the concentrate and stirred to filter the precipitated solid, wash with ethyl acetate, and dry to obtain 3-(5-((S)-1-aminopropyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride (0.520 g, 95.1%) in the form of a gray solid.
[1151] Step 12) Synthesis of tert-butyl (2-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)propyl)ureido)phenyl)-2-methylpropoxy)ethoxy)(methyl)carbamate
[1152]
[1153] A solution of tert-butyl (2-(2-(4-amino-2-chlorophenyl)-2-methylpropoxy)ethoxy)(methyl)carbamate (0.070 g, 0.188 mmol), phenyl chloroformate (0.028 mL, 0.226 mmol), and N,N-diisopropylethylamine (0.066 mL, 0.377 mmol) dissolved in tetrahydrofuran (2 mL) was stirred at 0 °C for 1 hour, and then the reaction mixture was concentrated under reduced pressure. 3-(5-((S)-1-aminopropyl)-1-oxoisoindolin-2-yl)piperidin-2,6-diionic hydrochloride (0.10 MN,N-dimethylformamide solution, 2.824 mL, 0.282 mmol) and N,N-diisopropylethylamine (0.132 mL, 0.753 mmol) were added to the concentrated reaction mixture and stirred for 14 hours at room temperature. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 5g cartridge; ethyl acetate / hexane = 70% to 100%) to obtain tert-butyl (2-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)propyl)ureido)phenyl)-2-methylpropoxy)ethoxy)(methyl)carbamate (0.084 g, 63.8%) in the form of a blue oil.
[1154] LRMS (ES) m / z 722.0 [M+Na] + .
[1155] Step 13) Synthesis of 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)propyl)urea
[1156]
[1157] Trifluoroacetic acid (0.459 mL, 5.998 mmol) was added to a solution of tert-butyl (2-(2-(2-2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)propyl)ureido)phenyl)-2-methylpropoxy)ethoxy)(methyl)carbamate (0.084 g, 0.120 mmol) dissolved in dichloromethane (1.5 mL) at room temperature, and the mixture was stirred for 15 minutes at the same temperature. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (C18, 6 g cartridge; acetonitrile / 0.1% aqueous formic acid solution = 10% to 50%) to obtain 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)propyl)urea (0.030 g, 41.8%) in the form of an ivory solid.
[1158] 1H-NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.56 (d, J = 3.0 Hz, 1H), 7.69 (d, J = 7.7 Hz, 1H), 7.56 (d, J = 2.4 Hz, 1H), 7.52 (s, 1H), 7.44 (d, J = 7.8 Hz, 1H), 7.25 (d, J = 8.8 Hz, 1H), 7.08 (dd, J = 8.7, 2.3 Hz, 1H), 6.83 (dd, J = 7.7, 3.6 Hz, 1H), 5.09 (dd, J = 13.2, 4.8 Hz, 1H), 4.69 (q, J = 7.2 Hz, 1H), 4.45 (dd, J = 17.4, 2.7 Hz, 1H), 4.31 (d, J = 17.1 Hz, 1H), 3.65 (s, 2H), 3.66-3.62 (m, 2H), 3.50-3.46 (m, 2H), 2.97-2.84 (m, 1H), 2.64-2.55 (m, 1H), 2.50 (s, 3H), 2.43-2.30 (m, 1H), 2.03-1.93 (m, 1H), 1.74 (p, J = 7.0 Hz, 2H), 1.34 (s, 6H), 0.86 (t, J = 7.3 Hz, 3H); LRMS (ES) m / z 600.3 [M+H] + .
[1159]
[1160] Example 78: Synthesis of 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethoxy)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea
[1161] Step 1) Synthesis of 2-(2-(2-chloro-4-nitrophenoxy)ethoxy)ethanol-1-ol
[1162]
[1163] 2-chloro-1-fluoro-4-nitrobenzene (1.000 g, 5.697 mmol), diethylene glycol (5.407 mL, 56.967 mmol), and potassium carbonate (0.866 g, 6.266 mmol) were stirred at 80 °C for 20 hours, after which the temperature was lowered to room temperature to terminate the reaction. A 1 N aqueous hydrochloric acid solution was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 25 g cartridge; ethyl acetate / hexane = 20% to 50%) to obtain 2-(2-(2-chloro-4-nitrophenoxy)ethoxy)ethanol-1-ol (1.370 g, 91.9%) in the form of ivory oil.
[1164] 1 H-NMR (400 MHz, CDCl3) δ 8.29 (d, J = 2.7 Hz, 1H), 8.14 (dd, J = 9.1, 2.7 Hz, 1H), 7.01 (d, J = 9.1 Hz, 1H), 4.34 - 4.27 (m, 2H), 4.00 - 3.93 (m, 2H), 3.80 - 3.75 (m, 2H), 3.74 - 3.69 (m, 2H); LRMS (ES) m / z 283.9 [M+Na] + .
[1165] Step 2) Synthesis of tert-butyl (2-(2-(2-chloro-4-nitrophenoxy)ethoxy)ethoxy)(methyl)carbamate
[1166]
[1167] 2-(2-(2-chloro-4-nitrophenoxy)ethoxy)ethanol-1-ol (1.350 g, 5.159 mmol), tert-butyl hydroxy(methyl)carbamate (1.045 mL, 7.739 mmol), and triphenylphosphine (2.030 g, 7.739 mmol) were dissolved in tetrahydrofuran (50 mL), and diisopropyl azodicarboxylate (1.524 mL, 7.739 mmol) was added at 0 °C and stirred at room temperature for 17 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 25 g cartridge; ethyl acetate / hexane = 0% to 30%) to obtain tert-butyl (2-(2-(2-chloro-4-nitrophenoxy)ethoxy)ethoxy)(methyl)carbamate (1.541 g, 76.4%) in the form of a white solid.
[1168] LRMS (ES) m / z 413.1 [M+Na] + .
[1169] Step 3) Synthesis of tert-butyl (2-(2-(4-amino-2-chlorophenoxy)ethoxy)ethoxy)(methyl)carbamate
[1170]
[1171] tert-butyl (2-(2-(2-chloro-4-nitrophenoxy)ethoxy)ethoxy)(methyl)carbamate (1.540 g, 3.940 mmol) was dissolved in ethanol (30 mL) / water (6 mL), and iron (11.004 g, 197.022 mmol) and ammonium chloride (0.632 g, 11.821 mmol) were added at room temperature and stirred at 80 °C for 30 minutes, after which the temperature was lowered to room temperature to terminate the reaction. The reaction mixture was filtered through a Celite pad to remove the solid, and the solvent was removed from the filtrate under reduced pressure. The concentrate was then purified and concentrated by column chromatography (SiO2, 25 g cartridge; ethyl acetate / hexane = 25% to 75%) to obtain tert-butyl (2-(2-(4-amino-2-chlorophenoxy)ethoxy)ethoxy)(methyl)carbamate (1.304 g, 91.7%) in the form of a yellow liquid.
[1172] 1 H-NMR (400 MHz, DMSO-d6) δ 6.85 (d, J = 8.7 Hz, 1H), 6.62 (d, J = 2.6 Hz, 1H), 6.46 (dd, J = 8.7, 2.7 Hz, 1H), 4.90 (s, 2H), 4.01 - 3.96 (m, 2H), 3.93 - 3.88 (m, 2H), 3.74 - 3.69 (m, 2H), 3.67 - 3.62 (m, 2H), 3.01 (s, 3H), 1.41 (s, 9H); LRMS (ES) m / z 383.1 [M+Na] + .
[1173] Step 4) Synthesis of tert-butyl (2-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenoxy)ethoxy)ethoxy)(methyl)carbamate
[1174]
[1175] A solution of tert-butyl (2-(2-(4-amino-2-chlorophenoxy)ethoxy)ethoxy)(methyl)carbamate (0.069 g, 0.191 mmol), phenyl chloroformate (0.029 mL, 0.229 mmol), and N,N-diisopropylethylamine (0.067 mL, 0.382 mmol) dissolved in tetrahydrofuran (2 mL) was stirred at 0 °C for 1 hour and then concentrated. To the concentrated reaction mixture, 3-(5-(aminomethyl)-1-oxoisoindolin-2-yl)piperidin-2,6-diionic hydrochloride (0.10 MN,N-dimethylformamide solution, 2.868 mL, 0.287 mmol) and N,N-diisopropylethylamine (0.134 mL, 0.765 mmol) were added and stirred at room temperature for 18 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 5g cartridge; methanol / ethyl acetate = 0% to 10%) to obtain tert-butyl(2-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenoxy)ethoxy)ethoxy)(methyl)carbamate (0.078 g, 62.1%) in the form of a white solid.
[1176] LRMS (ES) m / z 682.2 [M+Na] + .
[1177] Step 5) Synthesis of 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethoxy)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea
[1178]
[1179] Trifluoroacetic acid (0.454 mL, 5.938 mmol) was added to a solution of tert-butyl (2-(2-(2-2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenoxy)ethoxy)ethoxy)(methyl)carbamate (0.078 g, 0.119 mmol) dissolved in dichloromethane (1.2 mL) at room temperature, and the mixture was stirred for 15 minutes at the same temperature. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (C18, 12 g cartridge; acetonitrile / 0.1% aqueous formic acid solution = 5% to 55%) to obtain 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethoxy)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea (0.055 g, 82.7%) in the form of a white solid.
[1180] 1 H-NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.82 (s, 1H), 7.68 (d, J = 7.8 Hz, 1H), 7.63 (d, J = 2.4 Hz, 1H), 7.51 (s, 1H), 7.43 (d, J = 7.9) Hz, 1H), 7.19 (dd, J = 8.9, 2.3 Hz, 1H), 7.03 (d, J = 8.9 Hz, 1H), 6.96 (t, J = 5.8 Hz, 1H), 5.09 (dd, J = 12.9, 4.6 Hz, 1H), 4.48-4.37 (m, 3H), 4.30 (d, J = 17.3 Hz, 1H), 4.12-4.06 (m, 2H), 3.75-3.71 (m, 2H), 3.69-3.64 (m, 2H), 3.63-2.58 (m, 2H), 2.50 (s, 3H), 2.95-2.85 (m, 1H), 2.63-2.55 (m, 1H), 2.44-2.32 (m, 1H), 2.04-1.96 (m, 1H); LRMS (ES) m / z 560.2 [M+H] + .
[1181]
[1182] Example 79: Synthesis of 1-(3-chloro-4-((2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)oxy)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea
[1183] Step 1) Synthesis of tert-butyl 2-(2-chloro-4-nitrophenoxy)-2-methylpropanoate
[1184]
[1185] Tert-butyl 2-bromo-2-methylpropanoate (1.607 mL, 8.643 mmol) was added to a solution of 2-chloro-4-nitrophenol (0.500 g, 2.881 mmol) and potassium carbonate (1.991 g, 14.405 mmol) dissolved in N,N-dimethylformamide (10 mL) at room temperature, and the mixture was stirred at 80 °C for 16 hours, after which the temperature was lowered to room temperature to terminate the reaction. A saturated aqueous ammonium chloride solution was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 10%) to obtain tert-butyl 2-(2-chloro-4-nitrophenoxy)-2-methylpropanoate (0.838 g, 92.1%) in the form of a colorless oil.
[1186] LRMS (ES) m / z 338.1 [M+Na] + .
[1187] Step 2) Synthesis of 2-(2-chloro-4-nitrophenoxy)-2-methylpropan-1-ol
[1188]
[1189] Diisobutyl aluminum hydride (1.0 M tetrahydrofuran, 5.528 mL, 5.528 mmol) was added to a solution of tert-butyl 2-(2-chloro-4-nitrophenoxy)-2-methylpropanoate (0.582 g, 1.843 mmol) dissolved in tetrahydrofuran (26 mL) at 0 °C and stirred for 2 hours at the same temperature. Then, at 0 °C, 2.0 M aqueous sodium hydroxide solution was added to the reaction mixture and stirred for 30 minutes to terminate the reaction. The reaction mixture was filtered through a Celite pad to remove the solid, water was added to the filtrate, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 30% to 80%) to obtain 2-(2-chloro-4-nitrophenoxy)-2-methylpropan-1-ol (0.429 g, 94.8%) in the form of a pale yellow solid.
[1190] 1 H-NMR (400 MHz, CDCl3) δ 8.31 (d, J = 2.7 Hz, 1H), 8.16 (dd, J = 9.1, 2.7 Hz, 1H), 6.99 (d, J = 9.1 Hz, 1H), 3.95 (s, 2H), 1.41 (s, 6H); LRMS (ES) m / z 246.0 [M+H] + .
[1191] Step 3) Synthesis of tert-butyl 2-(2-(2-chloro-4-nitrophenoxy)-2-methylpropoxy)acetate
[1192]
[1193] 2-(2-chloro-4-nitrophenoxy)-2-methylpropan-1-ol (0.444 g, 1.807 mmol), tert-butyl 2-bromoacetate (2.120 mL, 14.459 mmol), and tetrabutylammonium hydrogen sulfate (0.491 g, 1.446 mmol) were dissolved in toluene (10 mL), and 5.0 M aqueous sodium hydroxide solution (36.148 mL, 180.738 mmol) was added at 0 °C and stirred for 3 hours at the same temperature, followed by additional stirring for 3 hours at room temperature. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 10%) to obtain tert-butyl 2-(2-(2-chloro-4-nitrophenoxy)-2-methylpropoxy)acetate (0.372 g, 57.2%) in the form of an ivory solid.
[1194] LRMS (ES) m / z 382.1 [M+Na] + .
[1195] Step 4) Synthesis of 2-(2-(2-chloro-4-nitrophenoxy)-2-methylpropoxy)ethanol-1-ol
[1196]
[1197] Diisobutyl aluminum hydride (3.085 mL, 3.085 mmol) was added to a solution of tert-butyl 2-(2-(2-chloro-4-nitrophenoxy)-2-methylpropoxy)acetate (0.370 g, 1.028 mmol) dissolved in tetrahydrofuran (10 mL) at 0 °C, and stirred for 1 hour at the same temperature. Then, at 0 °C, 2.0 M aqueous sodium hydroxide solution was added to the reaction mixture and stirred for 30 minutes to terminate the reaction. The reaction mixture was filtered through a Celite pad to remove the solid, water was added to the filtrate, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 30% to 70%) to obtain 2-(2-(2-chloro-4-nitrophenoxy)-2-methylpropoxy)ethanol-1-ol (0.150 g, 50.2%) in the form of ivory oil.
[1198] 1 H-NMR (400 MHz, CDCl3) δ 8.30 (d, J = 2.7 Hz, 1H), 8.15 (dd, J = 9.1, 2.7 Hz, 1H), 6.98 (d, J = 9.1 Hz, 1H), 3.99 (s, 2H), 3.72 - 3.67 (m, 2H), 3.63 - 3.58 (m, 2H), 1.39 (s, 6H); LRMS (ES) m / z 312.0 [M+Na] + .
[1199] Step 5) Synthesis of tert-butyl (2-(2-(2-chloro-4-nitrophenoxy)-2-methylpropoxy)ethoxy)(methyl)carbamate
[1200]
[1201] 2-(2-(2-chloro-4-nitrophenoxy)-2-methylpropoxy)ethanol-1-ol (0.144 g, 0.495 mmol), tert-butyl hydroxy(methyl)carbamate (0.100 mL, 0.743 mmol), and triphenylphosphine (0.195 g, 0.743 mmol) were dissolved in tetrahydrofuran (5 mL), and diisopropyl azodicarboxylate (0.146 mL, 0.743 mmol) was added at 0 °C and stirred at room temperature for 16 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 5g cartridge; ethyl acetate / hexane = 0% to 10%) to obtain tert-butyl (2-(2-(2-chloro-4-nitrophenoxy)-2-methylpropoxy)ethoxy)(methyl)carbamate (0.160 g, 77.1%) in the form of a yellow oil.
[1202] LRMS (ES) m / z 441.2 [M+Na] + .
[1203] Step 6) Synthesis of tert-butyl (2-(2-(4-amino-2-chlorophenoxy)-2-methylpropoxy)ethoxy)(methyl)carbamate
[1204]
[1205] tert-butyl (2-(2-(2-chloro-4-nitrophenoxy)-2-methylpropoxy)ethoxy)(methyl)carbam...
Claims
1. Compounds selected from urea derivative compounds represented by the following chemical formula 1, pharmaceutically acceptable salts thereof, hydrates thereof, and stereoisomers thereof: [Chemical Formula 1] (In the above chemical formula 1, Above A 1 is R 7 -(R 8 )NO-, R 9 -O-(R 10 )N-, R 11 -(R 12 )N-(R 13 )N- and; The above R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 Each is independently hydrogen, an alkyl group, an aminoalkyl carbonyl group, an alkylaminoalkyl carbonyl group, a heterocycloalkyl carbonyl group, an aminoalkyl group, an alkylaminoalkyl group, a hydroxyalkyl carbonyl group, a cycloalkyl group, a halocycloalkyl group, a heterocycloalkyl group, a heterobicycloalkyl group, a cycloalkyl-alkyl group, a heterocycloalkyl-alkyl group, a hydroxycarbonylalkyl group, an alkylhydroxycarbonylalkyl group, an aminecarbonylalkyl group, or an alkylaminecarbonylalkyl group; The above R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 The above-mentioned alkyl group, cycloalkyl group, and heterocycloalkyl group are substituted or unsubstituted with one or more types selected from the group consisting of halogens and alkyls; Above A 2 is an alkyl group, an alkoxyalkyl group, an alkylaminocarbonylalkyl group, an alkylcarbonylaminoalkyl group, a carbonylalkyl group, an alkylaminoalkyl-alkyl group, an alcohol-alkoxyalkyl group, an alkylalkoxy-alkoxy group, or an alkylaminoalkyloxyalkyl group; Above A 2 The above alkyl group and alkoxy group are substituted or unsubstituted with one or more selected from the group of halogens and alkyls; The above R 1 , R 2 , R 4 and R 5 Each is independently hydrogen, a halogen group, an alkyl group, a hydroxyl group, an alkoxy group, an amine group, an alkylamine group, a nitrile group, a difluoromethyl group, or a trifluoromethyl group; The above R 3 is hydrogen or an alkyl group; The above R 6 is hydrogen, deuterium, or an alkyl group; The above X 1 is NH, C(=O), O or CF2; The above X 2 is O, S, and NH; The above Y is CH2 or C(=O) 2. In Paragraph 1, Above A 1 is R 7 -(R 8 )NO-, R 9 -O-(R 10 )N-, R 11 -(R 12 )N-(R 13 )N- and; The above R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 are each independently hydrogen, (C1-C5 alkyl) group, H2N-(C1-C5 alkyl)-C(=O)-, (C1-C5 alkyl)HN-(C1-C5 alkyl)-C(=O)-, (C3-C8 heterocycloalkyl)-C(=O)-, H2N-(C1-C5 alkyl)-, (C1-C5 alkyl)HN-(C1-C5 alkyl)-, HO-(C1-C5 alkyl)-C(=O)-, (C3-C8 cycloalkyl) group, (C3-C8 heterocycloalkyl) group, (C7-C 11 Heterobicycloalkyl) group, (C3-C8 cycloalkyl)-(C1-C5 alkyl)-, (C3-C8 heterocycloalkyl)-(C1-C5 alkyl)-, HO-C(=O)-(C1-C5 alkyl)-, (C1-C5 alkyl)-OC(=O)-(C1-C5 alkyl)-, H2N-C(=O)-(C1-C5 alkyl)- or (C1-C5 alkyl)HN-C(=O)-(C1-C5 alkyl)- and; The above R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 The above (C1-C5 alkyl) group, (C3-C8 cycloalkyl) group and (C3-C8 heterocycloalkyl) group are substituted or unsubstituted with one or more selected from the group consisting of halogens and C1-C5 alkyls; Above A 2 is -(C1-C5alkyl)-, -(C1-C5alkyl)-O-(C1-C5alkyl)-, -(C1-C5alkyl)HN-C(=O)-(C1-C5alkyl)-, -(C1-C5alkyl)-C(=O)-NH(C1-C5alkyl)-, -C(=O)-(C1-C5alkyl)-, -(C1-C5alkyl)-N(C1-C5alkyl)-(C1-C5alkyl)-, -(C1-C5alkyl)-O-(C1-C5alkyl)-O-(C1-C5alkyl)-, -(C1-C5alkyl)-O-(C1-C5alkyl)-O- or -(C1-C5alkyl)HN-(C1-C5alkyl)-O-(C1-C5alkyl)- and; Above A 2 The above (C1-C5 alkyl) and (C1-C5 alkyl)-O are substituted or unsubstituted with one or more types selected from the group consisting of halogens and (C1-C5 alkyl); The above R 1 , R 2 , R 4 and R 5 Each is independently hydrogen, a halogen group, a (C1-C5 alkyl) group, a hydroxyl group, an alkoxy group, an amine group, a (C1-C5 alkyl)amine group, a nitrile group, a difluoromethyl group, or a trifluoromethyl group; The above R 3 is hydrogen or a (C1-C5 alkyl) group; The above R 6 is hydrogen, deuterium, or a (C1-C5 alkyl) group; The above X 1 is NH, C(=O), O or CF2; The above X 2 is O, S, or NH; A compound selected from urea derivative compounds characterized in that Y is CH2 or C(=O), pharmaceutically acceptable salts thereof, hydrates thereof, and stereoisomers thereof.
3. In Paragraph 1, The above chemical formula 1 is the following chemical formula 1a, 1b, or 1c; [Chemical Formula 1a] [Chemical Formula 1b] [Chemical Formula 1c] In the above chemical formulas 1a, 1b, and 1c, The above R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 Each is independently hydrogen, (C1-C3 alkyl) group, H2N-(C1-C3 alkyl)-C(=O)-, (C1-C3 alkyl)HN-(C1-C3 alkyl)-C(=O)-, (C3-C6 heterocycloalkyl)-C(=O)-, H2N-(C1-C3 alkyl)-, (C1-C3 alkyl)HN-(C1-C3 alkyl)-, HO-(C1-C3 alkyl)-C(=O)-, (C3-C6 cycloalkyl) group, (C3-C6 heterocycloalkyl) group, (C7-C9 heterobicycloalkyl) group, (C3-C6 cycloalkyl)-(C1-C3 alkyl)-, (C3-C6 heterocycloalkyl)-(C1-C3 alkyl)-, HO-C(=O)-(C1-C5 alkyl)-, (C1-C5 alkyl)-OC(=O)-(C1-C5 alkyl)-, H2N-C(=O)-(C1-C5 alkyl)- or (C1-C5 alkyl)HN-C(=O)-(C1-C5 alkyl)- and R 12 and R 13 A compound selected from urea derivative compounds characterized by being linked and cyclized, pharmaceutically acceptable salts thereof, hydrates thereof, and stereoisomers thereof.
4. In Paragraph 3, A compound selected from urea derivative compounds characterized in that the (C1-C3 alkyl) group, the (C3-C6 cycloalkyl) group, or the (C3-C6 heterocycloalkyl) group is substituted or unsubstituted with one or more of the group consisting of F, Cl, and (C1-C3 alkyl), pharmaceutically acceptable salts thereof, hydrates thereof, and stereoisomers thereof.
5. In Paragraph 1, Above A 2 A urea derivative compound characterized by being -(C1-C3alkyl)-, -(C1-C3alkyl)-O-(C1-C3alkyl)-, -(C1-C3alkyl)HN-C(=O)-(C1-C3alkyl)-, -(C1-C3alkyl)-C(=O)-NH(C1-C3alkyl)-, -C(=O)-(C1-C3alkyl)-, -(C1-C3alkyl)-N(C1-C3alkyl)-(C1-C3alkyl)-, -(C1-C3alkyl)-O-(C1-C3alkyl)-O-(C1-C3alkyl)-, -(C1-C3alkyl)-O-(C1-C3alkyl)-O-, or -(C1-C3alkyl)HN-(C1-C3alkyl)-O-(C1-C3alkyl)-, a pharmaceutically acceptable salt thereof. A compound selected from its hydrates and stereoisomers.
6. In Paragraph 5, A compound selected from urea derivative compounds, pharmaceutically acceptable salts thereof, hydrates thereof, and stereoisomers thereof, characterized in that the above (C1-C3alkyl) and (C1-C3alkyl)-O are substituted or unsubstituted with one or more compounds selected from the group consisting of F, Cl, and (C1-C3alkyl).
7. In Paragraph 1, The above R 1 , R 2 , R 4 and R 5 A compound selected from urea derivative compounds characterized by each being independently hydrogen, F, Cl, Br, (C1-C5 alkyl) group, hydroxyl group, alkoxy group, or trifluoromethyl group, pharmaceutically acceptable salts thereof, hydrates thereof, and stereoisomers thereof.
8. In Paragraph 1, The above R 3 A compound selected from urea derivative compounds characterized by being hydrogen, a methyl group, an ethyl group, a propyl group, or an iso-propyl group, pharmaceutically acceptable salts thereof, hydrates thereof, and stereoisomers thereof.
9. In Paragraph 1, The above R 6 A compound selected from urea derivative compounds characterized by having a hydrogen, deuterium, or methyl group, pharmaceutically acceptable salts thereof, hydrates thereof, and stereoisomers thereof.
10. In Paragraph 1, The above X 1 A compound selected from urea derivative compounds characterized by being NH, C(=O), or CF2, pharmaceutically acceptable salts thereof, hydrates thereof, and stereoisomers thereof.
11. In Paragraph 1, The above X 2 A compound selected from urea derivative compounds characterized by being O or S, pharmaceutically acceptable salts thereof, hydrates thereof, and stereoisomers thereof.
12. In Paragraph 1, A compound selected from urea derivative compounds characterized in that Y is CH2 or C(=O), pharmaceutically acceptable salts thereof, hydrates thereof, and stereoisomers thereof.
13. In Paragraph 1, The compound of Formula 1 above is a compound selected from a urea derivative compound selected from the group consisting of compound numbers 1 to 81 below, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a stereoisomer thereof: Compound No. 1: 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea; Compound No. 2: 1-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-(4-(((methylamino)oxy)methyl)phenyl)urea; Compound No. 3: 1-(4-(2-(2-(aminooxy)ethoxy)ethyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride; Compound No. 4: 1-(3-chloro-4-(((methylamino)oxy)methyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea; Compound No. 5: 1-(4-((aminooxy)methyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride; Compound No. 6: 2-amino-N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)acetamide; Compound No. 7: N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-2-(methylamino)acetamide; Compound No. 8: N-((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)azetidine-3-carboxamide; Compound No. 9: 3-amino-N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)propanamide hydrochloride; Compound No. 10: N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-3-(methylamino)propanamide hydrochloride; Compound No. 1: 4-amino-N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)butanamide hydrochloride; Compound No. 12: N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-4-(methylamino)butanamide hydrochloride; Compound No. 13: 2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-N-(2-((methylamino)oxy)ethyl)acetamide; Compound No. 14: 2-(aminooxy)-N-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethyl)acetamide; Compound No. 15: N-(2-aminoethoxy)-2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)acetamide hydrochloride; Compound No. 16: 2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-N-(2-(methylamino)ethoxy)acetamide; Compound No. 17: N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-2-hydroxyacetamide; Compound No. 18: N-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)2-hydroxy-N-methylacetamide; Compound No. 19: (2R)-N-((2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)benzyl)oxy)-2-hydroxypropanamide; Compound No. 20: (2R)-N-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)2-hydroxy-N-methylpropanamide; Compound No. 21: 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)urea; Compound No. 22: 1-(3-chloro-4-(2-(2-((ethylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride; Compound No. 23: 1-(3-chloro-4-(2-(2-((isopropylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride; Compound No. 24: 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)thiourea hydrochloride; Compound No. 25: 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea hydrochloride; Compound No. 26: 1-(3-chloro-4-(1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride; Compound No. 27: 1-(3-chloro-4-(1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea hydrochloride; Compound No. 28: 1-(3-chloro-4-(1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)methyl)thiourea hydrochloride; Compound No. 29: 1-(3-chloro-4-(1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)thiourea hydrochloride; Compound No. 30: 1-(4-(2-(2-(aminooxy)ethoxy)ethyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)methyl)thiourea hydrochloride; Compound No. 31: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea; Compound No. 32: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea; Compound No. 33: 1-(3-chloro-4-(2-(methyl(2-((methylamino)oxy)ethyl)amino)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride; Compound No. 34: 1-(4-((aminooxy)methyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)thiourea hydrochloride; Compound No. 35: 1-(3-chloro-4-(2-(2-((dimethylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea; Compound No. 36: 1-(3-chloro-4-(2-(2-((cyclopentylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea; Compound No. 37: 1-(3-chloro-4-(2-(2-((cyclobutylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea; Compound No. 38: 1-(3-chloro-4-((4-(((methylamino)oxy)methyl)piperidine-1-yl)methyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea 2,2,2-trifluoroacetate; Compound No. 39: 1-(3-chloro-4-(3,6,9-trioxa-2-azaudecane-11-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)methyl)urea hydrochloride; Compound No. 40: 1-(3-chloro-4-(6-methyl-3,7-dioxa-2,6-diazanonnan-9-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea; Compound No. 41: 1-(3-chloro-4-(1-(2-((cyclobutylamino)oxy)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea; Compound No. 42: 1-(3-chloro-4-(1-(2-((cyclobutylamino)oxy)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea; Compound No. 43: N-(2-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenyl)-2-methylpropoxy)ethoxy)-2-hydroxy-N-methylacetamide; Compound No. 44: (2R)-N-(2-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenyl)-2-methylpropoxy)ethoxy)-2-hydroxy-N-methylpropanamide; Compound No. 45: 1-(3-chloro-4-(1-(2-(((3,3-difluorocyclobutyl)amino)oxy)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea; Compound No. 46: 2-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-N-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-oxoacetamide; Compound No. 47: N-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-2-oxoacetamide; Compound No. 48: 2-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-N-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-oxoacetamide; Compound No. 49: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)thiourea; Compound No. 50: 1-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-(3-methyl-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)urea; Compound No. 51: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1R)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea; Compound No. 52: 1-(3-chloro-4-(2-methyl-1-(2-((oxetane-3-ylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea; Compound No. 53: 1-(4-(1-(2-(aminooxy)ethoxy)-2-methylpropane-2-yl)-3-chlorophenyl)-3-((1R)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea; Compound No. 54: 1-(4-(1-(2-(aminooxy)ethoxy)-2-methylpropane-2-yl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea; Compound No. 55: 1-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)-3-(3-methyl-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)urea 2,2,2-trifluoroacetate; Compound No. 56: 1-(3-chloro-4-(2-((methylamino)oxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea; Compound No. 57: 1-(3-chloro-4-(2-(2-((isopropylamino)oxy)ethoxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea; Compound No. 58: 1-(3-chloro-4-(2-(2-(methoxyamino)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea; Compound No. 59: 1-(3-chloro-4-(2-(2-(methoxyamino)ethoxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea; Compound No. 60: 1-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-(4-(2-(2-((methylamino)oxy)ethoxy)ethyl)-3-(trifluoromethyl)phenyl)urea; Compound No. 61: 1-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)-3-(4-(2-(2-((methylamino)oxy)ethoxy)ethyl)-3-(trifluoromethyl)phenyl)urea; Compound No. 62: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)methyl)urea; Compound No. 63: 1-(4-(1-(2-(((2-azaspiro[3,3]heptane-6-yl)amino)oxy)ethoxy)-2-methylpropane-2-yl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea; Compound No. 64: 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((1R)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea; Compound No. 65: 1-(3-chloro-4-(2-(2-((cyclobutylamino)oxy)ethoxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea; Compound No. 66: 1-(3-chloro-4-(2-methyl-1-(2-(((1-methylazetidin-3-yl)amino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)urea; Compound No. 67: 1-(3-chloro-4-(1-(2-(((1,1-dioxydothiethane-3-yl)amino)oxy)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)methyl)urea; Compound No. 68: 1-(3-chloro-4-(2-((((cyclopropylmethyl)amino)oxy)ethoxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea; Compound No. 69: 1-(3-chloro-4-(2-((((cyclopropylmethyl)amino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea; Compound No. 70: 1-(4-(1-(2-(((2-oxaspyro[3,3]heptane-6-yl)amino)oxy)ethoxy)-2-methylpropane-2-yl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea; Compound No. 71: 1-(4-(2-(4-aminopiperazine-1-yl)ethyl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea 2,2,2-trifluoroacetate; Compound No. 72: 1-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)-3-(4-(1-(2-((methylamino)oxy)ethoxy)propane-2-yl)-3-(trifluoromethyl)phenyl)urea; Compound No. 73: 1-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)-3-(4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)-3-(trifluoromethyl)phenyl)urea; Compound No. 74: 1-(3-chloro-4-(1-(2-(((cyclopropylmethyl)amino)oxy)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea; Compound No. 75: 1-(3-chloro-4-(1-(2-(methoxyamino)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea; Compound No. 76: 1-(3-chloro-4-(1-(2-(isopropoxyamino)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)ethyl)urea; Compound No. 77: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)propyl)urea; Compound No. 78: 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethoxy)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea; Compound No. 79: 1-(3-chloro-4-((2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)oxy)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea; Compound No. 80: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-4-methoxy-1-oxoisoindolin-5-yl)methyl)urea; Compound No. 81: 1-(3-chloro-4-(2-methyl-1-(2-((methylamino)oxy)ethoxy)propane-2-yl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-4-hydroxy-1-oxoisoindolin-5-yl)methyl)urea.
14. In Paragraph 1, A compound selected from urea derivative compounds, pharmaceutically acceptable salts thereof, hydrates thereof, and stereoisomers thereof, characterized in that the above-mentioned pharmaceutically acceptable salt is a salt of an inorganic or organic acid selected from the group consisting of hydrochloric acid, hydrobromide, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvate, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid, and toluenesulfonic acid.
